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Nature has evolved enzymes to solve the complex biochemical problems of life through 
directed evolution over millions of years. But, to solve the needs of today’s society, enzymes 
must be able to evolve more quickly and “smartly”. Artificial metalloenzymes are an elegant 
solution to add new functionality to enzymes while utilizing the power of genetic memory from 
the host protein matrix. These systems can be especially useful in establishing biorthogonal 
reactions in living systems and have been extensively investigated in the Ward Lab at the 
University of Basel.  
The aim of this thesis is to expand the current repertoire of biorthogonal catalysts by 
synthesizing gold(I)-based artificial metalloenzymes as well as gold(I)-functionalized 
somastotatin analogues and optimize their catalytic potential via directed evolution or 
systematic screening. This includes the design of new “close-to-release” substrates for 
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1. General Introduction 
Enzymes display unmatched catalytic activity while functioning in sophisticated cascades and 
in complex biological environments. Artificial metalloenzymes (ArMs) are one way of mimicking 
nature’s most efficient catalysts in order to introduce complex organometallic reactivities in 
vivo. ArMs are composed of a synthetic, catalytically competent metallocofactor integrated into 
a protein matrix. The result is a hybrid catalyst capable of combining the benefits of 
homogeneous and enzymatic catalysis.1 
1.1 The Biotin-(Strept)Avidin Technology 
Avidin and its relation to the vitamin biotin were initially discovered while investigating egg 
white in the late 1920s.2 Its function may be linked to bacterial inhibition by removing biotin, a 
crucial bacterial metabolite, from the environment.3 Despite the low sequence identity (~30%),4 
Avidin and the structurally related Streptavidin (Sav) isolated first from Streptomyces avidinii, 
both form homotetrameric structures constituting of -barrel motifs that each bind biotin nearly 
irreversibly (Kd > 10-14 M).5–7 In the 1970s, Whitesides and Wilson utilized this supramolecular 
anchoring strategy to incorporate biotinylated diphosphinerhodium(I) into avidin.8 The goal was 
to benefit from the second coordination sphere of the host protein to induce enantioselectivity 
to rhodium(I)-based asymmetric hydrogenation. This innovative approach achieved modest 
enantioselectivity as the biotechnological tools necessary to optimize the protein matrix were 
missing. These limitations also affected the development of other ArM designs e.g. based on 
metal substitution of carboxypeptidase A.9  
Decades later and with new tools with regards to protein engineering and organometallic 
catalyst design in hands, the field of ArMs including the biotin-Sav technology experienced a 
revival.10 The applications of Sav in biotechnology go far beyond ArM design and include the 
purification and detection of biomolecules,11,12 the construction of nanomaterials,13,14 its use in 
immunotherapy15–17 as well as the transport of drugs via protein-delivery systems.18 In contrast 
to avidin, Sav does not bear any glycosylation domains and consists of a very different primary 
sequence. As a result, Sav is more acidic which reduces nonspecific binding, prevents pseudo-
catalysis and minimizes undesired agglomeration. Furthermore, Sav displays exceptional 
stability: it tolerates large variations in pH, high amounts of organic solvent and remains stable 
even above 70 °C.19 This versatile protein was used to incorporate a diverse range of 
biotinylated organometallic catalyst for the preparation of ArMs with applications in: 
hydrogenation,20,21 sulfoxidation,22 dihydroxylation,23 alcohol oxidation,24 transfer 
hydrogenation,25–27 Suzuki cross-coupling,28 C-H activation,29 and metathesis.30 In combination 
with established Sav expression systems, in can be fairly straight-forward to develop Sav-
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based directed evolution protocols in order to optimize these ArMs towards high catalytic 
activity but also towards new regio- and/or enantioselectivities.30–33 
1.2 Gold in Catalysis 
Gold has been used by humans for ten-thousands of years. It is associated with intrinsic worth 
(monetary system), divine principles (golden ratio, golden rule) and great achievements (Nobel 
prize, Olympic medal). Gold crafts have retained their “shining dawn” (aurum) over millennia 
due to the outstanding stability of this element towards oxidation.34 While catalyst derived from 
transition metals including palladium, iridium, rhodium and ruthenium have been extensively 
explored since the 1970s, gold has been undeservedly neglected for decades. Already back 
in 1973 Geoffrey Bond stated: “We are at a loss to understand why these catalytic properties 
of gold have not been reported before, especially since the preparative methods we have used 
are in no way remarkable.” 35 And in 1998 David Thompson followed: “In addition, it is 
noticeable that most areas of gold science are at an earlier stage of evolution than that already 
attained for neighboring elements in the Periodic Table, and although some of the potential 
applications are at an early stage of development, many significant developments can be 
anticipated in the future.” 36 In the shadow of Nobel-prize winning osmium (2001), rhodium 
(2001), titanium (2001), ruthenium (2001 and 2005) and palladium (2010) catalysis, it took 
another decade for the field of gold catalysis to seriously take off.37–40 
While elemental gold is inert, gold nanoparticles, gold(I) complexes or gold (III) complexes can 
be used for gold catalysis. The strong Lewis acidity, the potential to stabilize cationic 
intermediates and coordinate unsaturated bonds combined with exceptional stability towards 
both oxygen and acidic protons imparts unique reactivity to this set of catalysts.41 In contrast 
to other transition metals, gold(I) and gold (III) complexes do not readily cycle between 
oxidation states and thus rarely follow the typical oxidative addition/reductive elimination 
pattern.42 Instead, new modes of reactivity were discovered, including dual-gold catalysis.43 
The strong relativistic contractions in the 6s orbital of gold does not only result in strengthened 
gold-ligand bonds but also in stabilizing gold-gold interactions, a phenomenon referred to as 
“aurophilicity”.42 In this study, we are especially interested in utilizing the alkynophilic, Lewis 
acid-like properties of Au(I) complexes to convert alkynes in a biorthogonal and selective 
manner under mild reaction conditions.  
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2. Aim & Summary of individual Chapters 
2.1 Aim of this Thesis: 
The aim of this thesis is to expand the current repertoire of biorthogonal catalysts by 
synthesizing palladium(II)-and gold(I)-based artificial metalloenzymes. The course of action 
was: i) the synthesis of biotinylated N-heterocyclic cofactors, ii) the synthesis of compatible 
substrates, iii) the introduction of the cofactors into Sav and chimeric analogues therof and 
finally iv) the optimization of the corresponding ArM via directed evolution or systematic 
screening. Additionally, gold(I)-functionalized somastotatin analogues were investigated for 
the controlled uncaging of fluorophores via a newly developed “close-to-release” reaction.  
 
2.2 Chapter 1: Dual-Gold-based chimeric ArMs 
An artificial hydroaminase was engineered and evolved to perform either single- or dual-gold 
catalysis. Guided by modeling, a chimeric streptavidin equipped with a hydrophobic lid 
shielding its active site was designed, which enforces the advantageous positioning of two 
synergistic biotinylated gold cofactors. Three rounds of directed evolution using E. coli cell-free 
extracts led to the identification of mutants favoring either the anti-Markovnikov product (an 
indole carboxamide with 96% regioselectivity, 51 TONs) resulting from a dual gold -
activation of an ethynylphenylurea substrate or the Markovnikov product (a phenyl-
dihydroquinazolinone with 99% regioselectivity, 333 TONs) resulting from the -activation of 
the alkyne to gold. 
 
2.3 Chapter 2: Systematic Screening of Gold-based ArMs 
Gold-based ArMs were systematically screened to optimize their performance in the periplasm 
of E. coli. Various reactions were investigated including the uncaging of protected-indole and 
the hydroamination of 2-aminopent-4-ynoic acid to 2,3-dihydroproline. However, only two 
reactions proved viable: (i) the hydroamination of 2-ethynylaniline towards indole and (ii) the 
hydroarylation of pro-coumarin derivatives. The use of a systematic screening platform 
provided sufficient training set data for machine learning approaches. Furthermore, efficient 




2.4 Chapter 3: Intramolecular Heck Reaction 
The synthesis of 2-iodo-N-vinylaniline derivatives and their role in the intramolecular Heck 
cyclization was investigated. The corresponding substrates should be transformed to pro-
metabolites, with the goal to implement the Heck reaction in an artificial Tryptophan synthase 
pathway. Different palladium complexes were prepared to catalyze the cyclization of tosyl-
protected 2-iodo-N-vinylaniline to the corresponding indole in aqueous THF. Attempts to 
deprotect the substrate and/or the product were not successful, while the synthesis of 
unprotected substrates failed. As a result, the project was not further pursued, and 
palladium(II)-based ArM were not further investigated in this thesis. 
 
2.5 Chapter 4: Gold-triggered Drug-Release Systems 
A new “close-to-release” methodology was developed utilizing intramolecular gold-cyclization 
followed by spontaneous 1,2-elimination to release umbelliferone. Chimeric gold ArMs proved 
highly efficient in uncaging umbelliferone in MES buffer. The simple reaction procedure could 
prove useful for systematic screening efforts. In order to facilitate medical applications, gold-
functionalized peptides were prepared based on cyclic somastotatin analogues. These 
peptides catalyzed the close-to-release reaction albeit with lower conversions. What’s more, 
in aqueous mixtures of acetonitrile, the gold-functionalized peptides quantitatively performed 





3. Chapter 1: Dual-Gold-based chimeric ArMs 
 
 
Christoffel, F., Igareta, N., Pellizzoni, M., Tiessler-Sala, L., Lozhkin, B., 
Spiess, D., Lledos, A., Maréchal, J., Peterson, R., Ward, T. R., Design and 
Evolution of Chimeric Streptavidin for Protein-Enabled Dual Gold Catalysis. 




3.1 Outline of the Authors Contribution 
TRW, RLP and FC conceived and designed the study. FC, MMP and BL contributed to the 
synthesis of the substrates, products and complexes. NVI, DCS, RLP and FC contributed to 
mutagenesis, protein expression, protein purification and protein characterization. NVI 
performed the crystallization, X-ray structure determinations and the native MS experiments. 
FC performed the catalytic, preparative, and deuterium-labeling experiments, designed the 
screening protocol and recorded the data. TRW, FC and NVI analyzed the data. JDM, AL, and 
LTS contributed to the molecular modelling experiments.  
 
3.2 Introduction 
Thanks to their unique affinity towards alkynes, allenes and alkenes, gold complexes have 
attracted significant attention for their catalytic potential.44–49 In addition to the activation of 
unsaturated substrates via -coordination, terminal alkynes undergo dual-gold activation via 
synergistic ,-coordination.43,50–55 This mode of activation, which proceeds via a diaurated 
transition state, affords distinct products/regioisomers, significantly broadening the scope of 
gold-catalyzed reactions. Such synergistic action of two metals in catalysis is reminiscent of 
polynuclear metalloenzymes, whereby (at least) two metals act in concert to catalyze 
challenging reactions.56–59 
In the context of in vivo ligation and bioconjugation, alkynes occupy a place of choice,  as 
this functional group was shown to be bio-orthogonal, thus finding widespread use in “click” 
chemistry.60–63 Although Cu and Ru are privileged catalysts in this context,64,65 recent reports 
suggest that gold-complexes maintain catalytic activity in a cellular environment, albeit for a 
different type of reactivity.66–72 To the best of our knowledge however, these biocompatible 





Figure 1 Engineering and evolving an artificial hydroaminase (HAMase) based on dual-gold 
activation of alkynes. Chemo-genetic optimization of the catalytic performance relies on combining: a 
biotinylated cofactor and b a tailored chimeric protein to assemble c an ArM equipped with two adjacent 
gold cofactors. Genetic optimization is guided by d modelling to identify e  advantageous amino acids 
for directed evolution to favor f either ,-activation or -activation of the alkyne to afford either indole 2 
or quinazolinone 3 respectively. Modified and reprinted with permission from Springer Nature.73 
With the aim of complementing natural enzymes,74 ArMs have experienced a renaissance in 
the past two decades.8,75–81 For this purpose, an abiotic metal cofactor is compartmentalized 
within a protein scaffold which can be optimized by genetic means. Thus far, more than 40 
reactions can be catalyzed by ArMs.10 Current challenges in the field include i) protein-
accelerated catalysis, whereby a pre-catalyst is activated upon incorporation within the host 
protein,29,82 ii) dual catalysis83,84 and iii) compatibility of the ArM with a cytosolic 
environment.10,85,86 Privileged scaffolds for ArMs include: carbonic anhydrase,87 
hemoproteins,88,89 prolyl oligopeptidase,90 lactococcal multiresistance regulator,78 four helix-
bundles,58,91 nitrobindin,92 human serum albumin,93 and (strept)avidin.8,86,94 As a result of the 
unique topology of Sav favoring the localization of two close-lying biotinylated probes in a 
hydrophobic environment, we set out to engineer and evolve a biocompatible artificial 
hydroaminase (HAMase hereafter) based on either single95 or dual-gold activation of the 
alkyne, Figure 1. 
3.3 Results and Discussion 
As reported by Asensio52,96 and van der Vlugt97, the regioselectivity for the hydroamination of 
ethynylurea 1 is by-and-large governed by the mode of activation of the alkyne by gold: the 
canonical -activation favors the quinazolinone 3 (Markovnikov, 6-exo-dig addition product), 
while the dual -gold activation affords preferentially the indole 2 (anti-Markovnikov, 5-endo-
dig addition product)52,97,98 Upon -coordination of the alkyne to gold, the pKa of the terminal 
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C–H bond is lowered, thus favoring its deprotonation and coordination by a second gold to 
afford the -activation mode.96 Accordingly, the spatial arrangement of the two gold species 
is critical in determining the regioselectivity of the reaction. We thus selected the gold-catalyzed 
cyclization of the ethynylurea 1 to engineer and evolve a dual-gold catalyzed hydroaminase 
(HAMase) based on the biotin-streptavidin technology. 
Thanks to its dimer of dimers quaternary structure, which places the valeric acid side chains 
of two proximal biotins 19.8 Å apart (pdb: 3ry299), we designed N-heterocyclic carbene ligands 
equipped with a biotin anchor introduced at various positions, Figure 2 a.100 We hypothesized 
that the relative position of two gold moieties within the biotin binding vestibule may influence 
the mode of alkyne-activation as reflected by the indole 2 vs the quinazolinone 3 ratio. 
Sterically-crowded imidazolium precursors were metalated using a one-step procedure,101 and 
less-hindered carbenes were prepared through transmetalation of the silver-carbene 
complex,102 to afford the corresponding gold complexes: biot-Au 1-5, SI Figure 1103–105 These 
are air- and water stable and can be stored for months as stock solutions in DMSO at 5 ºC.  
Figure 2 Chemo-genetic optimization of HAMase activity. a Biotinylated gold complexes biot–
Au 1-5 tested b in the presence of streptavidin isoforms c for the hydroamination of substrate 1 to 
afford indole 2 or quinazolinone 3. Screening conditions using purified Sav samples: Vtot 200 L 
(VDMSO 15 L), [Sub] 5 mM, [Au] 50 M, [Sav] 100 M, [MES-buffer] 50 mM, pH 5, 37 °C for 24 h. d 
Bio-additive-based screening of biot-Au 2 · Sav-SOD K121A allows identifying detrimental cellular 
components. Reaction conditions: Vtot 200 L (VDMSO 15 L), [Sub] 2.5 mM, [bio-additive] 2.5 mM, 
[biot-Au 2] 50 M, [Sav] 100 M, [MES-buffer] 50 mM, pH 5, 37 °C for 24 h. *cross-reaction with 
the substrate. Modified and reprinted with permission from Springer Nature.73 
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Initial studies using Au(I)-complexes bearing either commercially-available NHCs or biot-Au 1-
5 in buffered aqueous solutions afforded < 1 turnover (TON, using 7.5 % DMSO, [substrate 1] 
= 5 mM and [Au] = 50 M = 1 mol %, 24 hours at room temperature), SI Table 1. Addition of 
wild-type streptavidin (Sav WT hereafter, 25 M, corresponding to 100 M biotin-binding sites, 
BBS) to a biotinylated cofactor biot-Au 1-5 improved the catalytic activity leading to up to 12 
TONs and affording the quinazolinone 3 exclusively, Figure 2 b-c, SI Figure 2 and SI Table 
1. This “protein-acceleration” phenomenon upon addition of Sav was not observed with 
cofactors devoid of biotin or with Me2biot-Au 2 which bears a dimethylated biotin anchor and 
thus a markedly decreased affinity towards streptavidin as highlighted by a HABA 
displacement assay, SI Figure 3.106 Fine-tuning the reaction conditions revealed that MES 
buffer at pH = 5 affords the highest TONs, without significantly affecting the regioselectivity, SI 
Figure 4-8. Next, we selected biot-Au 2 and screened it in the presence of a focused library 
of Sav isoforms bearing mutations at S112 and/or K121. While the TON could be improved, 
especially in the presence of small/hydrophobic residues at position K121, the critical 3:2 ratio, 
diagnostic of the gold-activation mode, remained heavily biased in favor of the 6-exo-dig 
product 3, SI Figure 9 and SI Table 2. The addition of various bio-additives in fiftyfold excess 
vs. catalyst was tolerated in most cases. Reduced glutathione and cysteine poisoned the 
catalytic system, fortunately only at higher concentrations (> 20x[biot-Au 2]). Strikingly, biotin 
inhibits the ArM already at low concentrations (> 4x[biot-Au 2]). These results highlight the 
promising bio-robustness of the ArM, suggesting it may be used in a cellular medium, SI Table 
3. With directed evolution in mind, this is a highly desirable feature as it allows screening cell-
free extracts (cfe), without the need to purify the streptavidin mutants.107,108 
Inspection of the > 30 X-ray structures of ArMs based on the biotin-streptavidin technology 
reveal a tendency for biotinylated metal cofactors to be poorly localized within the biotin-binding 
vestibule.94 We attribute this to its shallow topology, thus allowing a biotinylated cofactor to 
adopt multiple poses, resulting in reduced occupancy.109 Multiscale-modeling strategies on 
some of these systems illustrate that the pronounced flexibility of the cofactor may compromise 
the regiospecificity of the reaction.110 With the aim of shielding the biotin-binding vestibule, 
consisting of two eight-stranded -barrels facing each other, we surveyed the literature for 
naturally-occurring dimerization domains present in -sheet-rich proteins. We identified a 
potential candidate fitting this criterion: the superoxide dismutase C (sodC) from 
M. tuberculosis (pdb: 1pzs111), which includes a ~ 30 amino acid dimerization domain. This lid 
forms an interface that spans across the ~ 29 Å of the two Greek Key -barrel subunits of 
sodC. We thus set out to engineer a chimera consisting of the dimerization domain of sodC 
inserted in the 3-4 loop of the Sav to yield a Sav-SOD, Figure 3 a. To our delight, Sav-SOD 
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could be expressed in the soluble fraction in high yield (typically > 100 mg/L) in shake flasks 
using E. coli BL21 DE3, SI Figure 10-11. 
To scrutinize the effect on the perturbation resulting from the addition of the sodC dimerization 
domain, we performed Isothermal Titration Calorimetry measurements (ITC) with biotin. 
Nanomolar binding affinity for biotin is retained over a wide range of temperatures (10 to 40 ºC). 
At 25 ºC, the Kd is 4.2 nM with standard binding enthalpy Hº = – 20.90 kcal/mol and binding 
enthalpy TSº = – 9.49 kcal/mol. The standard free energy Gº = – 11.4 kcal/mol at 25 ºC.112 
These parameters suggest that the biotin-binding is primarily enthalpically-driven. Comparison 
of the turn-on fluorescence upon incorporation of the biotinylated solvatochromic fluorescent 
reporter 4-N,N-dimethylamino-1,8-naphthalimide (biot-4DMN) in Sav and Sav-SOD K121A 
reveals a > 2.5 and 20 fold increase in fluorescence compared to the free biot-4DMN, 
accompanied by a blue shift (em = 532 and 526 nm vs. 556 nm). Such increase in fluorescence 
accompanied by an ipsochromic shift, have been attributed to increased hydrophobicity.112,113 
Furthermore, thermal shift assay highlights an increased thermal stability of the apo chimeric 
protein compared to apo Sav WT. We thus surmise that the SOD-lid stabilizes the protein and 
significantly contributes to provide a hydrophobic and shielded environment for organometallic 
catalysis. 
To gain structural and mechanistic insight on the influence of the protein scaffold, we refined 
an integrative computational procedure that we have developed to model various ArMs, Figure 
3 b.114 We analyzed the formation of the 6-exo-dig product 3 and 5-endo-dig product 2 
catalyzed by biot-Au 2 · Sav WT, biot-Au 2 · Sav K121A and biot-Au 2 · Sav-SOD K121A. 
For this purpose, we applied the following workflow: i) DFT calculations on the “theozyme”, the 
core catalytic center (urea 1 coordinated to one or two biotinylated gold catalysts) for both - 
and dual -activation modes. DFT calculations (B3LYP-D3 functional) were performed using 
continuum water solvent conditions.115,116 ii) With no X-ray structure of the Sav-SOD available, 
structural modelling (with Modeller117) was carried out on this system followed by classical 
Molecular Dynamics (MD) simulations (AMBER Force field118) up to convergence. Then, after 
inclusion of biot-Au 2 into the protein vestibule by protein-ligand docking, MD on the three Sav 
scaffolds biot-Au 2 · Sav-WT, biot-Au 2 · Sav K121A and biot-Au 2 · Sav-SOD K121A were 
performed to determine the conformational space available for substrate binding. iii) 
Incorporation of the transition state structures for the 6-exo-dig and 5-endo-dig pathways in 
water (see i)) by protein-ligand docking approaches (using GaudiMM119 and Gold5.8.1120) into 
the most representative structures of the MD simulations for the three Sav scaffolds (we term 
these “pseudo-transition states”), and iv) further refinement by MD of the best results obtained 
for systems with reasonable predicted affinity (in iii)). The final simulations were analyzed 
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focusing on: a) the complementarity of transition state structures for the 6-exo-dig and 5-endo-
dig within the Sav vestibule, and b) the number of gold cofactors biot-Au 2 involved (i.e. one 
or two). The influence of the host protein on the transition state structures helped identify amino 
acid residues to randomize during directed evolution. 
The DFT calculations revealed that the competition between - and dual -activation modes 
also operates in water. The difference between the Gibbs energy barriers for both pathways is 
about 2 kcal mol-1 (19.5 vs. 21.5 kcal mol-1 for 6-exo-dig and 5-endo-dig mechanisms, 
respectively), suggesting that subtle changes in the first or second coordination sphere of the 
metal may significantly affect the ratio between both products. Calculations of the barriers in 
solvents of different dielectric constant suggest that the regioselectivity is not significantly 
affected by the polarity of the medium. We surmised that a shift in regioselectivity may be 
promoted by the protein environment. DFT calculations carried out on small models were used 
to evaluate the impact on the ground- and transition states structures of the gold complexes 
both in bulk water and in the confined, hydrophobic environment provided by the biotin-binding 
vestibule. Scrutiny of the active site led us to hypothesize that, following -coordination, the 
alkyne’s C-H may be deprotonated by close-lying amino acids or a water molecule to afford a 
di-aurated −acetylide species: (Au-C = 2.01 Å) and (Au-C = 2.28, 2.33 Å) and a Au—Au 
distance ~3 Å. 
Having identified transition state structures in water for the isolated cofactor (in the absence of 
the protein scaffold), three different pseudo-transition states embedded in the protein were 
evaluated whereby 1TS-1Au and 2TS-2Au and 1TS-2Au. The transition state 1TS-1Au 
corresponds to the -activated TS which occupies half of the biotin-binding vestibule, with a 
second, unligated biot-Au 2 occupying the neighboring biotin binding site. The transition state 
2TS-2Au is similar to 1TS-1Au, but includes two gold complexes, each activating an alkyne 
via -coordination. Finally, the transition state 1TS-2Au2 contains two gold complexes 




Figure 3 Design and structural characterization of the chimeric ArM: a Protein topology diagram of 
the sequence of one Sav-SOD monomer (left) and the computed structure of chimeric Sav-SOD 
resulting from a 200 ns MD simulation (right); the SOD insert is highlighted in pink; residues subjected 
to saturation mutagenesis are underlined; blue arrows and orange cylinders represent -sheets and -
helices respectively. b Workflow for the computational design and optimization of transition states in 
chimeric streptavidin. Identification of most promising amino acid residues to subject to mutagenesis. 
Modified and reprinted with permission from Springer Nature.73 
Molecular modeling of biot-Au 2 · Sav WT provides the best fit for the pseudo-transition state 
1TS-1Au when inserted into the catalytic vestibule of Sa. Worse complementarities were 
computed for 2TS-2Au and severe clashes with the amino acids on position 121 were 
predicted for 1TS-2Au. All these pseudo-transition state structures are rather solvent-exposed, 
with minimal impact of the second coordination sphere, resulting in similar energy barriers and 
similar predicted regioselectivity compared to the free cofactor. Both the free cofactor and biot-
Au 2 · Sav WT are thus predicted to favor −activation to afford quinazolinone 3. Gratifyingly, 
in vitro experiments support the model, revealing that biot-Au 2 · Sav WT affords exclusively 
quinazolinone 3, Figure 2 c. 
In the case of biot-Au 2 · Sav K121A, similar or worse fitting scores compared to Sav WT are 
computed for all pseudo-transition states, except for 1TS-2Au. In fact, the score associated 
per cofactor reveals that the binding affinity of 1TS-2Au is close to the value obtained for 1TS-
1Au (that corresponds to a single transition state geometry with no geometric constraint from 
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the adjacent Sav monomer), SI Table 6. These results suggest that a single-point mutation 
K121A improves the docking score of 1TS-2Au compared to 1TS-1Au. This reflects a modest 
shift in favor of -alkyne coordination which should allow for the formation of the anti-
Markovnikov product indole 2. These findings are supported by experiments: the 
regioselectivity (3:2) varies from 100:0 (for biot-Au 2 · Sav WT) to 83:17 for biot-
Au 2 · Sav K121A, Figure 2 c and Table 1.  
X-ray quality crystals of biot-Au 2 · Sav-SOD (including various point mutants) were obtained 
through co-crystallization. Although a resolution down to 1.8 Å was achieved, the SOD-lid 
could not be fully resolved due to its high flexibility, PDB 7ALX. We thus set out to model the 
structure of biot-Au 2 · Sav-SOD K121A, starting with homology modeling, followed by a long 
classical MD (200 ns), Figure 4 b.121 The resulting models are stable with the SOD-lid 
presenting the highest degree of flexibility (RMSF 2.63). Next, we docked biot-Au 2 into the 
system. Good complementarities were obtained by collective motion of the entire SOD-lid. This 
hydrophobic lid contributes to shield both cofactors from the solvent. A second MD (300 ns) 
placed both biot-Au 2 cofactors sufficiently close to synergistically engage in -activation of 
a terminal alkyne. To our delight, biot-Au 2 · Sav-SOD K121A indeed displayed the highest 5-
endo-dig regioselectivity (i.e. 62:38 for 3:2) and TONs of up to 40, Figure 2 c and Table 1. We 
thus selected biot-Au 2 · Sav-SOD K121A for directed evolution. 
Docking of the three pseudo-transition state models into Sav-SOD K121A reveal that the best 
complementarity is obtained for 1TS-1Au and 1TS-2Au (especially for TS5), Figure 4 c-d. 
Scoring values for 2TS-2Au were extremely low as there is limited space for such a large 
pseudo-transition state in the Sav-SOD’s vestibule. This also suggests that the possibility of 
another substrate approaching 1TS-2Au to form 2TS-2Au is unlikely in chimeric Sav-SOD. 
Depending on the transition state, the substrate(s) occupies different positions within the active 





Figure 4 Analysis of the transition state structure and close-lying amino acid residues in 
chimeric Sav: a Schematic representation of postulated gold-catalyzed hydroamination reaction 
mechanisms within the biotin-binding vestibule. b X-ray crystal structure of biot-Au 2 · Sav-SOD K121A 
(magenta) overlaid with the MD model (blue). c,d Computed transitions state for the biot-Au 2-catalyzed 
6-exo-dig (1TS-1Au) and for the 5-endo-dig cyclization (1TS-2Au) docked within Sav-SOD K121A. e 
Close-up view of the X-ray structure of biot-Au 2 · Sav-SOD K121A. Anomalous electron density 
(displayed as red mesh at 5) assigned to Au and modeled with a 50% occupancy; no electron density 
for Cl was detected. Electron density map (2Fo-Fc) for the biot-Au 2 (displayed as grey mesh at 1) 
biot-Au 2 (green stick), close-lying amino acid residues (magenta stick representation), Au as golden 
sphere, Cl as green sphere and the protein as cartoon representation. Reprinted with permission 
from Springer Nature.73 
The most notable difference is a 180-degree rotation of the substrate between 1TS-1Au (6-
exo-dig) compared to 1TS-2Au (5-endo-dig). Further residue- contribution analysis of 1TS-
14 
 
2Au and 1TS-1Au (to afford 5-endo-dig and 6-exo-dig products respectively) in the active ArM 
were performed. Calculations were carried out using Cytoscape122 as implemented in UCSF 
Chimera123 (for a qualitative analysis of main interactions along the MDs) followed by MMGBSA 
(to extract indicative energetic values). Direct interactions of gold with close-lying amino acids 
are very weak (e.g. purely VdW contacts). Both pseudo-transition state structures reveal 
common interactions between the coordinated substrate 1 and the residues SOD-N8, SOD-I9, 
SOD-A3 and Sav-N118. For 1TS-1Au, additional contacts were identified: from Sav-S112 to 
S122, especially T114. This increased number of contacts is traced back to the high level of 
flexibility of the 1TS-1Au versus the 1TS-2Au. As the SOD lid is highly flexible (and disordered 
in the X-ray structure), we selected close-lying residues belonging to Sav rather than the SOD-
lid. Accordingly, the following amino acids were selected for the directed evolution campaign: 
S112, T114, T115, N118, K121 and S122, Figure 4 e. 
 
Figure 5 Directed Evolution of an HAMase Based on Sav-SOD. a Streamlined protocol for the 
genetic optimization of biot-Au 2 · Sav-SOD in cfe using a 96-well plate assay. b Scatterplot of 2500 
cfe experiments displaying the two evolutionary trajectories Sav-SOD GGG (red) and Sav-SOD SFG 
(blue), for amino acid positions selected for mutagenesis, see panel c, ultimately leading to the 
identification of biot-Au 2 · Sav-SOD T-A-SFG and biot-Au 2 · Sav-SOD N-SN-GGG. Reaction 
conditions for 96-well cfe screening: Vtot 400 L (VDMSO 20 L), [Sub] 2.5 mM, [Cofactor] 6.25 M, MES-
buffer:lysis-buffer (1:1), pH ~5.5, sealed at 37 °C for 4 days. c Evolution trajectory of HAMase using 
purified Sav isoforms of the evolution of biot-Au 2 · Sav-SOD. Reaction conditions for catalysis with 
purified protein samples: Vtot 200 L (VDMSO 15 L), [Sub] 5 mM, [Cofactor] 50 M, [Sav] 100 M, [MES-
buffer] 50 mM, pH 5, 37 °C for 24 h except optimized reaction conditions* for 6-exo-dig: Vtot 400 L 
(365 L of MES-buffer, 50 mM, pH 5) [Sub] 2.5 mM, [biot-Au 2] 2.5 M, [Sav] 5 M, 39 °C for 72 h and 
for 5-endo-dig: Vtot 100 L (VMES 45 L,), [Sub] 15 mM, [Diamide] 15 mM, [biot-Au 2] 100 M, [Sav] 
200 M, 37 °C for 72 h. Reprinted with permission from Springer Nature.73 
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Having engineered an evolvable hydrophobic environment lining the biotin-binding vestibule 
and identified promising residues, we set out to optimize the HAMase by directed evolution. 
Building on the computational insight, we selected biot-Au 2 · Sav-SOD K121A as starting 
scaffold for the iterative saturation mutagenesis. The free cofactor biot-Au 2 did not display 
significant HAMase activity in the absence of Sav, either using MES buffer or cfe, Table 1 and 
SI Table 4. We hypothesize that as biot-Au 2 is insoluble in the aqueous cfe, the gold is 
shielded from poisoning by the cellular debris (in particular soluble thiols). Upon 
compartmentalization within Sav, a soluble and active ArM results, whereby the protein 
(partially) shields the cofactor from these detrimental metabolites, thus restoring catalytic 
activity, as previously observed in related studies.93,124 We were delighted to observe HAMase 
activity upon addition of biot-Au 2 to E. coli cfe (BL21 DE3) containing Sav and Sav-SOD, SI 
Table 4 and SI Figure 10. This strategy allows bypassing the laborious protein purification 
step and complements our previous high-throughput screening platforms based on periplasmic 
and surface-display.10,31,32,125–127  
Table 1 Selected Results of evolved ArMs using purified HAMasesa. Best hits for either regioisomer are 
highlighted in boldb,c and were tested on preparative scaled,e.  
Entry Sav-Mutants Total TONa Selectivity (3:2) 
1 no streptavidin 0.3 ± 0.1 100:0 
2 Sav K121A 21.2 ± 0.9 82:18 
3 Sav-SOD K121A 39.3 ± 1.9 62:38 
4 Sav-SOD N118G K121G S122G 57.5 ± 4.7 45:55 
5 Sav-SOD S112N N118G K121G 
S122G 
64.6 ± 2.1 32:68 
6 Sav-SOD S112N T114S T115N 
N118G K121G S122G 




7 Sav-SOD N118S K121F S122G 38.6 ± 1.0 99:1 
8 Sav-SOD S112T N118S K121F 
S122G 
42.0 ± 1.1 97:3 
9 Sav-SOD S112T T115A N118S 
K121F S122G 




aThe analytical experiments were carried out in quadruplicates. The combined turnover 
for both products in relation to [biot-Au 2] is displayed as well as the 
quinazolinone:indole ratio (3:2) with standard reaction conditions: Vtot 200 L (VDMSO 
15 L), [Sub] 5 mM, [biot-Au 2] 50 M, [Sav] 100 M, [MES-buffer] 50 mM, pH 5, 
37 °C for 24 h.; bOptimized reaction conditions 5-endo-dig with the following changes: 
Vtot 100 L (VMES 45 L, VDMSO 20 L), [Sub] 15 mM, [Diamide] 15 mM, [biot-Au 2] 
100 M, [Sav] 200 M, 37 °C for 72 h; cOptimized reaction conditions 6-exo-dig with 
the following changes: Vtot 400 L (365 L of MES-buffer 50 mM, pH 5) [Sub] 2.5 mM, 
[biot-Au 2] 2.5 M, [Sav] 5 M, 39 °C for 72 h; dPreparative reaction (0.2 mmol): 72% 
yield of indole 2 and 6% yield of quinazolinone 3; ePreparative reaction (0.1 mmol): 
47% yield of quinazolinone 3 and no isolable trace of indole 2. 
 
First, positions N118, K121 and S122 were mutated simultaneously using a library consisting 
of NDT codons at these three positions, Figure 5 a, SI Table 5 and SI Figure 11.128,129. For 
this purpose, thirteen 96-well plates, representing 24% coverage, were grown. Each well was 
subjected to a biotin-4-fluorescein (B4F) binding assay to identify biotin-binding Sav-SOD-
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mutants that were then evaluated in catalysis. Twelve hits including Sav-SOD N118G K121G 
S122G (GGG hereafter) and Sav-SOD N118S K121F S122G (SFG hereafter) were quantified 
by UPLC-MS and displayed either the highest TON or the highest regioselectivity. They were 
sequenced, expressed, purified by affinity chromatography and tested in vitro. Next, the twelve 
hits were subjected to another round of directed evolution targeting position S112 with 18-
possible amino acid combinations using VMA and NDT codons. The best six hits were 
expressed, purified and evaluated. Mutants Sav-SOD S112N N118G K121G S122G (N-GGG) 
and Sav-SOD S112T N118S K121F S122G (T-SFG) were identified as most promising for 5-
endo-dig product 2 and 6-exo-dig product 3 respectively. These two quadruple mutants were 
subjected to another round of mutagenesis, targeting simultaneously positions T114 and T115. 
From this screening campaign, the following trends emerge: i) large amino acids at position 
K121 favor the 6-exo-dig product 3, suggesting that the clashes observed via computational 
studies between K121 and the -gold intermediate are also valid for other mutants. ii) 
Reactions conditions used for cfe experiments tend to generally favor the formation of 6-exo-
dig product 3. iii) After two rounds of directed evolution starting from Sav-SOD K121A, clear 
evolutionary trajectories favoring either regioisomer emerge (scaffold GGG favors the indole 2 
and SFG favors the quinazolinone 3 pathways respectively), Figure 5 b and SI Figure 10. To 
validate these trends, the most promising Sav chimeras were expressed in shake flasks and 
purified. Significant improvement of activity and selectivity over various generations were 
observed. Ultimately, we identified two chimeras Sav-SOD S112N T114S T115N N118G 
K121G S122G (N-SN-GGG) and Sav-SOD S112T T115A N118S K121F S122G (T-A-SFG) 
for the production of either regioisomer: biot-Au 2 · Sav-SOD T-A-SFG and Sav-SOD N-SN-
GGG afforded 333 and 51 TONs with a ratio 3:2 of 99:1 and 4:96 respectively, Figure 5 c, 
Table 1 and SI Table 6. To further validate these results, the two best chimeras were scaled-
up (> 500 mg) and the two HAMases were tested on preparative scale (0.1 mmol and 0.2 mmol 
respectively): biot-Au 2 · Sav-SOD T-A-SFG afforded quinazolinone 3 with 47% isolated yield 
and no isolable amount of indole 2 (> 99:1 regioselectivity) while biot-Au 2 · Sav-SOD N-SN-
GGG afforded quinazolinone 3 and indole 2 in 6% and 72% isolated yield respectively 
(8:92 regioselectivity), SI Figure 12-15.  
To confirm that the 5-endo-dig product 2 isolated using the evolved HAMase Sav-SOD N-SN-GGG 
and Sav-SOD T-A-SFG indeed results from a dual-gold mechanism –rather than a single-gold 
mechanism– we carried out preparative-scale reactions in D2O. The dual activation mechanism 
proceeds via a di-aurated intermediate, which then undergoes deutero-deauration to regenerate 
the catalyst and release the (di-deuterated) product 2-d2, SI Figure 16. Gratifyingly, both 1H-NMR 
and HR-MS studies confirm that the isolated indole 2-d2, is indeed equally di-deuterated at its C2 
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and C3 position (> 98% by 1H-NMR), SI Figure 16-17. We thus conclude that the formation of the 
indole 2 through either evolved HAMase indeed proceeds via a dual-gold mechanism. 
Finally, six structurally-related ethynylureas 1a-1f were tested for their regioselective 
cyclization in the presence of the two evolved chimeric HAMases, Table 2 and SI Table 7. In 
some cases, the limited solubility and water-stability of these aromatic ureas proved 
challenging. Nevertheless, both chimeras afforded preferentially either the quinazolinone- 
(Sav-SOD T-A-SFG) or the indole products (Sav-SOD N-SN-GGG). 
Table 2 Substrate scope using the fourth generation of biot-Au 2 · Sav-SOD mutants obtained with the 
optimized reaction conditions for either 5-endo-diga or 6-exo-digb products.  






































The experiments were carried out in duplicate. The combined turnover for both products is displayed in 
relation to [biot-Au 2] as well as the quinazolinone:indole ratio (3:2). aOptimized reaction conditions 5-endo-
dig: Vtot 100 L (VMES 45 L, VDMSO 20 L), [Sub] 15 mM, [Diamide] 15 mM, [biot-Au 2] 100 M, [Sav] 200 M, 
[MES-buffer] 50 mM, pH 5, 37 °C for 24 h; bOptimized reaction conditions 6-exo-dig: Vtot 400 L (VMES 365 L, 
VDMSO 12 L) [Sub] 2.5 mM, [biot-Au 2] 6.25 M, [Sav] 12.5 M, [MES-buffer] 50 mM, pH 5, 39 °C for 48 h; c 
with following changes: [biot-Au 2] 2.5 M, [Sav] 5 M, for 24 h. For a summary of results using the 
unoptimized reaction conditions used in Table 1, see SI Table 7. 
 
3.4 Conclusion 
Natural metalloenzymes often rely on dual-catalysis to functionalize challenging substrates. 
Capitalizing on the unique topology of the biotin-binding vestibule of streptavidin, we designed 
an artificial hydroaminase that proceeds via a -activation of a terminal alkyne by two 
biotinylated gold cofactors. To ensure the positioning of the two gold moieties, streptavidin’s 
biotin-binding vestibule was equipped with a hydrophobic lid, borrowed from superoxide 
dismutase c.111 In silico modelling of the resulting chimeric HAMase provided insight into the 
two mechanistic manifolds, and revealed close-lying amino-acid residues to target by directed 
evolution, to favor the preferential formation of the anti-Markovnikov product indole 2 over the 
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Markovnikov product quinazolinone 3. These two products result from the dual-gold -
activation and the single gold -activation reaction manifolds respectively. Thus far, 
optimization of ArMs’-performance was mostly focused on optimizing enantioselectivity.77 In 
addition to displaying remarkable levels of enantiocontrol, enzymes excel at imposing catalyst 
control to address regioselectivity challenges. Herein, we combined protein engineering and 
directed evolution to fine-tune the second coordination sphere around the abiotic cofactor to 
control the regioselectivity of the hydroamination reaction. Despite its pronounced thiophylicity, 
the biotinylated cofactor biot-Au 2 could be used in the presence of E. coli cell free extracts, 
thus significantly simplifying the directed evolution campaign. We tentatively assign this feature 
to the cofactor’s insolubility in the reaction medium. Upon solubilization resulting from binding 
to Sav, the cofactor is partially shielded from thiols thus affording biocompatible, active and 
selective artificial hydroaminases. Current efforts are aimed at integrating this versatile dual-
activation reaction in vivo to complement the natural metabolism. 
3.5 Appendix: Mechanistic Studies 
Asensio and co-workers initially explored the alternative reaction pathways from the metal-
catalyzed hydroamination of these aromatic ethynylureas by combining deuteration 
experiments and x-ray diffraction.96 They were successful in preparing and crystallizing -
coordinated gold-acetylide complexes from the trimethylsilane adduct in stoichiometric 
amounts of gold complex. In the presence of additional gold complexes, these -coordinated 
complexes regioselectively reacted to form aurated indoles. In contrast, the same gold 
complexes catalyzed the conversion of urea 1 to quinazolinone in the absence of base, while 
in the presence of base, indole was formed, Figure 6. In the 5-endo dig cyclization leading to 
the corresponding indole, the preformation of a -coordinated complex was determined to be 
a crucial factor for the regioselectivity of the reaction. The formation of this intermediate can 
occur either in the presence of a strong base (e.g. triethylamine) or via -coordination of two 
gold species. 
 
Figure 6 Gold(I)-catalyzed hydroamination of urea 1 and its corresponding gold-acetylide performed by 
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Asensio and co-workers.96 Reprinted with permission from Springer Nature.73 
In order to provide strong evidence, that the regioselectivity was indeed predominantly directed 
by the coordination mode of the gold cofactors and not by basic amino acids or other reagents, 
we conducted a set of deuteration experiments complementary to the experiments performed 
by Asensio and co-workers. Instead of following the fate of a deuterated alkyne in a sealed 
reaction at -30 °C which is not transposable to biorthogonal chemistry, Figure 7, we performed 
the opposite: we investigated the deuterium incorporation into the corresponding products (2 
and 3) by performing the reaction in D2O, Figure 8. It did not allow us to monitor the 
incorporation of deuterium into the quinazolinone, as these methylene protons are too acidic 
and reversibly exchanged in water. This phenomenon was observed by Asensio and co-
workers and forced them to conduct their experiments in a dry environment at low 
temperatures. However, by characterizing the indole from reactions ran in D2O we can 
determine whether the 5-endo dig product was formed via base-assisted -coordination (which 
should yield mono-deuterated indole) or via -coordination of two gold centers (which, upon 
protodeauration, would yield di-deuterated indole 2-d2).  
 
Figure 7 Low-temperature deuteration experiments performed by Asensio and co-workers.96 
Gratifyingly, we isolated di-deuterated indole 2-d2 with over 98% double-deuterium 
incorporation at the C1 and C2 positions. We further highlighted that no reversible proton-
deuterium exchange occurs at these positions. Shaking a sample of indole 2-d2  in the 
presence of H2O (37 °C, 16 h) did not lead to any deuterium-hydronium-scrambling. 
Furthermore, shaking a sample of indole 2 in D2O did not lead to any deuterium incorporation 
in C1 and C2, Figure 9. We thus conclude, that the two deuterion detected on indole 2-d2 via 
1H NMR and HR-MS were a result of the dual-coordination of two gold-species in a -






Figure 8 Isotopic product-distribution of the HAMase biot-Au 2 · Sav-SOD N-SN-GGG carried out 
in D2O. a Deuteration profile of quinazolinone 3 and indole 2 resulting from the gold-catalyzed 
hydroamination. For the quinazolinone 3, all highlighted protons/deuterons are readily exchanged in 
D2O/H2O; b 1H NMR analysis of the indole 2-d2 isolated from preparative reactions in H2O (top) and D2O 
(bottom, the urea N–H is readily exchanged in the presence of traces of H2O) and c HR-MS analysis of 
2-d2 resulting from the reaction performed in D2O. Reprinted with permission from Springer Nature.73 
We further highlighted, that spontaneous proton-deuterium exchange occurs on the methylene 
moiety of quinazolinone 3 through similar experiments via 1H NMR and HR-MS. In contrast to 
indole 2, quinazolinone 3 revealed the incorporation of up to three deuterion in the presence 





Figure 9 Stacked 1H NMR spectrum confirming the inertness of indole 2 and 2-d2 towards deuterium-
proton exchange at the indole’s C2 and C3 positions (highlighted in red). In contrast, the urea proton 
(blue) is readily exchanged. Reprinted with permission from Springer Nature.73 
We further tried to crystallize the acetylide gold-complex in the protein by adding urea 1 or the 
corresponding N,N-dimethylated urea to crystal samples of various biot-Au 2 Sav chimera 
without success. We hypothesize that by methylating the urea moiety, the substrate may still 
coordinate with the acetyl moiety to the gold cofactors but resist intramolecular 
hydroamination. Unfortunately, most crystals dissolved upon addition of substrate. The few 
that survived did yield an X-ray diffraction pattern, but with no electron density corresponding 
to any substrate derivative. 
reference indole 2  
recorded in DMSO-d6 
indole 2 isolated from the HAMase 
carried out in H2O stirred at 37 °C for 
16 h in D2O prior to 
1H NMR, 
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Following purification, 2-d2 was 
dissolved in H2O:DMSO-d6 and 
stirred at 37 °C for 16 h prior to  
1H NMR, spectra recorded in 
H2O:DMSO-d6 (2:1) 
indole 2-d2 isolated from the 
HAMase carried out in D2O 





Figure 10 Stacked 1H NMR spectrum displaying the autodeuteration of quinazolinone 3 in D2O on the terminal 
alkene. Such a rapid H-D exchange in quinazolinone 3 was already reported by Asensio and co-workers96. 
Reprinted with permission from Springer Nature.73 
 
Figure 11 HR-MS Spectrum of quinazolinone 3 injected (a) from H2O:MeCN (1:1) over direct injection (DI), (b) 
from D2O:MeCN (1:1) over DI and (c) from D2O:MeCN (1:1) over HPLC into HR-MS displaying the autodeuteration 
of quinazolinone 3 in D2O and the subsequent proton/deuterium exchange when submitted to HPLC. Reprinted 
















































200 210 220 230 240 250 260 270 280 290 m/z
a b c 
23 
 
3.6 Appendix: Cooperativity Studies 
Our best ArM biot-Au 2 · Sav-SOD N-SN-GGG yielded 96% of 5-endo dig indole 2 as a result 
of optimized dual-gold catalysis. Such high 5-endo dig selectivities through the stochastic 
assembly of two monomeric gold species into two adjacent catalytic pockets would be 
improbable for a tetrameric scaffold. Under normal conditions, the side-by-side pattern occurs 
in three out of six (seven, if one counts the empty Sav) different assembly patterns of the ArM, 
Figure 12. This leaves three other patterns with only one bound cofactor, capable of only 
performing single-gold catalysis. In the best case scenario, where side-by-side incorporation 
always produces the 5-endo dig product at similar reaction rates, we would anticipate a 
maximum of 50% of dual gold catalysis leading to a maximum of 50% 5-endo dig indole 2. 
 
Figure 12 Incorporation pattern for Sav-SOD-based ArMs. a Incorporation pattern allowing for dual-
catalysis due to the side-by-side incorporation of two cofactors. b Incorporation pattern with only 1 
cofactor per dimeric unit only capable of single-catalysis. 
We hypothesized that for our best 5-endo dig ArMs, there could be two additional factors 
contributing to such high regioselectivity outside of chemogenetic optimization: (i) the reaction 
rate of the single-gold site could be drastically reduced by selected amino acid residues, thus 
mono-occupied sites are “turned off” and (ii) the cofactor could be preferentially incorporated 
as a dimer (cooperativity) suggesting that the cofactor in solution may dimerize or agglomerate. 
There is some evidence for (i) and substantial evidence for (ii), it may well be a mixture of both.  
When evaluating the evolutionary trajectory of our ArMs, we can observe that from Sav-SOD 
GGG towards N-SN-GGG an increase in regioselectivity is predominantly achieved by 
decreasing the amount of 6-exo dig product and not by increasing the turnover of 5-endo dig 
product, Figure 5. This may be a small hint towards (i) but further evidence would be needed 
to validate this hypothesis. 
For our second hypothesis (ii), we gathered substantial evidence from HR-MS experiments, 
Diffiusion Ordered SpectroscopY (DOSY) and X-ray diffraction patterns. When investigating 
X-ray data of the ArM, we could observe full occupation of all biotin bindings sites by at least 
the ligand, some gold(I) may decompose under irradiation. This, in combination with HABA 
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titrations highlightes, that the ArM can be fully loaded with up to four cofactors. When 
investigating the free cofactors (biot-Au 1-5) in CD2Cl2 and the corresponding non-biotinylated 
gold complex analogues via DOSY, we could observe a significantly lower diffusion constant 
even considering the molecular weight difference, Figure 13, SI Table 8. Rough estimates, 
derived from the diffusion coefficients, suggest a predominantly dimeric nature of biot-Au 1-5 
in CD2Cl2.  
 
Figure 13 Aggregation of biotinylated gold complexes. (a) Overlay of recorded DOSY spectra for 
various gold complexes (b) Graphical representation of the estimated aggregation states calculated from 
the corresponding diffusion coefficients and adjusted to the molecular weight of the corresponding 
complex in relation to boc-Au 2. (c) Dynamic equilibrium of biot-Au 2 in solution 
HPLC into HR-MS spectra of biot-Au 1-5 display clear patterns for dimeric aqua-complexes 
with the corresponding isotope patterns resulting from the same HPLC peak, Figure 14 a-b. 
While recording native MS spectra of biot-Au 2 in different Sav at high cone voltages a large 
peak at m/z=1551 arouse which may indicate the release of dimeric biot-Au 2 under such 
harsh conditions, Figure 14 c. This pattern is identical to dimeric isotope patterns recorded 
from direct injection into HR-MS, Figure 14 d. 
Catalytic experiments were conducted where: (i) the ratio of cofactor to BBS was varied and 
(ii) the ArM was titrated with biotin, Figure 15 and Figure 16. Interestingly, Sav-SOD N-SN-
GGG displays a completely different reactivity- and selectivity pattern compared to Sav-SOD 
T-A-SFG: While for T-A-SFG the amount of 5-endo dig product seems to increase almost 
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linearly with higher cofactor:BBS ratio at low levels. For N-SN-GGG the ratio increases from 
0.125 to 0.75 cofactor:BBS drastically and then remains constant. It must be pointed out, that 
even at such low cofactor:BBS ratios as 0.125, quinazolinone is still produced with >40% 
selectivity. This kind of behavior again hints towards the incorporation of two biot-Au 2 
simultaneously. However, we know that in the case of biotin to Sav titration, no cooperative 
effect occurs. Therefore, we titrated the protein with biotin before addition of the cofactor. We 
maintained standard reaction conditions using 0.5 eq of cofactor per BBS. As biotin is 
incorporated randomly, it would stochastically block BBS and drastically reduce the 
Figure 14 HR-MS spectrum of dimeric gold complexes. a HPLC chromatogram of biot-GlyAu 2  
indicating a single peak with, b two species recorded on the connected HR-MS: the monomer and 
the dimer. c Native-MS spectrum at maximum cone-voltage displaying the release of biot-Au 2-
aquadimer complex in aqueous solution from streptavidin wild type soaked with the gold complex. 
d HR-MS (DI) spectrum of biot-Au 2 with the recorded dimeric species. 
Figure 15 The influence of different cofactor/BBS ratio on the catalytic performance of the 
ArM. a Catalytic experiments with Sav-SOD N-SN-GGG displaying saturation in selectivity at 0.5 
eq of cofactor/BBS and in reactivity at 1.0 eq of cofactor/BBS. b Catalytic experiments with Sav-
SOD T-A-SFG displaying continues increase in reactivity and linear increase in indole 2 at low 
levels with increasing amounts of cofactor. 
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incorporation of biot-Au 2-dimer in a side-by-side manner. The catalytic results support this 
hypothesis. For N-SN-GGG, the reactivity is completely shut down by adding only 0.5 eq of 
biotin per BBS. This means, when half the BBS are available the ArM is almost incapable of 
performing 5-endo dig cyclization. The ArM does not switch towards single-gold catalysis when 
the other binding sites are blocked by biotin. This is not true for the single gold 6-exo dig 
cyclization reaction: Titration T-A-SFG with biotin has almost no effect up to a ratio of 1 
biotin/BBS. Afterwards the reactivity steadily decreases but is still maintained at lower levels 
even after addition of 4 biotin/BBS.  
 
Figure 16 Biotin titration experiment. a Titrating biot-Au 2 · Sav-SOD N-SN-GGG with biotin causing 
an almost complete shutdown in reactivity at 0.5 eq biotin/BBS. b Titrating biot-Au 2 · Sav-SOD T-A-
SFG with biotin causing slow and steady decrease in reactivity. 
All these results lead us to the conclusions that the biotinylated gold complexes are likely to 
dimerize and/or agglomerate. This may favour the cooperative incorporation of dimers into the 
protein in a side-by-side manner which is crucial for dual-gold catalysis. This behavior may 
increase the stability of these gold complexes in aqueous media. Furthermore, optimized dual-




3.7 Appendix: Linker Studies 
To improve dual-gold catalysis in the ArM, we hypothesized that a longer linker may position 
the gold centers in closer proximity, facilitating 5-endo dig cyclization. In a first attempt, we 
planned to extend biotin with an additional glycine residue, then couple it to the ligand and 
finally add gold, Figure 17. Glycine was coupled to biotin via either NHS-ester or peptide 
coupling to yield biot-Gly. A second peptide coupling allowed the addition of biot-Gly to the 
SIMes ligand in good yield (83%). Unfortunately, we were not able to introduce gold to this 
biotinylated ligand as the ligand decomposed and gold precipitated on the surface of the vial. 
Coupling biot-Gly to aurated SIMes boc-Au 2 was unsuccessful and yielded a complex 
mixture. 
 
Figure 17 Failed synthesis route of biot-GlyAu 2. This route is based on the pre-functionalization of 
the NHC-ligand with extended biotin and subsequent gold insertion. However, the insertion of gold on 
the biotinylated ligand was unsuccessful and led to precipitation. 
As a result, another strategy was pursued in which the ligand was first extended by boc-
protected glycine, followed by gold insertion and subsequent biotinylation, Figure 18. 
Gratifyingly, biot-GlyAu 2 was obtained in 24% yield over these three steps. Again, 
biotinylation proved challenging and drastically reduced the yield of the final product. 
Nonetheless, enough cofactor was obtained for characterization and a limited screening of Sav 
mutants. 
As expected, biot-GlyAu 2 did exceedingly well in producing the 5-endo dig indole 2, Figure 
19a. Over a set of 11 different Sav and Sav-SOD mutants, a rather consistent 60% to 80% of 
the product was indole 2. Thus, biot-GlyAu 2 did outperform biot-Au 2 in terms of 
regioselectivity towards indole 2 for this set of mutants. However, the fact that the 
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regioselectivity was only moderately influenced by the Sav isoform, over a very diverse set of 
mutants was concerning. While for biot-Au 2-based ArMs, both reactivity and selectivity could 
be markedly varied through genetic optimization of the scaffold, this may not be the case for 
biot-GlyAu 2, Figure 19 a-b. 
 
Figure 18 Synthetic route to biot-GlyAu 2. This route is based on the extension of the NHC-ligand 
with protected glycin followed by gold coordination and final biotinylation. 
Computational insight of the binding of both cofactors to Sav revealed, that biot-Au 2 is located 
closer to the surface of the binding vestibule due to the smaller linker length, Figure 20 a. 
When engaging in dual-gold catalysis, the transition state is again forced to be located closer 
to the protein surface, Figure 20 b. Interactions between the amino acids and the ligand as 
well as the substrate are frequent. In the case of biot-GlyAu 2, the cofactor is located further 
away from the protein surface, Figure 20 c. Extensive interactions between amino acid 
residues and glycine can be computed with only limited interaction of amino acids to the ligand. 
As a result, we concluded that although biot-GlyAu 2 performs well in 5-endo dig cyclization, 
it is not suitable for ArM-design as in our experiments it displayed limited sensitivity to genetic 
optimization. Accordingly, directed evolution on this ArM may be challenging. 
 
Figure 19 Sav and Sav-SOD mutant screening with biot-Au 2 and biot-GlyAu 2. a While 
proteinogenic variation of the Sav and Sav-SOD constructs had limited effect on the regioselectivity of 




Figure 20 Comparison of biot-Au 2- and biot-GlyAu 2-based ArMs and transition states via 
molecular modelling. a Comparison of the incorporation depth of biot-Au 2 (pink) and biot-GlyAu 2 
(cyan) into the biotin binding pocket. b Dual-gold transition state of two biot-Au 2. c Dual-gold transition 
state of two biot-GlyAu 2. 
 
3.8 Appendix: Unreactive Substrates for Dual-Gold Catalysis 
Would it be possible to translate our dual-gold catalysis system towards alkenes? The group 
of Hartwig has developed interesting rhodium-based catalysts capable of catalyzing the 
regioselective intramolecular hydroamination of vinyl arenes, however with no 
enantioselectivity, Figure 21.130,131 Our plan was to utilize the regioselectivity of our dual-gold 
system and combine it with potential enantioselectivity directed from the protein itself to 
optimize the enantioselective intramolecular hydroamination of vinyl arenes 13 
enantioselectively towards the desired regioisomer. We followed the synthetic procedure of 
Hartwig and co-workers and prepared vinyl arene 13 in four steps from phenyl butanoic acid 
16, Figure 22. Unfortunately, we could not detect any of the desired reaction products when 
screening a small set of Sav-SOD constructs with biot-Au 2 (MES buffer pH 5, 37 °C, 24 h). 




Figure 21 The gold-catalyzed hydroamination of vinyl arene 13 may lead to various regio- and/or 
enantiomers. 
 







4. Chapter 2: Systematic Screening of Gold-based ArMs 
 
 
Vornholt, T., Christoffel, F., Pellizzoni, M., Panke, S., Ward, T. R. & Jeschek, M. 
Systematic Engineering of Artificial Metalloenzymes for New-to-Nature Reactions. 




4.1 Outline of the Authors Contribution 
MJ and TRW conceived and supervised the study. S.P. advised the project. FC and MMP 
developed the gold-catalyzed indole and coumarin cyclization in vitro. FC synthesized the 
corresponding substrates and cofactors. TV prepared the Sav library and carried out the 
biological systematic screening experiments as well as the machine learning studies. TV 
designed the original versions of Figure 25-26, which were modified by FC and reprinted with 
permission from TV and the publisher AAAS.  
4.2 Introduction 
ArMs can display remarkable performance for biorthogonal reactions under mild reaction 
conditions while protecting the cofactor from poisoning by biomolecules. These features 
allowed several groups to utilize ArM technology for in vivo applications.67,125,126,132 The 
possibility of performing abiotic reactions in vivo may be translated to enable the on-site 
synthesis of crucial metabolites and/or derivatives thereof in an organism. The potential of 
substituting, complementing and/or diversifying the natural metabolism opens the door for a 
wide field of applications including (i) the continuous evolution of ArMs in a Darwinian spirit 
through selection pressure to optimize catalytic efficiency, (ii) the treatment of metabolic 
disease through the substitution of defective metabolic routes via ArM cascades, (iii) the 
adaptation of microorganisms to synthetic metabolites (xeno-nutrients)133, and (iv) the 
regulation of microorganism behavior through incorporation of artificial metabolism sensitive to 
physical or chemical properties such as light, pH, etc. 
In order to investigate these ambitious metabolistic challenges, a catalytic system would be 
required that displays a strong (chemical) signal over a noisy (biochemical) background 
present in a living cell. A strong signal can be achieved by utilizing an efficient catalysts with 
high TONs and by focusing on metabolites that already have a large impact when present at 
low quantities such as tryptophan and/or proline.134 A way of reducing the background is the 
design of auxotroph organisms. Crucial metabolites will be delivered through the medium and 
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gradually decreased with the increase in efficiency of the ArM. Specifically, when utilizing ArM 
technology, it must be assured that the free cofactor does not significantly contribute to the 
biochemical background of the system. Sav-technology turns out to be a promising system, 
due to the strong binding of the cofactor and the capability of accelerated catalysis through 
assembly of the ArM (i.e. protein-acceleration catalysis). An optimal case would be, if the 
cofactor employed is only activate once incorporated into the ArM.  
Our newly designed Au(I)-Sav system displayed many desired features required for the 
implementation into artificial metabolism: (i) the ArM proved stable under physiological 
conditions, (ii) the ArM performed biorthogonal reactions, (iii) the free cofactor was significantly 
less active than the ArM and finally (iv) the catalytic activity and selectivity could be improved 
by genetic optimization of the protein. As a result, we investigated the competence of Au(I)-
Sav systems to catalyze the production of key metabolites including indole (for Trp) and 
dehydro-L-proline (for Pro). Furthermore, we explored the possibility of preparing key API-
building blocks and fluorescent molecules with this system. 
4.3 Results and Discussion 
For our first project, the synthesis of indole 2 via hydroamination of 2-ethynylaniline 1, we 
started by screening biotinylated cofactors biot-Au 1-2 in MES buffer, Figure 23. Initial 
experiments were promising, as indole was detected, albeit with moderate TON. This was not 
such a big concern, as the free cofactors displayed a much lower activity. However, all samples 
contained significant amounts of side products. We verified, that the first side product was the 
hydrated substrate aminoacetophenone 3 and hypothesized that the second side product may 
be the dimerized hydrated substrate 4. Fortunately, the hydration was a slow side reaction 
occurring in the background even in the absence of cofactor. With mutants displaying higher 
TONs towards indole, the ratio of indole/3 increased steadily. The same behavior was not 
observed for the dimeric side product, which only occurred in the presence of ArM. Higher 
TON of indole yielded higher amounts of dimer 4, albeit in such low quantity that we did not 
investigate the problem further. We were pleased to see, that such low concentrations of 3 
would not harm E. Coli and thus not prevent the system from being applied in vivo.  
From a small screening of all single mutants Sav K121X and Sav S112X, as well as some Sav 
L124X mutants, biot-Au 1 · Sav K121L was determined to be the most effective ArM 
(~30 TON) for this reaction. In contrast to the previous chapter, biot-Au 1 clearly outperformed 





Figure 23 In vitro optimization of the hydroamination of 2-ethylynaniline. a  The reaction of 2-
ethynylaniline leads to the formation of indole, aminoacetophenone (AAP) and a dimeric species of AAP. 
b  With increasing activity of the ArM the ratio of indole/AAP changes in favor of indole. c  Display of the 
five best Sav K121X single mutants. d  Display of the best S112X single mutants. e  Display of the four 
best L124X single mutants. Reaction conditions: [biot-Au] = 10 M; [Sav] = 20 M; [Sub] = 1 mM; in 
200 L, 37 °C for 24 h 
As we were not only interested in complementing the natural metabolism in E. coli but also in 
designing simpler methods to optimize ArMs, we started investigating fluorescent reactions in 
parallel to the hydroamination. HPLC analysis is often the bottleneck of directed evolution. 
Samples need to be purified (centrifugation, filtration), diluted, and successively injected into 
an HPLC/UPLC. The analysis of a single 96-well plate can take up to ~10 h (UPLC with ~5 min 
method) to ~72 h (HPLC with ~40 min method). On the other hand, a Tecan plate reader can 
analyze a 96-well plate in under 5 min with no laborious purification steps prior to analysis. For 
this reason, we investigated the hydroarylation of coumarin derivatives, Figure 24 a. The aryl-
phenylpropiolate 5 can be readily prepared from phenylpropiolic acid and 3-
(diethylamino)phenol via a Steglich esterification. The corresponding product is non-
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fluorescent. Upon gold-catalyzed hydroarylation, a green, fluorescent phenyl-coumarin 
derivative 6 is obtained. The strong fluorescence of the product allows  to monitor the 
conversion via Tecan plate reader. We screened a selection of Sav mutants (Sav WT, Sav 
K121A, Sav K121L, Sav K121I) and cofactors (biot-Au 1-5) at two different ArM concentrations 
(10 M and 1 M). The first two rows of the plate contain a dilution line for the calibration curve 
in doublets. The other rows contain various Sav mutants, while the columns contain different 
cofactors, except the first column which contains the substrate with only the protein. The third 
and the ninth column contains ArMs with biot-Au 2. Already by eye, one can see, that biot-
Au 2 outperforms all other cofactors, Figure 24 b. Fluorescent read confirms the observation, 
Figure 24 c. Unfortunately, one can also see a very noisy fluorescent read. We could detect a 
decrease in fluorescence in the dilution line as well, indicating that the product either 
decomposes, auto-quenches or disappears (i.e. absorbed in plastic well-plate?), Figure 24 d. 
Nonetheless, biot-Au 2 · Sav K121A and biot-Au 2 · Sav K121A clearly outperform ArMs 
based on other cofactors over the whole reaction timeline. We decided to proceed with biot-
Figure 24 vitro optimization of the hydroarylation of phenylpropiolate YY. a The hydroamination 
of phenylpropiolate YY yields phenyl coumarin XY. b Dark 96 well screening plate under the UV lamp 
after 24 h of reaction time. c Screening results of the 96 well plate obtain via TECAN fluorescence 
measurement. Highlighted are the best performing ArMs. Reaction conditions: [biot-Au] = 10 M; [Sav] 
= 20 M; [Sub] = 1 mM; in 200 L, 37 °C for 24 h. d Average decrease in fluorescence of the most 




Au 2 for the systematic screening of further Sav isoforms for the hydroarylation. Despite the 
noisy background, the performance order of the ArMs is consistent over the whole reaction 
time. 
Having determined the optimal cofactors for hydroamination (biot-Au 1) and hydroarylation 
(biot-Au 2) we systematically screened Sav S112X-K121X double mutants via a periplasmic 
expression system.95 An universal and automated screening protocol on a robotic platform was 
developed by TV and MJ that facilitated the screening of improved ArMs (Ruthenium- and 
Gold-based) for diverse reactions (metathesis, coumarin-deallylation, indole-deallylation, 
hydroamination and hydroarylation),Figure 25 a. However, herein we will only focus on the 
hydroamination (I) and the hydroarylation (II), Figure 25 b-d.  
In order to achieve a good trade-off between accessibility to the cofactor, expression levels, 
and compatibility of the reaction a periplasmic expression system was implemented. Therein, 
a signal peptide of the outer membrane protein A (OmpA) was N-terminally fused to T7-tagged 
streptavidin.30 
Figure 25 Systematic screening of gold-based hydroaminases and hydroarylases. a. Overview 
of the screening workflow. Circular arrows represent centrifugation steps for buffer exchange. b Cell-
specific activity of 400 ArMs mutated at Sav positions 112 and 121 normalized to the activity of wild-
type Sav (S112 K121). The displayed activities are product concentrations after 20 hours of reaction 
(mean of biological duplicates). Note that the screenings for reactions II was performed using robotics. 
c Activity distribution in the Sav mutant library for the two ArM reactions. Violins comprise 400 double 
mutants with the 10 most active ArMs depicted as circles. d Validation of hits from the 400 mutant 
screens. Bars are mean activity of eight biological replicates with SD (error bars) and individual 
replicates (circles). Mutants are designated by the amino acids in positions 112 and 121. Modified 
and reprinted with permission from TV and AAAS.95 
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Then, a full factorial and sequence-verified library consisting of all 400 double-mutants of Sav 
S112X-K121X (X representing all 20 canonical amino acids) was prepared. This allowed for a 
systematic sequence-activity landscape for the two gold-catalyzed reactions, Figure 25 b. A 
substantial variation of the activity pattern was observed between the two gold-catalyzed 
reactions indicating the existence of distinct interactions between cofactor, protein and 
substrate. Interestingly, the most promising mutations from the initial in vitro screen, namely 
K121L for the hydroamination and K121A for the hydroarylation are also present in the top 
three of the whole-cell screening, Figure 25 c-d. For a final validation, the three most-active 
double-mutants for the hydroamination (Sav S112F K121Q, Sav S112L K121L and Sav S112D 
K121L) and the hydroarylation (Sav S112L K121G, Sav S112F K121G and S112G K121A) 
were purified and tested in vitro, Figure 26 a. Substantial improvement of up to 7-to 10 fold 
was recorded over Sav WT and/or free cofactor. However, the ranking of corresponding Sav 
hits changed from in vivo to in vitro, likely due to the change in reaction conditions. 
A further benefit of using sequence-verified libraries is the exploration of the relation between 
biophysical properties and catalytic activity. Corresponding spider graphs are an effective way 
to simultaneously visualize the effect of individual amino acids and biophysical properties for 
different positions. Herein, positive deviations from zero indicate a beneficial effect on catalysis 
by the individual amino acid and vice versa. Amino acids are clustered by biophysical 
Figure 26 Amino acid effects and implications for future ArM engineering. a In vitro turnover 
number of ArM variants identified in the periplasmic screening. For each reaction, the three most active 
variants identified in the whole-cell screening were purified, and their TON was determined. Reactions 
were carried out at 37 °C and 200 rpm for 20 hours. Bars represent mean TONs of technical triplicate 
reactions with SD as error bars and individual replicates as circles. For comparison, the free cofactor 
and wild-type Sav variant (wt) were included. Mutants are designated by the amino acids in positions 
112 and 121. b Effect of amino acids on ArM activity. Points outside and inside the dark gray circles 
indicate a positive and negative effect, respectively. Values were standardized by subtracting the mean 
activity of all 400 mutants and dividing by the corresponding SD. The mean across all 20 variants 




properties. A general trend emerges, where hydrophobic and aromatic amino acids provide a 
positive effect, while basic amino acids seem to be rather detrimental, Figure 26 b. 
4.4 Conclusion 
In the first chapter, randomized iterative saturation mutagenesis was used to obtain efficient 
and selective hexa Sav-SOD mutants for the hydroamination of aromatic ureas. Some 
advantages of this method include a simple library preparation (NDT-VMA codons), low 
sequencing cost (only ~3% of the wells were sequenced) and rapid exploration of multiple 
positions (6 positions). Even with an automation setup, it would be challenging to screen so 
many positions in a full-factorial library (64 000 000 reactions). In the near future, this may 
however not be necessary. Full-factorial libraries do not only allow detecting mutants that are 
the result of synergistic interactions (which can not be detected by iterative approaches), but 
they provide a full activity landscape of the ArM. This activity landscape can form a strong test 
set for machine learning approaches and guide directed evolution with yet unknown efficiency. 
Furthermore, this approach does not require any oversampling which drastically reduces the 
amount of catalyst and substrate required for the same number of positions. Herein, the two 
gold catalyzed reactions were significantly optimized and validated in vitro. The hit biot-
Au 1 ∙ Sav S112D K121L afforded indole with ~80 TON and may provide a good starting point 
for the directed evolution of Trp-deficient E. Coli in a Darwinian manner. 
4.5 Appendix: Unreactive Substrates & Proline Metabolism 
Other substrates were explored that upon reaction with gold-based ArMs could lead to crucial 
metabolites for E. Coli. As previous reports on the directed evolution of allylic deallylase of 
fluorogenic allyl-carbamate-protected coumarins gave promising TONs of up to 150 and could 
later be translated to the uncaging of indole with almost 600 TON, we hypothesized that we 
may be able to utilize gold-based ArMs to deprotect tert-butylcarbamate indole 7, Figure 27 
a.32,85,95,135 We could detect a modest increase (up to 50%) in the deprotection of tert-
butylcarbamate indole 7 in the presence of gold-ArMs compared to the background 
deprotection of the solvent, Figure 27 b. The improvement was marginal, and the background 
deprotection too significant. Such strong background reactions are not viable for in vivo design 




Figure 27 Gold-catalyzed deprotection of indole carbamates. a tert-butyl carbamate indole 7 is 
subjected to gold-catalyzed deprotection screening in aqueous conditions. b Screening results of tert-
butyl carbamate indole 7 displaying a strong background reaction with minor improvement in Sav WT 
and Sav K121L. Reaction conditions: [Au] = 5 M; [Sav] = 10 M; [Sub] = 5 mM; 37 °C for 24 h; analyzed 
via UPLC-MS. 
In a second attempt, we explored the hydroamination of 2-aminopent-3-ynoic acid 9 to 
dihydroproline 10 which upon reduction through Ec-proC could yield L-proline 11, Figure 28. 
Interestingly, the corresponding pro-dihydroproline could be synthesized stereoselectively 
from proline in five steps, Figure 29.136 Unfortunately, we were not able to detect any product 
from the reaction of various gold-based ArMs with the pro-hydroproline substrate. 
 
 
Figure 28 Hydroamination of 2-aminopent-4-ynoic acid 9 to 2,3-dihydroproline 10 with 











5. Chapter 3: Intramolecular Heck Reaction 
 
Christoffel, F. & Ward, T. R. Palladium-Catalyzed Heck Cross-Coupling Reactions 





5.1 Outline of the Authors Contribution 
TRW and FC conceived and designed the study. FC synthesized and characterized the 




Figure 30 Graphical abstract depicting a standard Heck cross-coupling reaction. Reprinted with 
permission from Springer Nature.137 
Palladium-catalyzed cross-coupling reactions have emerged as one of the most versatile tools 
in organic chemistry. Extensive efforts were made to adapt these reactions to aqueous media, 
not only for the purpose of environmental concerns but also to expand the scope, increase the 
efficiency and implement bio-compatible protocols. Among different palladium cross-coupling 
reactions, the Heck reaction turned out to be the most challenging in an aqueous environment, 
Figure 30. This led to various original developments in catalyst design. 
The Heck cross-coupling reaction (HCR hereafter) was discovered independently by T. 
Mizoroki in 1971 and R. F. Heck in 1972 and is generally referred to as the palladium-catalyzed 
arylation of olefins. In the presence of catalytic amounts of palladium, an aryl (pseudo)halide 
reacts with an alkene in the presence of a base to afford the corresponding arylated alkene, 
Figure 31.138,139 What first started as a method for the synthesis of stilbenes from styrenes 
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quickly developed into one of the most versatile and efficient reactions to synthesize 
substituted olefins both in academia and in industry. Together with Ei-ichi Negishi and Akira 
Suzuki, Richard F. Heck was awarded the Nobel Prize in Chemistry in 2010 “for palladium-
catalyzed cross-couplings in organic synthesis”.140 Among the reviews covering Pd-catalyzed 
cross-coupling reactions,141–144 one should mention the one by Beletskaya and co-workers145 
as it covers some of the most unique properties of the HCR. 
 
Figure 31 The Heck-Mizoroki cross-coupling reaction reported in the early 70s. 138,139 Reprinted 
with permission from Springer Nature.137 
Beside minimizing organic waste and avoiding hazardous reaction conditions, running Pd-
catalyzed cross-coupling reactions in water presents many benefits. Indeed, the use of water 
as a solvent offers the following attractive features: i) it may simplify the purification of the 
product; ii) it allows for an easy recovery and recycling of the catalyst iii) as water is one of the 
most polar solvents, it can accelerate catalysis by promoting the migratory insertion and 
protecting the catalyst by displacing labile ligands from its coordination sphere; iv) the use of 
water may invert the selectivity of intramolecular HCR and provide an environment for 
protective-group free synthesis of complex building blocks; v) Finally, efficient and robust 
aqueous Pd-catalyzed cross-coupling reactions have found use in bioorthogonal chemistry in 
vivo. 10,126,132,146–151 
In 1988, Beletskaya and co-workers discovered a ligand-free Pd(OAc)2-catalyzed reaction of 
water soluble arylhalides with acrylic acid in water in the presence of K2CO3 as base. High 
yields (> 95 %) were obtained using moderate reaction conditions (50-100 °C) which, at that 
time, were comparable to reactions performed under anhydrous conditions in polar aprotic 
solvents including MeCN, DMF, DMA, NMP, etc.152 Calabrese and co-workers reported in 1990 
the use of a sulfonated water-soluble phosphine ligand for aqueous Pd-catalyzed HCR, Figure 
32.153 Since 2000, many sophisticated Pd-based catalysts were developed for the aqueous 





Figure 32 First reports on aqueous homogeneous Heck reactions.152,153 Reprinted with permission 
from Springer Nature 
Previous efforts in transferring palladium catalysis towards biorthogonal chemistry via ArM 
technology were successful. These artificial Suzukiases149 and Heckases157 displayed 
remarkable stereo- and enantioselectivity but only limited stability with regards to the palladium 
cofactor. An oxygen-free environment and/or the addition of up to 75% organic solvent (DMF, 
DMSO, ethylene glycol) were required which restricts the use of such systems towards in vitro 
chemistry. With the goal to push ArM-based palladium chemistry in vivo and complement the 
natural metabolism, we set out to design an artificial Heckase based on the biotin-streptavidin 
technology and integrate it toward in vivo-production of tryptophan. 
5.3 Results and Discussion 
The goal of this project was to develop an artificial Heckase to prepare indole in vivo. 
Therefore, we needed to design (i) a biocompatible Heck reaction to yield indole, (ii) a 
biocompatible Palladium catalyst capable of binding to Sav, and finally (iii) integrate the 
corresponding Heckase into the in vivo-production of tryptophan. Unfortunately, we did not 
succeed with the first two targets and were thus not able to design an artificial Heckase for 
indole production. This chapter summarizes the challenges faced during this project in tackling 
pro-indole substrate synthesis, biotinylated Pd-NHC synthesis and the biostability of substrates 
and catalysts. 
The first attempt was to synthesize 2-iodo-N-vinylaniline from 2-iodo aniline. Interestingly, this 
rather simple small molecule was not commercially available and there were no reports on its 
synthesis, Figure 33 a. Nucleophilic substitution of vinyl halides with the aniline was not 
successful. It was quickly clear that the aniline had to be protected. During this project, we 
prepared boc-protected, formyl-protected, acetyl-protected, tosyl-protected and nosyl-




Figure 33 Substrate synthesis for the Heckase project. a The synthesis of indole via artificial 
Heckase from 2-iodo-N-vinylaniline. b The protection of 2-iodo aniline with boc, formyl, acetyl, tosyl and 
nosyl groups. 
Our next substrate attempt focused on boc-protected 2-iodo aniline 4, which was acetylated in 
very good yield to acetyl aniline 9, Figure 34. We hypothesized that upon reduction of 9, 
trapping of hemiaminal with TMS to yield 10 followed by elimination would yield boc-protected 
vinyl aniline 11. Unfortunately, TMS-protected hemiaminal 10 decomposed into a mixture of 
compounds. No vinyl aniline 11 was detected. 
 
Figure 34 Synthesis route towards boc-protected pro-indole 11. 
Another attempt focused on the olefination of formyl aniline 5 with the petasis titanocene 13, 
which can be readily prepared from titanocene 14, Figure 35. The reactions were not 




Figure 35 Synthesis route towards pro-indole 2 via petasis olefination. 
Next, we started from acetyl aniline 6, in the hope it would be less prone to decomposition 
compared to formyl aniline 5, Figure 36. We pursued two routes which both relied on the 
nucleophilic substitution of halides to aniline 6. We were again not able to couple 
dibromoethane, but traces of vinyl-acetyl aniline 15 could be detected. Unfortunately, we could 
not improve the nucleophilic substitution of vinyl bromide to aniline 6 to provide useful yields 
of 15. 
 
Figure 36 Synthesis route towards acetyl-protected pro-indole 15. 
Our final attempts relied on the use of sulfonamide protecting groups, Figure 37. We protected 
2-iodo aniline with tosyl and nosyl groups to yield 7 and 8 in very good yields. Attempts to 
directly couple vinyl bromide were not successful. However, upon reaction with dibromoethane 
we could generate bromoethyl anilines 17 and 19 in very good yields. Subsequent nucleophilic 
elimination with KOtBu yielded the sulfonamide-protected vinyl anilines 18 and 20 in moderate 




Figure 37 Synthesis route towards tosyl- and nosyl-protected pro-indole 18 and 20. 
Various attempts in deprotecting the sulfonamide without losing or destroying the vinyl moiety 
were not successful, Figure 38. Nosyl vinyl aniline 20 could be deprotected in the presence of 
HF and pyridine, the product isolated was however acetyl aniline 6. As a result, we decided to 
screen our Heck reactions with the corresponding sulfonamides 18 and 20. We hoped that 
eventually we could find a way to deprotect the corresponding sulfonamide indoles e.g. through 
thiols that can be found in E. Coli.  
 
Figure 38 Attempts to deprotect tosyl- and nosyl-vinyl anilines 18 and 20 to get pro-indole 2 
yielded acetyl aniline 6. 
We first screened various commercial palladium sources and ligands and quickly realized, that 
in pure degassed DMF, at 120 °C the intramolecular Heck reaction of tosyl vinyl aniline 18 
worked very well, Figure 39. However, upon addition of water most commercial sources did 
not perform at all. For this reason, we synthesized five different palladium complexes, four of 
them containing NHC ligands to test for aqueous intramolecular Heck reactions, Figure 
40.149,158–162  
 
Figure 39 Reaction screening for the intramolecular Heck reaction of tosyl-protected vinyl aniline 




Figure 40 Various Palladium complexes were prepared according to literature procedures.149,158–
163 
The corresponding Pd complexes performed very differently in 1:1 mixtures of DMF and water 
at 80 °C. While the three Pd-NHC complexes Pd2, Pd3 and Pd5 catalyzed the reaction rather 
well, Pd1 and biotinylated complex Pd4 did not display any activity, Table 3 entry 1-5. The 
addition of Sav WT to Pd4 did not improve catalysis. Next, we investigated more biocompatible 
reaction conditions (40 °C and 2:8 DMF:water) Table 3 enty 6-10. Sulfonated complex Pd5 
performed best with 90% conversion. However, in the absence of organic solvent (DMF) or 
base (NaOAc), Pd5 was inactive. We were planning to design a sulfonated and biotinylated 
Pd-NHC complex that would retain the activity of Pd5 but be susceptible to protein engineering 
on Sav. However, before starting such a synthetic endavour, we wanted to make sure that we 
could cleave of the protecting group to release the crucial metabolite indole in vivo. 
Unfortunately, we could not detect clean conversion of the nosyl substrate 20 to the 
corresponding indole. Upon catalysis a complex mixture of various products was obtained. 
Thus, we did not pursue the synthesis of more thiol-labile dinitrogenated substrates. We 
hypothesized that, thiols such as cysteine or glutathione that can be present in rather high 
concentrations in vivo may support the deprotection of the sulfonamide from the corresponding 
indole. However, we were unable to deprotect tosyl- or nosyl indole under biocompatible 
reaction conditions, Figure 41.   
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Table 3 Selected Results of Pd-catalyzed intramolecular Heck coupling of tosyl-protected 2-iodo-N-vinyl 
aniline with Pd1-5 in aqueous degassed DMF.  
Entry Palladium Catalyst Temperature Water content Conversiona 
0 - 80°C 50% 0% 
1 Pd1 80°C 50% 0% 
2 Pd2 80°C 50% 53% 
3 Pd3 80 C 50% 83% (27%b) 
4 Pd4 80°C 50% 0% (0%c) 
5 Pd5 80°C 50% 99% 
6 Pd1 40°C 80% 0% 
7 Pd2 40°C 80% 24% 
8 Pd3 40°C 80% 30% 
9 Pd4 40°C 80% 0% 
10 Pd5 40°C 80% 90%(0%d) 
aThe analytical experiments were carried out in duplicates with the following reaction conditions: Vtot 
400 L, [Sub] 10 mM, [Pdcat] 2 mM, [NaOAc] 4 mM, [AgOTf] 4 mM, 40 °C or 80 °C for 24 h. b In the 
absence of AgOTf. c In the presence of 2 eq Sav WT no improvement was detected. d No conversion in the 
absence of DMF, or NaOAc. Reactions run with other bases such as triethylamine gave lower conversion. 
 
 
Figure 41 Deprotection attempts of nosyl-protected indole 22 in the presence of various thiols. 
5.4 Conclusion 
In conclusion, we designed an intramolecular Heck reaction to yield protected indoles in 
aqueous mixtures at moderate temperatures. We faced synthetic challenges when designing 
unprotected enamine 2. Analogues thereof with labile protecting groups either decomposed or 
were synthetically challenging, while analogues bearing stable protecting groups generated 
indoles that couldn’t be deprotected under biocompatible conditions. These challenges, 
combined with the difficulty of preparing biotinylated Pd complexes, lead us to pursue the gold-
catalyzed hydroamination: commercial substrates could be converted to indoles without the 
need for additives, bases and/or degassed solvents. Furthermore, the biotinylated gold 




6. Chapter 4: Gold-triggered Drug-Release Systems 
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6.1 Outline of the Authors Contribution 
TRW, VS and FC conceived and designed the study. FC and VS developed the gold-catalyzed 
“close-to-release” cyclization of pro-furan substrates. FC and PM developed the gold-catalyzed 
“close-to-release” cyclization in “4.6 Appendix: Unreactive Substrates”. NVI and FC prepared 
the Sav isoforms. NVI and BL prepared the LM3 and the TATE peptide on rink amide and trityl 
resin, respectively. FC and NVI developed the peptide functionalization with gold-NHC 
complexes. BL synthesized the sulfimidated NHC ligands and FC the gold complexes thereof. 
6.2 Introduction 
The work on aqueous transition metal catalysis laid the foundation for bioorganometallic 
chemistry and subsequent biorthogonal, metal-based uncaging reactions. Such an uncaging 
reaction is commonly referred to a reaction where a protecting moiety is cleaved of a probe in 
the presence of a catalyst to release an active payload.137,164,165 Cellular mechanisms rely 
heavily on metalloproteins containing first-row transition metals such as iron, copper and zinc. 
In contrast, second row transition metals are rarely found in natural metalloproteins.166,167 For 
this reason, biocompatible second row transition metals form an interesting source of 
biorthogonal catalysts with promising applications in the uncaging of active ingredients in 
vivo.168 
Over the last decades, ruthenium and palladium were extensively used in various biorthogonal 
reactions including the uncaging of allenes,169 allyls,170,171 propargyls,85,172–178 
propargyloxycarbonyls (Proc),179–185 allyloxycarbonyls (Alloc),32,132,194,195,186–193 azides189,196 and 
napthyls,197 Figure 42. Initial developments of these reactions usually rely on the uncaging of 
fluorescent molecules such as rhodamine and/or coumarin. These fluorescent probes facilitate 
reaction control in vitro as well as in vivo and allow the detection of products at very low 
concentrations. As a result, fluorescent probes were widely uncaged in living systems including 
various cell types, bacteria, C. elegans, zebrafish and mice. One of the first reports of such 
biorthogonal uncaging in living systems relied on the ruthenium-catalyzed Alloc-cleavage of 
rhodamine 110 in HeLa cells by Meggers and co-workers in 2006.188 The same reaction was 






Figure 42 Biorthogonal, transition-metal-catalyzed uncaging reactions in living systems. Various 
payloads including fluorophores and active pharmaceuticals were protected with transition-metal 
cleavable moieties. The corresponding protected ingredients could be uncaged in various living systems 
including cells, bacteria, C. elegans, zebrafish and mice.170,171,180–189,172,190–197,173–179 
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In contrast to the many uncaging reactions catalyzed by Ru and Pd applied in various 
organisms, Au-catalyzed uncaging has been undeservingly underrepresented. In fact, Au-
catalysts display remarkable biocompatibility, low toxicity, good reactivity at room temperature 
and a propensity to coordinate alkynes, the most widely used biorthogonal functional group. 
Thiols such as cysteine or glutathione are known to poison gold-catalysts and are present at 
significant concentrations in cells. However, smart catalyst design can protect the 
corresponding gold-complex from harmful metabolites while simultaneously increasing the 
reactivity towards the desired reaction, see chapter 1. In 2017, the groups of Tanaka and 
Unciti-Broceta recognized this potential and developed the first gold-catalyzed propargyl and 
Poc-uncaging reactions in living systems and/or in biological medium.67,68  
A common disadvantage of these simple uncaging reactions is the cleaved moiety which 
consists of a simple unsaturated ether or carbonyl group with no possibilities for further 
functionalization. Especially for medical applications, it would be useful to modulate the 
chemical and physiological properties of the prodrug to be very different to the active drug. For 
this reason, in 2020, the group of Tanaka developed the uncaging of large 2-
alkynylbenzamides to release substituted amines in the presence of gold.198 This allowed, to 
drastically change the hydrophilicity of the prodrug, preventing it to enter healthy cells, while 
upon uncaging, the corresponding chemotherapeutic could easily penetrate into the HeLa cell. 
Unfortunately, the reaction does require equimolar amounts of catalyst to proceed in vivo. 
6.3 Results and Discussion 
Driven by our progress in designing highly active gold ArMs including hydroarylases and 
hydroaminases, we were interested in utilizing them for biorthogonal uncaging. The driving 
force of generating aromatic intermediates proved to be an efficient tool to design “close-to-
release” probes.197,198 A Report on intramolecular cyclizations of substituted 3-butyne-1,2-diols 
into furans with the elimination of water in the presence of ruthenium encouraged us to design 
a novel “close-to-release” protocol based on profuran substrates, Figure 43.199 We decided to 
utilize umbelliferone as the payload, as coumarin-based fluorophores have a large difference 
in fluorescence intensity upon release.200 Furthermore, various active pharmaceutical 
ingredients (API) contain coumarin moieties.201–204 From glycerol, we could synthesize TMS-
protected profuran 3 in two steps with 80% overall yield, Figure 44. Following a Mitsunobu 
reaction with triphenylphosphine beads, umbelliferone was coupled to profuran 3 and after 
filtration subsequently deprotected in TBAF to yield protected umbelliferone 4. Initial 
Figure 43 Modification of the ruthenium-catalyzed dehydrative intramolecular cyclization to 




experiments in aqueous buffers with different ruthenium-catalysts including biotinylated 
Grubbs-Hoveyda 2nd generation catalyst197 were not successful in cleaving the butynol moiety 
form umbelliferone and releasing the payload. However, it was also reported that gold 
complexes can perform similar dehydrative intramolecular cyclizations to yield furan 
derivatives.205 This motivated us to investigate the capability of our gold-ArMs from chapter 1 
and 2 to catalyze this intramolecular cyclization with subsequent 1,2-elimination under 
aqueous conditions. To our delight, we could detect a clear blue fluorescence of the previously 
clear reaction vial upon exposure to UV-light already after two hours of reaction time. A simple 
pre-screening to evaluate the optimal cofactor and Sav-system followed. A dark 96 well plate 
was loaded with different biotinylated gold complexes biot-Au 1-5 and Sav as well as Sav-
SOD mutants similar to the hydroarylation screening in chapter 2, Figure 24. The results show 
a clear preference for biot-Au 2 as the optimal cofactor and Sav-SOD K121A as the optimal 
Sav construct, Figure 45. In three hours, this ArM achieved 68% conversion of caged 
umbelliferone 4. 
 
Figure 44 Synthesis of caged umbelliferone 4 from glycerol. 
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Despite the promising initial results, the turnover of the best-performing system is still moderate 
(6-7 TON). Follow up screenings at lower catalyst loadings (2 mol%) yielded even lower TONs 
(>3). Nevertheless, Sav-SOD K121A ∙ biot-Au 2 would be an ideal starting point for a 
systematic optimization protocol as detailed in chapter 2.95 
In order to broaden the spectrum of our newly designed close-to-release reactions towards 
smaller gold catalysts, we collaborated with the Fani Group from the University Hospital of 
Basel. With their assistance, cancer-targeting cyclic peptides p-Cl-Phe-cyclo(D-Cys-Tyr-D-4-
amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr-NH2 (LM3) and H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-
Cys-Thr-OH (TATE) were prepared,  Figure 46.206,207 These peptides are known tumor-
targeting somastotatin analogues and act as either agonist (TATE) or antagonist (LM3). 
Simplified, antagonists (commonly referred to as “blockers”) are compounds that upon binding 
to the target-receptor block the binding site (directly or indirectly) for potential agonists, the 
activity of the system is reduced or completely inhibited. Antagonists such as beta-blockers, 
antihistamines, etc. are widely used as APIs. On the other hand, agonists are compounds 
(peptides, hormones, neurotransmitter, etc.) that upon binding to the target-receptor induce an 
active response by the cell. Common agonists are insulin, 
Figure 45 Fluorescence Screening of caged umbelliferone 4. a The “close-to-release” reaction of 
caged umbelliferone 4 to furane and umbelliferone in MES buffer was screened at concentrated 
(10 mol%) and dilute (5 mol%) catalyst loadings. b The dark 96-well plate after 24 h of reaction time. 




Figure 46 Protected cancer-targeting peptides LM3 and TATE. 
calcitonin or oxytocin.208 Somastotatin agonists usually internalize upon binding to the target-
receptor allowing for an attached cargo to be delivered into the cell. In contrast, somastotatin 
antagonists display very low internalization rates and remain primarily on the cell surface. This 
may be a result of the fact, that antagonists usually bind to a larger population of binding 
sites.209 Both properties can be advantageous when designing targeted treatments and have 
been successfully used in the clinics. In a field referred to as Theranostics (Therapy & 
Diagnostics), a radioactive drug is attached to the cancer-targeting peptide. The peptide 
delivers the radioactive moiety into the desired target cell, and allows for targeted radiotherapy 
at the tumors even at highly metastatic stages.210 
Our plan was, to functionalize these peptides with gold to obtain cancer-targeting gold 
catalysts. In contrast to Sav-based ArMs, they could easily distribute around the body and 
selectively cover the surface of the desired cancer cells. In a further step, protected and thus 
less active chemotherapeutics would be added. These unreactive drugs would circulate in the 
blood before being selectively cleaved at the desired location to release the active therapeutic 
on/in the cancer cell. Obvious advantages would include the selective and catalytic release of 
active ingredients at the target location which would increase the therapeutic effect on the 
tumor while simultaneously reducing burden on healthy cells. For obvious reasons, we would 




The first step of this plan was to efficiently functionalize the peptides with gold. We decided, to 
follow a similar approach as with the Sav-projects. We utilized amino functionalized NHC 
ligands, which would be first transformed to the desired gold complex. Afterwards, the boc-
group was cleaved with gaseous hydrochloric acid and the unprotected gold complex was 
coupled to the carbonic acid moiety of with succinic acid modified LM3 and TATE, Figure 47. 
The gold-functionalized peptides were washed, cleaved from the resin and precipitated by 
addition of cold diethyl ether. Reaction control was performed using a standard three step 
Kaiser test which revealed the presence of free amines through the formation of a purple 
chromophore, Figure 48. A mild and a harsh cleaving protocol were tested. By only using 5% 
TFA, we could cleave TATE without removing the permanent protecting groups, while with 
95% TFA we would cleave TATE-Au and simultaneously remove all protecting groups on the 
peptide, Figure 49. In contrast, HR-MS spectrum of LM3-Au did not display the presence of 
the desired compound, but a pattern slightly lower in m/z indicating the potential decomposition 
of the urea moiety on the D-4-amino-Phe(carbamoyl) fragment. 
 
Figure 47 Synthesis of TATE-Au and LM3-Au on trityl resin and rink amide resin, respectively. 
Ad hoc reaction control was done via Kaiser test and later verified via HPLC into HR-MS. Yields of the 
gold-functionalized peptides were around 1 mg and could not be determined exactly as the reactions 




Figure 48 Kaiser Test. a The reaction of ninhydrin with amino acids leads to a complex reaction 
resulting in the formation of Ruhemanns Purple a strong purple chromophore. b Eppendorf tubes 
displaying common color patterns appearing in the Kaiser Test. 
Before upscaling the synthesis of the most promising peptide and improving on the purification, 
we tested the available samples of TATE-Au and LM3-Au on the hydroarylation of pro-
coumarin 9 and the close-to-release reaction of pro-furan 4 while comparing it to the 
performance of biot-Au 2 · Sav-SOD K121A, Figure 50. First screenings in MeCN:H2O (1:1) 
highlighted the capability of both gold-functionalized peptides to catalyze the hydroarylation of 
pro-coumarin 9 almost quantitatively, clearly outperforming the ArM under these conditions, 
Error! Reference source not found. entry 6-11. 
 




Figure 50 Screening the gold-functionalized peptides for the intramolecular hydroarylation and 
the close-to-release reaction. 
In contrast, the close-to-release reaction did not proceed in aqueous acetonitrile. However, 
when run in MES buffer (50 mM, pH 5), the ArM displays quantitative conversion. The two 
peptides also catalyze the reaction, albeit in much lower conversions (11% for LM3-Au and 
7% for TATE-Au). The reaction conditions seem to have a large influence on these reactions. 
Interestingly, while MES buffer was crucial for the close-to-release, it proved detrimental for 
the hydroarylation, Table 4 entry 3 vs 4 and entry 9 vs 10. Further reaction improvement may 
be possible through careful tuning of the reaction conditions and/or by utilizing HPLC-purified 
peptide analogues which both require larger amounts of gold-functionalized peptides LM3-Au 
and TATE-Au. The coupling of succinic anhydride with LM3 gave better results compared to 
the sequential coupling of protected succinic acid followed by deprotection and second 
coupling, Table 4 entry 3 vs 3b and entry 4 vs 4b. 
Table 4 Selected Results of LM3-Au and TATE-Au-catalyzed intramolecular cyclization reactions.  
Entry Au-Catalyst Substrate Solvent Conversiona 
0 - 4 MES pH 5 0% 
1 - 4 MeCN:H2O (1:1) 0% 
2 biot-Au 2 · Sav-SOD K121A 4 MES pH 5 99% 
3 LM3-Au 4 MeCN:H2O (1:1) 1% (0%b) 
4 LM3-Au 4 MES pH 5 11% (0%b) 
5 TATE-Au 4 MES pH 5 7% (1%c) 
6 - 9 MES pH 5 0% 
7 - 9 MeCN:H2O (1:1) 0% 
8 biot-Au 2 · Sav-SOD K121A 9 MeCN:H2O (1:1) 37% 
9 LM3-Au 9 MES pH 5 0% 
10 LM3-Au 9 MeCN:H2O (1:1) 97% 
11 TATE-Au 9 MeCN:H2O (1:1) 99% (96%c) 
aThe conversion was determined via UPLC-MS at 321 nm. Reaction condition Vtot 500 L, [Sub] 1 mM, 
[Au] 20 M and [Sav] 40 M (ArM) or ca 0.5 mg/mL (peptide), 39 °C for 3 days. b LM3-Au synthesized 
via sequential coupling of protected succinic acid followed by gold complex. c TATE-Au cleaved under 





A new close-to-release reaction was developed in which an intramolecular cyclization of 
butynol followed by a 1,2-elimination forms furan and releases umbelliferone. This reaction 
was catalyzed by chimeric ArM biot-Au 2 · Sav-SOD K121A to yield quantitative conversion. 
Further studies in transferring the system in vivo could allow for the design of highly efficient 
close-to-release ArMs by utilizing the developed systematic screening protocol from chapter 
2. 
To facilitate the medical application of the newly designed close-to-release reaction, the 
system was expanded to enable gold-catalysis on cancer-targeting peptides. Gold-
functionalized peptides LM3-Au and TATE-Au were synthesized in small quantities to test the 
highly-efficient hydroarylation of pro-coumarin substrate 9. These peptides were also capable 
of releasing umbelliferone from pro-furan substrate 4 albeit in lower conversion. We discovered 
a large influence of the solvent which may complicate in vivo applications. Further attempts in 
designing more efficient close-to-release probes were of limited success, see appendix below. 
Nevertheless, we could establish the first proof-of-concept of gold-catalysis on cancer-
targeting peptides by utilizing a newly designed, biorthogonal close-to-release reaction. We 
believe that this could be a significant step towards utilizing biorthogonal transition-metal-
chemistry for targeted therapy, with an immense potential against highly metastatic cancer. 
6.5 Appendix: Unreactive Substrates  
As the optimization of reaction conditions is not a viable solution for improving a system aiming 
to function in vivo, we investigated other candidates for the gold-catalyzed close-to-release 
strategy. We experimented with substrates that after gold-catalyzed intramolecular cyclization 
could spontaneously undergo elimination or self-immolation to release a cargo. As we 
designed artificial hydroaminases capable of transforming 2-ethynylaniline to indole, we 
hypothesized that we could utilize this aromatization to force a self-immolation in para-position. 
We thus prepared alcohol 15 from methyl ester 11 in four steps and coupled it via a Mitsunobu 
reaction to umbelliferone, Figure 51. The corresponding substrate 16 did not react to release 
umbelliferone in the presence of biot-Au 2 · Sav-SOD K121A. No diagnostic fluorescence was 
observed. UPLC-MS analysis revealed the presence of only the substrate in the reaction 





Figure 51 The synthesis of 2-ethynylaniline-derived “close-to-release” probes. 
 
Figure 52 A self-immolative substrate for the gold-catalyzed uncaging of umbelliferone. No 
conversion of 16 was detected in the presence of biot-Au 2 · Sav-SOD K121A, only the substrate 16 
was detected after UPLC-MS analysis of the reaction mixture. 
Another approach was based on the synthesis of pro-naphthalene substrates that proved 
efficient when combined with ring-closing metathesis to release a cargo following spontaneous 
1,4-elimination.197 Upon zinc-coupling of propargyl bromide, mono-or dimethoxy aldehydes 18 
and 19 respectively were converted into the corresponding aromatic butynol 20 and 21, Figure 
53. Umbelliferone was again coupled to the close-to-release substrate via a Mitsunobu 
reaction. The corresponding alkyne could be extended via Sonogashira coupling to yield 
product 24, Figure 54. An interesting perk of this approach was, the electronics of the substrate 
could be modulated through the incorporation of functional groups on the aromatic moiety 
which eventually could allow to improve the spontaneous elimination. Substrates 22, 23 and 
26 were tested in the presence of a selection of ArMs, Figure 55. Unfortunately, we could not 
achieve the large improvement in cargo-release that we hoped for. We only detected little 






Figure 53 The synthesis of pro-naphthalene-derived “close-to-release” substrates 22 and 23. 
 
Figure 54 The synthesis of carbamate 26 for the gold-catalyzed “close-to-release” reaction. 
 
Figure 55 Gold-catalyzed “close-to-release” reaction of pro-naphthalene in the presence of gold 
complexes. 
6.6 Appendix: Sulfimide Gold-NHC complex  
In order to expand the scope of ArMs towards new hosts, we set out to evalute new protein 
scaffolds, thus requiring new ligand/cofactor designs. Instead of coupling a highly polar moiety 
such as biotin or sulfonamide over a linker to a ligand, we thought about designing an all-in-
one solution: a ligand with polar moieties in the back that would simultaneously function as the 
binding moiety to the protein. As part of this thesis, I designed an experimental procedure to 
generate stable gold-complexes from the rather exotic ligands prepared by BL. The challenges 
herein were the protecting groups on the sulfimide moiety. They were crucial for the NHC 
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synthesis, but often proved difficult to cleave. Our first attempts with benzyl-protected ligand 
30 were thus unsuccessful as we could not cleave the benzyl group from the gold complex 31, 
Figure 56.  
 
Figure 56 No deprotection of benzyl-protected sulfimide-NHC complex 31 achieved. 
As a result, a boc-protected analogue was prepared 33, Figure 57. The boc-protected ligand 
was easily deprotected in the presence of trifluoroacetic acid in CH2Cl2 to yield 34. Subsequent 
gold insertion in the present of an inorganic base in acetone yielded the corresponding gold 
complex 35. The formation of the desired complex was confirmed by LC-MS and HR-MS, 
Figure 58. Very clean spectra displaying only the expected masses were obtained. 
Unfortunately, 1H-NMR analysis was ambiguous, Figure 59. A rather messy spectrum was 
obtained which, however clearly highlighted the functionalization of the ligand on the 
imidazolidene moiety, as no imidazolidene peak was detected. Further experiments are 
needed to unambiguously describe the nature of the complex and prepare preparative 
quantities of the complex. This should not constitute a big challenge, as a simple synthetic 
protocol for the complex was developed. 
 
 





Figure 58 HR-MS and ESI-MS spectrum of sulfimide gold complex 35. a HR-MS spectrum 
after HPLC. b ESI-MS spectrum from direct-injection.  
 
Figure 59 1H NMR spectrum of sulfimide gold complex 35.  
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7. Final Conclusion and Outlook 
In the past, precious metals including palladium, ruthenium, iridium and rhodium were 
introduced to Sav utilizing phosphine ligands, N-heterocyclic carbenes, piano-stool complexes 
and sulfonamides. The repertoire of ArMs was now extended by the addition of gold(I) via 
biotinylated N-heterocyclic carbenes. The initial hypothesis that gold would be an ideal catalyst 
for biorthogonal and biocompatible reactions led to the development of gold-based 
hydroaminases and hydroarylases based on the biotin-streptavidin technology. These ArMs 
proved highly efficient (TONs > 350) and robust, displaying good activity in the periplasm of E. 
coli as well as in cell-free-extracts. As a result, screening protocols allowing for the systematic 
screening of Sav double-mutants (periplasm) or the directed evolution of chimeric Sav (cell-
free-extracts) were established. We utilized the unique property of gold to engage in dual-gold-
catalysis by designing a chimeric Sav variant where a protein fragment from superoxide 
dismutase shields the solvent-exposed binding pocket. The presence of two close-lying gold 
moieties leads to a shift in regioselectivity, giving access to a new set of products. The chimeric 
ArM was evolved to produce either the anti-Markovnikov product, an aromatic quinazolinone, 
or the Markovnikov product, an indole. Nonchimeric analogues were used for the optimization 
of hydroarylases and hydroaminases. The latter catalyzed the transformation of 2-ethynyl 
aniline to indole, a crucial metabolite in the tryptophan synthase pathway. Similar approaches 
to access indole via palladium-based ArMs were not successful due to synthetic challenges 
around the substrate and a lack of biostability of the cofactor. 
Bioorthogonal gold(I) catalysis was extended beyond ArM technology, by functionalizing 
somastotatin analogues LM3 and TATE with gold(I) N-heterocyclic carbene complexes. The 
corresponding gold peptides were stable and catalytically active. Coumarin analogues were 
obtained quantitatively via hydroarylation induced by gold-functionalized peptides without the 
need of base or additives. Furthermore, we designed a new close-to-release protocol allowing 
for the release of umbelliferone by the addition of gold-functionalized ArMs or peptides. 
Therein, pro-furan moieties are used to temporarily protect hydroxyl groups. In the presence 
of gold ArMs or gold peptides this group is cleaved after intramolecular cyclization followed by 
1,2-elimination to release the alcohol and furan. 
In the course of this thesis, the first systematic screening of gold ArMs, the first dual-gold ArMs 
and the first gold-functionalized somastotatin analogues were designed, optimized and 
successfully implemented in gold catalysis. The remarkable acceleration in catalytic 
performance of the gold cofactor upon incorporation into Sav and the remarkable biostability 
makes these gold ArMs privileged catalyst for biorthogonal catalysis. As the field of gold 
catalysis is steadily expanding, there will be more and more reactions available for gold-ArM 
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technology where genetic optimization allows for exceptional activity and stereoselectivity. As 
part of this study, the gold-ArMs were limited to alkynes, as other substrates were unreactive. 
Alternative ligand design may allow to expand this reactivity towards alkenes or allenes. N,O-
ligands have shown good activity in aqueous solvent coordinating and stabilizing Au(III), after 
biotinylation they may allow to expand the substrate scope beyond alkynes.211–214  
In parallel to these projects, a novel “close-to-release” reaction was developed which is 
compatible with the gold ArMs and gold peptides from our now established repertoire. So far, 
umbelliferone was efficiently uncaged in MES buffer. Substrate derivatization proved 
challenging but could give access to promising pro-drugs. Especially for metastatic cancer, the 
targeted release of chemotherapeutics could drastically mitigate side effects. The synthesis of 
pro-furan-protected doxorubicin or endoxifen could give a good starting point to investigate the 
therapeutic feasibility of this novel reaction. Furthermore, preparation, purification and 
characterization of the gold-peptides must be improved before further investigation of its utility 








8. Experimental and Supplementary Information 
8.1 General Methods: 
Procedures for the synthesis of the gold complexes were carried out in oven-dried glassware 
under a dry nitrogen atmosphere with rigorous exclusion of moisture and oxygen from reagents 
and glassware using standard Schlenk techniques or a MBraun Labstar glove box workstation. 
Dry solvents were directly purchased from Acros Organics and used without further 
purification. Water used for molecular biology and in the catalytic reactions was purified by 
Milli-Q Advantage system. Degassed solvents were prepared via three freeze-pump-thaw 
cycles. 
Chemicals were purchased from Sigma Aldrich, Acros Organics, Alfa Aesar or Fluorochem 
and used without further purification. All catalytic reactions were carried out with non-degassed 
solvents under air. Temperature was maintained using Thermowatch-controlled heating 
blocks. Analytical thin-layer chromatography (TLC) was performed on pre-coated Merck silica 
gel 60 F254 plates (0.25 mm) and visualized using UV light. Flash column chromatography was 
carried out on a Biotage Isolera using Silicycle SiliaFlash P60 (230-400 mesh) filled KP-Sil 
columns unless stated otherwise. Concentration refers to the removal of volatile solvents via 
distillation using a rotary evaporator Büchi R-300HL equipped with a thermostated bath B-300, 
a vacuum regulator CVC-3000, followed by residual solvent removal under high vacuum. 
1H NMR (500 MHz) and 13C NMR (126 MHz) spectra were recorded at room temperature on a 
Bruker 500 MHz or 600 MHz spectrometer. Data are summarized with the coupling constants 
described as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, 
m = multiplet, br = broad signal, bs = broad singlet, dd = doublet doublets, dt = doublet triplets, 
dq = doublet quartets, td = triplet doublets, ddd = doublet of doublet of doublets, ddt = doublet 
of doublet of triplets, dtd = doublet of triplet of doublets, dddd = doublet of doublet of doublet 
of doublets), coupling constants in Hertz (Hz). Chemical shifts (δ) are reported in ppm relative 
to the residual solvent peak. Peaks were fully assigned using 2D-NMR spectroscopy including 
COSY, NOESY, HMBC and HMQC. The NMR spectra were analyzed using MestreNova© 
NMR data processing software.  
GC-MS analysis was performed on a Shimadzu GCMS-QP2010S equipped with Agilent HP1-
1MS (length: 30 m; Diameter: 0.25 mm; Film: 0.25 µM). GC column flow 2.05 mL/min Helium. 
High-resolution mass spectrometry (HR-MS) was performed by the analytical facility of the 
chemistry department of the University of Basel on a Bruker maXis 4G QTOF ESI mass 
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spectrometer coupled to a Shimadzu LC. Prior to HR-MS submission, all samples were 
characterized via direct injection or LC from solutions in MeOH (gold complex synthesis) or 
MeCN (substrate synthesis) on a Shimadzu LCMS-2020. Native-MS was performed via direct 
injection (aqueous buffer) to a Bruker maXis 4G QTOF ESI mass spectrometer. 
Fluorescence assays were recorded on a Tecan fluorimeter Infinite M1000Pro. Samples were 
prepared on a clear 96-well plate. Measurements settings for Fluorescence Top Reading: 
Excitation Wavelength 485 nm, Emission Wavelength 520 nm, Excitation Bandwidth 5 nm, 
Emission Bandwidth 5 nm, Gain 94 (100%), Number of slashes 10, Flash frequency 400 Hz, 
Integration time 20 s, Lag time 0 s, Settle Time 100 ms. 
UPLC experiments were performed on an Acquity UPLC-H Class Bio from Waters equipped 
with a PDA set to 254 nm and a SQ detector 2 with the following column: ACQUITY UPLC, 
HSS T3 1.8 μm, 2.1 × 100 mm. Solvents for UPLC analysis were Milli-Q water and LC-MS 
grade acetonitrile, each containing 0.1% formic acid, later on referred to as (C) and (D). The 
flow rate was set to 0.60 ml/min and the column temperature was maintained at 40 °C. The 
method used includes the following parameters: ttotal = 9.00 min with 0.00 min – 90% C; 
0.60 min – 60% C; 6.95 min – 42% C; 7.20 min – 10% C; 7.80 min 10% C; 8.00 min – 90% C; 
8.50 min – 90% C end. Mass detection was performed in scan mode for positive ions (cone 
voltage 40 V, desolvation temperature: 600 °C) and SIR (m/z = corresponding substrate & 
products). Determined TONs and yields for catalysis are a mean of multiple sets of runs 
determined in relation to an internal standard (phthalane) at 254 nm processed with Waters 
TargetLynx unless stated otherwise. The standard deviation is displayed as error bars. 
Molecular biology reagents were purchased from New England Biolabs (NEB), Integrated DNA 






8.2 Chapter 1: Dual-Gold-based chimeric ArMs 
Substrate Synthesis 
General procedure A: urea substrates 1 and 1a-1f: 
The urea bearing substrates 1-1f were prepared according to a modified procedure of Medio-
Simon and co-workers.96 A 10 mL pressure tube equipped with a stirring bar was charged with 
the corresponding 2-alkynylaniline (1 eq) and the phenyl isocyanate (1 eq). The tube was 
sealed after the addition of CH2Cl2 (2 mL/mmol) and placed in a heating block at 80 °C. After 
5 h, the heating was stopped and the mixture was stirred until it reached room temperature. 
The urea precipitated as a white solid and was collected on a ground-glass frit. The white solid 
was washed by adding small portions of cold CH2Cl2 (2 mL). The precipitate was dried in vacuo 




The product was prepared according to the general procedure A and isolated as a white solid 
(1.20 g, 5.10 mmol, 99%). The spectra are in agreement with literature data.96 
1H NMR (500 MHz, DMSO-d6) δ 9.57 (s, 1H), 8.19 (s, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.52 – 7.45 
(m, 2H), 7.43 (dd, J = 7.7, 1.6 Hz, 1H), 7.35 (td, J = 8.5, 7.9, 1.6 Hz, 1H), 7.30 (t, J = 7.9 Hz, 
2H), 6.99 (td, J = 7.5, 1.3 Hz, 2H), 4.65 (s, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 152.18, 140.93, 139.52, 132.48, 129.65, 128.89, 122.12, 
121.94, 119.24, 118.29, 110.55, 87.46, 79.53. 
UPLC-MS: TR = 4.21 min; MS (ESI, pos) m/z: 237.24 [100 %, M+H]+. 









The product was prepared according to the general procedure A and isolated as a white solid 
(439 mg, 1.65 mmol, 82%). Rf 0.57 (cyclohexane:ethyl acetate 80:20) 
1H NMR (500 MHz, DMSO-d6) δ 9.40 (s, 1H), 8.13 (d, J = 8.4 Hz, 1H), 8.10 (s, 1H), 7.42 (dd, 
J = 7.7, 1.6 Hz, 1H), 7.37 (d, J = 9.0 Hz, 2H), 7.33 (t, J = 7.6 Hz, 1H), 6.97 (t, J = 7.5 Hz, 1H), 
6.88 (d, J = 8.9 Hz, 2H), 4.65 (s, 1H), 3.72 (s, 3H). 
13C NMR (126 MHz, DMSO-d6) δ 154.63, 152.29, 141.12, 132.49, 132.42, 129.61, 121.67, 
120.08, 119.00, 114.08, 110.29, 87.41, 79.53, 55.17. 
UPLC-MS: TR = 3.97 min; MS (ESI, pos) m/z: 266.83 [100 %, M+H]+. 




The product was prepared according to the general procedure A and isolated as a pale yellow 
solid (445 mg, 1.58 mmol, 79%). Rf 0.44 (cyclohexane:ethyl acetate 80:20) 
1H NMR (500 MHz, DMSO-d6) δ 10.26 (s, 1H), 8.40 (s, 1H), 8.21 (d, J = 9.2 Hz, 2H), 8.11 (d, 
J = 8.4 Hz, 1H), 7.71 (d, J = 9.1 Hz, 2H), 7.47 (dd, J = 7.8, 1.6 Hz, 1H), 7.42 – 7.35 (m, 1H), 
7.05 (t, J = 7.5 Hz, 1H), 4.70 (s, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 151.73, 146.12, 141.24, 140.16, 132.59, 129.72, 125.22, 
122.69, 119.61, 117.59, 111.22, 87.68, 79.33. 
UPLC-MS: TR = 5.30 min; MS (ESI, pos) m/z: 282.15 [100 %, M+H]+. 





The product was prepared according to the general procedure A and isolated as a white solid 
(535 mg, 1.90 mmol, 95%). Rf 0.43 (cyclohexane:ethyl acetate 80:20) 
1H NMR (500 MHz, DMSO-d6) δ 10.09 (s, 1H), 8.59 – 8.52 (m, 1H), 8.29 (s, 1H), 8.14 (d, J = 
8.4 Hz, 1H), 7.85 (dd, J = 8.2, 2.3 Hz, 1H), 7.73 – 7.68 (m, 1H), 7.59 (t, J = 8.1 Hz, 1H), 7.46 
(dd, J = 7.7, 1.5 Hz, 1H), 7.42 – 7.34 (m, 1H), 7.04 (t, J = 7.5 Hz, 1H), 4.70 (s, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 152.09, 148.18, 140.82, 140.37, 132.53, 130.23, 129.72, 
124.21, 122.45, 119.44, 116.55, 112.11, 110.97, 87.62, 79.36. 
UPLC-MS: TR = 5.20 min; MS (ESI, pos) m/z: 281.96 [100 %, M+H]+. 




The product was prepared according to the general procedure A and isolated as a white solid 
(219 mg, 0.875 mmol, 83%). 
1H NMR (500 MHz, DMSO-d6) δ 9.49 (s, 1H), 8.11 (s, 1H), 7.99 (d, J = 8.5 Hz, 1H),  7.45 (d, J 
= 8.4 Hz, 2H), 7.29 (t, J = 7.9 Hz, 2H), 7.25 (d, J = 2.1 Hz, 1H), 7.16 (dd, J = 8.7, 2.1 Hz, 1H), 
6.98 (t, J = 7.3 Hz, 1H), 4.60 (s, 1H), 2.23 (s, 3H). 
13C NMR (126 MHz, DMSO-d6) δ 152.25, 139.62, 138.49, 132.48, 131.00, 130.33, 128.86, 
122.00, 119.43, 118.22, 110.60, 86.98, 79.71, 19.95.  
UPLC-MS: TR = 5.28 min; MS (ESI, pos) m/z: 250.91 [100 %, M+H]+. 





The product was prepared according to the general procedure A and isolated as a white solid 
(390 mg, 1.362 mmol, 68%). 
1H NMR (500 MHz, DMSO-d6) δ 9.81 (s, 1H), 8.29 (s, 1H), 8.19 (dd, J = 8.5, 1.1 Hz, 1H), 8.14 
(d, J = 2.1 Hz, 1H), 7.85 (m, 2H), 7.80 (m, 1H), 7.50 (dd, J = 8.8, 2.2 Hz, 1H), 7.46 (m, 2H), 
7.37 (m, 2H), 7.01 (td, J = 7.5, 1.2 Hz, 1H), 4.69 (s, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 152.25, 140.86, 137.15, 133.70, 132.50, 129.64, 129.18, 
128.50, 127.45, 127.03, 126.38, 124.08, 121.99, 119.55, 119.25, 113.63, 110.61, 87.51, 79.51. 
UPLC-MS: TR = 7.55 min; MS (ESI, pos) m/z: 287.24 [100 %, M+H]+. 
HR-MS (ESI, pos): m/z calcd. for C19H14N2OH+ 287.1179 found 287.1174 [M+H]+; m/z calcd. 




The product was prepared according to the general procedure A and isolated as a white solid 
(990 mg, 3.03 mmol, 99%). 
1H NMR (500 MHz, DMSO-d6) δ 9.50 (s, 1H), 8.51 (s, 1H), 8.07 (dd, J = 8.5, 1.1 Hz, 1H), 7.46 
(dd, J = 7.8, 1.6 Hz, 1H), 7.36 (ddd, J = 8.7, 7.4, 1.7 Hz, 1H), 7.03 (td, J = 7.6, 7.5, 1.2 Hz, 1H), 
4.69 (s, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 151.58, 140.34, 132.51, 129.74, 122.53, 119.11, 110.89, 
87.67, 79.22. 
UPLC-MS: TR = 5.38 min; MS (ESI, pos) m/z: 326.26 [100 %, M+H]+. 
HR-MS (ESI, pos): m/z calcd. for C15H7F5N2ONa+ 349.0371 found 349.0366 [M+Na]+. 
General procedure B: indole products 2 and 2a-2f 
Procedure B1: Indole (1 eq) as a solution in dry THF (5 mL/mmol) was added dropwise to a 
solution of sodium (1.3 eq, cut in small pieces) in dry THF (5 mL/mmol). The mixture was 
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stirred under reflux for 16 h and then cooled to room temperature. The selected isocyanate 
(1 eq) as a solution in dry THF (5 mL/mmol) was added dropwise and the mixture was stirred 
for 5 h at room temperature. The mixture was cooled to 0°C before quenching the reaction with 
water (15 mL). The solution was diluted with ethyl acetate (15 mL), transferred to a separating 
funnel and extracted with ethyl acetate (3x10 mL). The combined organic phases were washed 
with brine (10 mL), dried over magnesium sulfate and the solvent was removed in vacuo. The 
product was recrystallized from a mixture of petroleum ether and diethyl ether. 
Procedure B2: Indole (1 eq) as a solution in dry THF (5 mL/mmol) was added dropwise to an 
ice-cold suspension of NaH (1.3 eq as a 60% suspension in mineral oil) in dry THF 
(5 mL/mmol). The solution was stirred for 30 min at 0 °C. Then, the selected isocyanate (1 eq) 
was added dropwise as a solution in dry THF (5 mL/mmol) upon which the solution turned red. 
The mixture was allowed to warm to room temperature and stirred for 16 h. The mixture was 
cooled to 0 °C and then quenched with water (15 mL). The solution was diluted with ethyl 
acetate (15 mL), transferred to a separating funnel and extracted with ethyl acetate (3x10 mL). 
The combined organic phases were washed with brine (10 mL), dried over magnesium sulfate 
and the solvent was removed in vacuo. The crude was purified via flash column 
chromatography (KP-Sil 50 g, linear gradient of 10% to 20% ethyl acetate in cyclohexane). 
Product 2 
 
The indole 2 was prepared according to the general procedure B1 and isolated as white 
crystals (752 mg, 3.18 mmol, 32%). 
1H NMR (500 MHz, DMSO-d6) δ 10.05 (s, 1H), 8.23 (d, J = 8.2 Hz, 1H), 8.04 (d, J = 3.6 Hz, 
1H), 7.70 – 7.59 (m, 3H), 7.39 (dd, J = 8.5, 7.3 Hz, 2H), 7.30 (ddd, J = 8.3, 7.1, 1.4 Hz, 1H), 
7.24 – 7.20 (m, 1H), 7.14 (td, J = 7.4, 1.1 Hz, 1H), 6.76 (d, J = 3.6 Hz, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 149.85, 138.39, 135.40, 129.70, 128.75, 125.58, 123.88, 
123.75, 122.23, 120.85, 118.17, 115.04, 106.41.  
UPLC-MS: TR = 5.09 min; MS (ESI, pos) m/z: 237.17 [100 %, M+H]+. 






The indole 2a was prepared according to the general procedure B2 and isolated as a white 
solid (232 mg, 0.871 mmol, 87%). Rf 0.36 (cyclohexane:ethyl acetate 80:20) 
1H NMR (500 MHz, DMSO-d6) δ 9.90 (s, 1H), 8.22 (d, J = 8.3 Hz, 1H), 8.01 (d, J = 3.6 Hz, 1H), 
7.63 (d, J = 7.7 Hz, 1H), 7.54 (d, J = 8.9 Hz, 2H), 7.28 (t, J = 7.7 Hz, 1H), 7.21 (t, J = 7.4 Hz, 1H), 
6.96 (d, J = 8.9 Hz, 2H), 6.74 (d, J = 3.6 Hz, 1H), 3.76 (s, 3H). 
13C NMR (126 MHz, DMSO-d6) δ 155.88, 149.93, 135.39, 131.10, 129.60, 125.42, 123.65, 
122.78, 122.08, 120.79, 115.01, 113.91, 106.26, 55.23. 
UPLC-MS: TR = 4.94 min; MS (ESI, pos) m/z: 267.23 [100 %, M+H]+. 




The indole 2b was prepared according to the general procedure B2 and isolated as a pale 
yellow solid (221 mg, 0.786 mmol, 79%). Rf 0.18 (cyclohexane:ethyl acetate 80:20) 
1H NMR (500 MHz, DMSO-d6) δ 10.60 (s, 1H), 8.30 (d, J = 9.2 Hz, 2H), 8.23 (d, J = 8.3 Hz, 
1H), 8.06 (d, J = 3.7 Hz, 1H), 7.95 (d, J = 9.2 Hz, 2H), 7.66 (d, J = 7.7 Hz, 1H), 7.33 (t, J = 7.7 
Hz, 1H), 7.25 (t, J = 7.4 Hz, 1H), 6.81 (d, J = 3.7 Hz, 1H) 
13C NMR (126 MHz, DMSO-d6) δ 149.56, 145.09, 142.53, 135.34, 129.86, 125.66, 124.84, 
124.06, 122.68, 121.00, 119.93, 115.09, 107.09. 
UPLC-MS: TR = 6.10 min; MS (ESI, pos) m/z: 282.22 [100 %, M+H]+. 
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HR-MS (ESI, neg): m/z calcd. for C15H10N3O3- 280.0728 found 280.0731 [M-H]-. 
Product 2c 
 
The indole 2c was prepared according to the general procedure B2 and isolated as a pale 
yellow solid (271 mg, 0.963 mmol, 96%). Rf 0.23 (cyclohexane:ethyl acetate 80:20) 
1H NMR (500 MHz, DMSO-d6) δ 10.47 (s, 1H), 8.65 (t, J = 2.3 Hz, 1H), 8.26 (d, J = 8.3 Hz, 
1H), 8.15 – 8.10 (m, 1H), 8.06 (d, J = 3.6 Hz, 1H), 7.99 (dd, J = 8.2, 2.3 Hz, 1H), 7.69 (t, J = 
8.2 Hz, 1H), 7.65 (d, J = 7.7 Hz, 1H), 7.32 (dd, J = 8.4, 7.0 Hz, 1H), 7.25 (t, J = 7.4 Hz, 1H), 
6.81 (d, J = 3.6 Hz, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 149.79, 147.97, 139.85, 135.36, 130.19, 129.79, 126.44, 
125.44, 124.00, 122.55, 120.96, 118.19, 115.11, 114.58, 107.00. 
UPLC-MS: TR = 5.95 min; MS (ESI, pos) m/z: 282.15 [100 %, M+H] +. 




The indole 2d was prepared according to the general procedure B1 and isolated as golden 
crystals (230 mg, 0.918 mmol, 46%). 
1H NMR (500 MHz, DMSO-d6) δ 9.97 (s, 1H), 8.10 (d, J = 8.4 Hz, 1H), 7.99 (d, J = 3.7 Hz, 1H), 
7.65 (dd, J = 8.3, 1.4 Hz, 2H), 7.39 (dd, J = 15.6, 7.6 Hz, 3H), 7.18 – 7.07 (m, 2H), 6.67 (d, J 
= 3.6 Hz, 1H), 2.40 (s, 3H). 
13C NMR (126 MHz, DMSO-d6) δ 149.79, 138.40, 133.67, 131.05, 129.91, 128.71, 125.50, 
125.11, 123.78, 120.77, 120.55, 114.72, 106.14, 20.94. 
UPLC-MS: TR = 6.48 min; MS (ESI, pos) m/z: 251.18 [100 %, M+H]+. 
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The indole 2e was prepared according to the general procedure B1 and isolated as a white 
solid (210 mg, 0.733 mmol, 73%). 
1H NMR (500 MHz, DMSO-d6) δ 10.25 (s, 1H), 8.28 (dd, J = 8.2, 1.0 Hz, 1H), 8.26 (d, J = 2.2 
Hz, 1H), 8.10 (d, J = 3.7 Hz, 1H), 7.94 (d, J = 8.8 Hz, 1H), 7.90 (m, 2H), 7.78 (dd, J = 8.8, 2.1 
Hz, 1H), 7.66 (dt, J = 7.7, 1.0 Hz, 1H), 7.51 (ddd, J = 8.0, 6.8, 1.3 Hz, 1H), 7.45 (ddd, J = 8.2, 
6.8, 1.3 Hz, 1H), 7.32 (ddd, J = 8.4, 7.1, 1.3 Hz, 1H), 7.24 (ddd, J = 8.1, 7.2, 1.1 Hz, 1H), 6.79 
(dd, J = 3.7, 0.8 Hz, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 149.93, 136.04, 135.42, 133.30, 130.04, 129.72, 128.31, 
127.50, 127.36, 126.49, 125.59, 124.93, 123.80, 122.28, 121.20, 120.87, 116.97, 115.07, 
106.53. 
UPLC-MS:TR = 8.20 min; MS (ESI, pos) m/z: 287.24 [100 %, M+H]+. 
HR-MS (ESI, pos): m/z calcd. for C19H14N2OH+ 287.1179 found 287.1175 [M+H]+; m/z calcd. 




The indole 2f was prepared according to the general procedure B2 and isolated as a white 
solid (305 mg, 0.935 mmol, 94%). 
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1H NMR (500 MHz, DMSO-d6) δ 10.36 (s, 1H), 8.21 (dd, J = 8.2, 1.0 Hz, 1H), 8.02 (d, J = 3.7 
Hz, 1H), 7.66 (dt, J = 7.7, 0.9, 0.9 Hz, 1H), 7.32 (ddd, J = 8.3, 7.1, 1.4 Hz, 1H), 7.26 (td, J = 
7.4, 7.3, 1.2 Hz, 1H), 6.84 (d, J = 3.6 Hz, 1H). 
19F NMR (471 MHz, DMSO-d6) δ -144.61 – -146.83 (m), -156.79, -160.53 – -164.73 (m). 
13C NMR (126 MHz, DMSO-d6) δ 149.66, 135.42, 129.70, 125.01, 124.34, 122.87, 121.06, 
115.05, 107.97. 
UPLC-MS: TR = 6.61 min; MS (ESI, pos) m/z: 326.24 [100 %, M+H]+. 
HR-MS (ESI, pos): m/z calcd. for C15H7F5N2ONa+ 349.0371 found 349.0373 [M+Na]+. 
 
General procedure C: quinazolininone products 3 and 3a-3f 
Prepared according to a modified procedure of Asensio and co-workers.52 An oven dried 
resealable test tube with a Teflon stirring bar was charged with the urea substrate (0.2 mmol 
or 0.4 mmol), [AuCl(IPr)] (5 mol%) and Silver hexafluoroantimonate(V) (7.5 mol%). The tube 
was flushed and backfilled with nitrogen three times before the addition of degassed DMF 
(1 mL/mmol). The tube was sealed with a Teflon screw-cap and placed in a heating block at 
60 ºC for 5 h. Then, the heating was stopped and the mixture was stirred until it reached room 
temperature. The crude was diluted with CH2Cl2 (2-3 mL), and filtrated over a plug of celite. 
The solvent was removed under reduced pressure. The products were purified via flash column 





The quinazolinone 3 was prepared according to the general procedure C and isolated as white 
solid (43 mg, 0.182 mmol, 46%). The spectra are in agreement with literature data.52 
1H NMR (500 MHz, DMSO-d6) δ 10.30 (s, 1H), 7.69 – 7.64 (m, 1H), 7.52 (dd, J = 8.3, 7.2 Hz, 
2H), 7.46 – 7.39 (m, 1H), 7.32 (ddd, J = 8.4, 7.3, 1.3 Hz, 1H), 7.29 – 7.25 (m, 2H), 7.00 (ddd, 
J = 8.3, 7.3, 1.2 Hz, 1H), 6.95 (dd, J = 8.1, 1.2 Hz, 1H), 4.77 (d, J = 1.9 Hz, 1H), 3.40 (d, J = 
1.9 Hz, 1H). 
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13C NMR (126 MHz, DMSO-d6) δ 149.24, 143.32, 138.66, 135.88, 130.41, 129.70, 129.37, 
127.99, 124.10, 122.14, 116.12, 114.77, 85.89.  
UPLC-MS: TR = 2.58 min; MS (ESI, pos) m/z: 236.91 [100 %, M+H]+. 
HR-MS (ESI, pos): m/z calcd. for C15H12N2OH+ 237.1022 found 237.1020 [M+H]+; m/z calcd. 




The quinazolinone 3a was prepared according to the general procedure C and isolated as a 
white solid (12 mg, 0.045 mmol, 23%). The spectra are in agreement with literature data.52 
1H NMR (500 MHz, DMSO-d6) δ 10.24 (s, 1H), 7.65 (dd, J = 8.2, 1.4 Hz, 1H), 7.35 – 7.25 (m, 
1H), 7.16 (d, J = 8.8 Hz, 1H), 7.05 (d, J = 8.9 Hz, 2H), 6.99 (ddd, J = 8.2, 7.3, 1.2 Hz, 1H), 6.93 
(dd, J = 8.1, 1.2 Hz, 1H), 4.76 (d, J = 1.7 Hz, 1H), 3.80 (s, 3H), 3.45 (d, J = 1.8 Hz, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 158.57, 149.42, 143.55, 130.35, 130.30, 124.12, 122.07, 
116.12, 114.86, 114.71, 85.73, 55.33.  
UPLC-MS: TR = 2.57 min; MS (ESI, pos) m/z: 267.16 [100 %, M+H]+. 




The quinazolinone 3b was prepared according to the general procedure C and isolated as a 
yellow solid (11 mg, 0.039 mmol, 10%). 
1H NMR (500 MHz, DMSO-d6) δ 10.46 (s, 1H), 8.41 – 8.32 (m, 2H), 7.94 (d, J = 9.2 Hz, 1H), 
7.70 (dd, J = 8.1, 1.4 Hz, 1H), 7.65 – 7.57 (m, 2H), 7.34 (ddd, J = 8.2, 7.3, 1.3 Hz, 1H), 7.03 
76 
 
(ddd, J = 8.2, 7.3, 1.2 Hz, 1H), 6.97 (dd, J = 8.1, 1.2 Hz, 1H), 4.85 (d, J = 2.4 Hz, 1H), 3.43 (d, 
J = 2.4 Hz, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 148.87, 146.87, 144.76, 142.86, 135.67, 131.25, 130.61, 
125.06, 124.14, 122.37, 116.05, 114.94, 86.66.  
UPLC-MS: TR = 2.94 min; MS (ESI, pos) m/z: 282.15 [100 %, M+H]+. 




The quinazolinone 3c was prepared according to the general procedure C and isolated as a 
pale yellow solid (43 mg, 0.153 mmol, 76%). 
1H NMR (500 MHz, DMSO-d6) δ 10.45 (s, 1H), 8.31 (dt, J = 7.0, 2.4 Hz, 1H), 8.20 (t, J = 1.6 
Hz, 1H), 7.84 – 7.79 (m, 2H), 7.71 (dd, J = 8.1, 1.3 Hz, 1H), 7.34 (ddd, J = 8.4, 7.4, 1.3 Hz, 
1H), 7.03 (td, J = 7.7, 1.2 Hz, 1H), 6.97 (dd, J = 8.1, 1.2 Hz, 1H), 4.85 (d, J = 2.4 Hz, 1H), 3.42 
(d, J = 2.4 Hz, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 149.09, 148.85, 143.06, 139.75, 136.86, 135.72, 131.18, 
130.56, 124.92, 124.17, 123.14, 122.31, 116.11, 114.93, 86.50. 
UPLC-MS: TR = 2.92 min; MS (ESI, pos) m/z: 282.29 [100 %, M+H]+. 
HR-MS (ESI, pos): m/z calcd. for C15H11N3O3H+ 282.0873 found 282.0869 [M+H]+. 
Product 3d 
 
The quinazolinone 3d was prepared according to the general procedure C and isolated as a 




1H NMR (500 MHz, DMSO-d6) δ 10.21 (s, 1H), 7.52 (t, J = 7.7 Hz, 2H), 7.48 (d, J = 1.9 Hz, 
1H), 7.45 – 7.37 (m, 1H), 7.28 – 7.22 (m, 2H), 7.14 (dd, J = 8.2, 1.8 Hz, 1H), 6.85 (d, J = 8.1 
Hz, 1H), 4.75 (d, J = 1.8 Hz, 1H), 3.37 (d, J = 1.8 Hz, 1H), 2.27 (s, 3H). 
13C NMR (126 MHz, DMSO-d6) δ 149.25, 143.40, 138.77, 133.55, 131.17, 131.05, 129.67, 
129.38, 127.92, 124.06, 115.90, 114.70, 85.62, 20.42.  
UPLC-MS: TR = 3.18 min; MS (ESI, pos) m/z: 251.04 [100 %, M+H]+. 
HR-MS (ESI, pos): m/z calcd. for C16H14N2ONa+ 273.0998 found 273.1000 [M+Na]+. 
Product 3e 
 
The quinazolinone 3e was prepared according to the general procedure C and isolated as a 
white solid (49 mg, 0.171 mmol, 86%). 
1H NMR (500 MHz, DMSO-d6) δ 10.38 (s, 1H), 8.07 (d, J = 8.6 Hz, 1H), 8.00 (ddd, J = 11.8, 
7.0, 2.0 Hz, 2H), 7.88 (d, J = 2.0 Hz, 1H), 7.70 (dd, J = 8.2, 1.4 Hz, 1H), 7.58 (ddd, J = 7.6, 
5.6, 1.6 Hz, 2H), 7.39 (dd, J = 8.6, 2.1 Hz, 1H), 7.34 (ddd, J = 8.3, 7.3, 1.3 Hz, 1H), 7.03 (td, J 
= 7.7, 1.2 Hz, 1H), 6.98 (dd, J = 8.0, 1.3 Hz, 1H), 4.82 (d, J = 2.0 Hz, 1H), 3.45 (d, J = 2.0 Hz, 
1H). 
13C NMR (151 MHz, DMSO-d6) δ 149.45, 143.36, 136.02, 135.91, 133.66, 132.31, 130.49, 
129.49, 128.06, 127.87, 127.68, 127.37, 126.64, 126.37, 124.16, 122.22, 116.19, 114.84, 
86.26. 
UPLC-MS: TR = 5.41 min; MS (ESI, pos) m/z: 287.24 [100 %, M+H]+. 






The quinazolinone 3f was prepared according to the general procedure C and isolated as a 
white solid (59 mg, 0.181 mmol, 90%). 
1H NMR (500 MHz, DMSO-d6) δ 10.75 (s, 1H), 7.75 (dd, J = 8.1, 1.3 Hz, 1H), 7.38 (ddd, J = 
8.3, 7.3, 1.3 Hz, 1H), 7.07 (ddd, J = 8.2, 7.3, 1.2 Hz, 1H), 6.99 (dd, J = 8.1, 1.2 Hz, 1H), 4.99 
(d, J = 3.2 Hz, 1H), 3.97 (d, J = 3.2 Hz, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 148.23, 140.31, 135.06, 131.01, 124.37, 122.98, 115.33, 
115.25, 86.69. 
19F NMR (471 MHz, DMSO-d6) δ -144.61 – -149.11 (m), -153.31, -161.92 (d, J = 4.7 Hz). 
UPLC-MS: TR = 2.79 min; MS (ESI, pos) m/z: 326.31 [100 %, M+H]+. 
HR-MS (ESI, pos): m/z calcd. for C15H7F5N2ONa+ 349.0371 found 349.0371 [M+Na]+. 
 
Synthesis of biotin analogues 
Biotin mesylate: BiotMs 
 
An oven-dried flask was charged with biotinol215 691 mg, 3.00 mmol, 1 eq), dry CH2Cl2 (30 mL), 
pyridine (10 mL) and diisopropylethylamine (1.24 mL, 7.50 mmol, 2.5 eq). The mixture was 
cooled to 0 °C before slowly adding mesyl chloride (0.69 mL, 9.0 mmol, 3 eq). The clear yellow 
solution was stirred (3 h at 0 °C) before quenching the mixture with the addition of water 
(30 mL). The solution was extracted with CH2Cl2 (3x30 mL), dried over magnesium sulfate and 
concentrated in vacuo. The product was precipitated from CH2Cl2 by the addition of 
diethylether to yield biotin mesylate (BiotMs) as a pale yellow solid (749 mg, 2.43 mmol, 81%). 
1H NMR (500 MHz, Chloroform-d) δ 4.54 (dd, J = 7.9, 4.9 Hz, 1H), 4.34 (dd, J = 7.8, 4.6 Hz, 
1H), 4.24 (t, J = 6.4 Hz, 2H), 3.16 (ddd, J = 8.0, 6.4, 4.5 Hz, 1H), 3.02 (s, 3H), 2.93 (dd, J = 
12.9, 5.0 Hz, 1H), 2.77 (d, J = 12.8 Hz, 1H), 1.77 (m, 2H), 1.70 (m, 2H), 1.47 (m, 4H). 
13C NMR (126 MHz, DMSO-d6) δ 162.70, 70.40, 60.99, 59.18, 55.39, 36.54, 28.32, 28.15, 
28.00, 24.96. 
UPLC-MS: TR = 2.43 min; MS (ESI, pos) m/z: 309.27 [100%, M+H]+; 331.03 [21%, M+Na]+. 




N,N-dimethyl biotin pentafluorophenyl ester 
 
N,N-dimethyl biotin was prepared according to a modified procedure of Dorofeeva and co-
workers.216 An oven-dried flask equipped with a reflux condenser was charged with D(+)-biotin 
(5.00 g, 20.5 mmol, 1 eq), aq. formaldehyde (9.17 mL, 37%, 123 mmol, 6 eq) and formic acid 
(30 mL). The mixture was refluxed for two days. The formic acid was removed in vacuo and 
the crude was dissolved in aq. NaOH (50 mL, 0.5 M). The aqueous mixture was filtered and 
acidified with aq. HCl (2 M) until the product precipitated. The filter cake was washed with 
water and diethyl ether to yield the dimethylated product as white flakes (4.68 g, 17.2 mmol, 
84%). The spectra are in agreement with the literature data. 
N,N-dimethyl biotin pentafluorophenol was prepared according to a modified procedure of 
Ward and co-workers.103 N,N-dimethyl biotin (300 mg, 1.10 mmol, 1 eq) was dissolved in dry 
DMF and triethylamine was added (0.27 mL, 1.93 mmol, 1.75 eq). After complete dissolution, 
pentafluorophenyl trifluoroacetate (0.28 mL, 1.65 mmol, 1.5 eq) was added dropwise. The 
mixture was stirred (90 min) before removing the solvent in vacuo. The crude was purified via 
flash column chromatography (KP-Sil 50 g, gradient of 2% to 15% methanol in CH2Cl2) to yield 
the product as a white solid (482 mg, 1.1 mmol, 99%). 
1H NMR (500 MHz, CD2Cl2) δ 4.15 (dq, J = 8.5, 4.3 Hz, 1H), 3.93 (dd, J = 8.8, 5.2 Hz, 1H), 
3.31 – 3.21 (m, 1H), 2.88 – 2.85 (m, 2H), 2.83 (s, 3H), 2.73 (s, 3H), 2.72 – 2.67 (m, 2H), 1.85 
– 1.73 (m, 2H), 1.73 – 1.58 (m, 2H), 1.57 – 1.48 (m, 2H). 
19F NMR (471 MHz, CD2Cl2) δ -153.41, -159.23, -163.35. 
13C NMR (126 MHz, CD2Cl2) δ 176.39, 169.90, 162.18, 162.15, 67.20, 64.74, 56.22, 56.09, 
35.80, 33.67, 33.11, 29.65, 29.62, 29.26, 29.22, 25.13. 







Hartwig Substrate Synthesis 
 
 
Vinylarene 13 was prepared according to the procedure of Hartwig and co-workers.130,131 The 
spectra are in agreement with literature data: 
Acid 17: 1H NMR (500 MHz, CDCl3) δ 7.40 (s, 2H), 7.34 (s, 2H), 7.28 (s, 1H), 5.32 (d, J = 1.0 
Hz, 2H), 5.11 (d, J = 1.3 Hz, 2H), 2.88 – 2.81 (m, 1H), 2.58 – 2.51 (m, 1H). 
Alcohol 18: 1H NMR (500 MHz, CDCl3) δ 7.33 (s, 2H), 7.25 (s, 2H), 7.19 (s, 1H), 5.22 (d, J = 
1.5 Hz, 1H), 5.02 (d, J = 1.4 Hz, 1H), 3.58 (t, J = 6.4 Hz, 2H), 2.53 (td, J = 7.5, 1.3 Hz, 2H), 
1.69 – 1.60 (m, 2H), 1.53 (s, 1H). 
Aldehyde 19: 1H NMR (500 MHz, CDCl3) δ 9.79 (s, 1H), 7.38 (s, 2H), 7.34 (s, 2H), 7.29 (s, 1H), 
5.33 (s, 1H), 5.10 (d, J = 1.3 Hz, 1H), 2.85 (td, J = 7.4, 1.3 Hz, 2H), 2.61 (td, J = 7.5, 1.5 Hz, 
2H). 
Methylamine 13: 1H NMR (600 MHz, DMSO-d6) δ 8.37 (d, J = 1.4 Hz, 1H), 7.51 – 7.42 (m, 2H), 
7.40 – 7.34 (m, 2H), 7.33 – 7.25 (m, 1H), 5.35 (s, 1H), 5.10 (d, J = 1.8 Hz, 1H), 2.72 (d, J = 7.5 
Hz, 2H), 2.54 (s, 2H), 2.41 (d, J = 1.3 Hz, 3H), 1.64 (s, 2H). 
13C NMR (151 MHz, DMSO-d6) δ 165.34, 146.88, 140.02, 128.47, 127.64, 125.84, 112.64, 
54.96, 48.73, 33.44, 31.60, 25.35. 
Piperidine 15: 1H NMR (500 MHz, CD2Cl2) δ 7.27 (d, J = 7.3 Hz, 2H), 7.25 – 7.21 (m, 2H), 7.18 
(s, 1H), 2.92 – 2.86 (m, 1H), 2.82 (d, J = 3.7 Hz, 1H), 2.79 (s, 1H), 2.24 (s, 3H), 1.94 (d, J = 
11.2 Hz, 1H), 1.91 – 1.84 (m, 2H), 1.74 (dd, J = 4.2, 2.9 Hz, 1H), 1.73 – 1.59 (m, 2H), 1.41 (dd, 




Synthesis of gold complexes 
General procedures D1 & D2: coordination to gold 
D1: An oven-dried flask was charged with the corresponding NHC salt (1 eq), Silver(I)oxide 
(0.6 eq) and degassed CH2Cl2 (10 mL/mmol). The mixture was stirred (4 h) at room 
temperature in the dark. The mixture was filtered through a plug of celite into a tube containing 
chloro(dimethylsulfide) gold(I) (1 eq). The resulting mixture was stirred for (16 h). The mixture 
was filtered through a plug of celite and the solvent was removed in vacuo.  
D2: Carried out according to a modified procedure of Nolan and co-workers:101 An oven-dried 
pressure tube was charged with the corresponding NHC salt (1 eq), chloro(dimethylsulfide) 
gold(I) (1 eq), potassium carbonate (2 eq) and acetone (5 mL, HPLC-grade). The tube was 
sealed and stirred (2 h at 65 °C). The mixture was cooled to room temperature and the solvent 
was removed in vacuo. Dry CH2Cl2 (10 mL) was added before filtering the crude through a 
plug of celite. The solvent was removed in vacuo.  
Purification: Dry CH2Cl2 (0.5 mL) was added to dissolve the crude from either protocols D1 or 
D2. Upon addition of dry hexane (4 mL) the corresponding gold complex precipitated as white 
crystals which were collected by carefully removing the solvent via syringe. Boc-protected gold 
complexes tend to be less stable than the corresponding biotinylated gold complexes. It is thus 




SI Figure 1 Synthesis of biotinylated gold complexes:(i) Ag2O, CH2Cl2, rt, 4 h then (CH3)2SAuCl, CH2Cl2, 
rt, 16 h, (ii) TFA, CH2Cl2, rt, 2 h, then biotin pentafluorophenyl ester, NEt3, DMF, rt, 16 h, (iii) 
(CH3)2SAuCl, K2CO3, acetone, 65 °C, 90 min, (iv) biotin mesylate, KI, K2CO3, acetone, reflux, 2 days, 
(v) HCl(g), CH2Cl2, rt, 4 h then Boc-Gly pentafluorophenyl ester, NEt3, DMF, rt, 16 h. 
 
General procedures E1 & E2: biotin coupling 
E1: An oven-dried flask was charged with the corresponding imidazolium salt or NHC complex 
(1 eq), degassed CH2Cl2 (2 mL) and trifluoroacetic acid (20 eq). The mixture was stirred at 
room temperature in the dark until full deprotection of the boc group (reaction control via 
ninhydrin-stained TLC after ca. 3 hours). The solvent and the trifluoroacetic acid were removed 
via high vacuum while gently heating the flask with the heat gun (<50 °C!). It is essential to 
remove all TFA before proceeding. The dried crude was dissolved in degassed DMF (2 mL). 
Pentafluorophenylbiotin (1 eq) and trimethylamine (20 eq) were added. The mixture was 
stirred (16 h) at room temperature in the dark. The solvent and the base were removed via 
high vacuum overnight to yield a yellow crude product. 
E2: According to a modified procedure of Plenio and co-workers:217 An oven-dried pressure 
tube was charged with the corresponding NHC salt (1 eq), potassium iodide (1.1 eq), biotin 
mesylate (1 eq), potassium carbonate (2 eq) and acetone (7 mL). The tube was sealed and 
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heated (65 °C for 2 days). The mixture was filtered through a plug of celite and the solvent was 
removed in vacuo. 
Purification: After careful removal of the solvents, the crude from either protocols E1 or E2 was 
purified via flash column chromatography (KP-Sil 10 g, gradient of 3% to 20% methanol in 
CH2Cl2). The product was diluted in dry CH2Cl2 (>1 mL) and precipitated by the addition of dry 
hexane. The purified biotinylated gold complexes were air- and moisture stable. Stock 
solutions of 2 mM in DMSO could be stored for months in the fridge without significant 
degradation of the biotinylated gold complexes (as revealed by HR-MS) or any inhibition of 
catalytic activity. 
Synthesis of the gold complex biot-Au 1 
 
Imidazolium salt L1 was prepared according to the procedure of Ward and co-workers in 6 
steps.103  
The gold complex L2 was prepared following the general procedure D1 yielding the product 
as a white solid (220 mg, 0.336 mmol, 93%): 
1H NMR (500 MHz, CD2Cl2) δ 7.11 (s, 2H), 7.02 (s, 2H), 5.04 (s, 1H), 4.28 (d, J = 6.2 Hz, 2H), 
4.02 (s, 4H), 2.37 (s, 6H), 2.34 (s, 6H), 2.33 (s, 3H), 1.46 (s, 9H). 
13C NMR (126 MHz, CD2Cl2) δ 195.34, 140.97, 139.74, 136.94, 136.76, 136.28, 135.23, 
130.19, 128.14, 51.32, 51.23, 28.68, 21.43, 18.47, 18.32. 
HR-MS (ESI, pos): m/z calcd. for C26H35AuClN3O2Na+ 676.1976 found 676.1970 [M+Na]+. 
 
The biotinylated gold complex biot-Au 1 was prepared following the general procedure E1 
yielding the product as a white solid (67 mg, 0.086 mmol, 36%): Rf 0.52 (MeOH: CH2Cl2 5:95) 
1H NMR (500 MHz, CD2Cl2) δ = 7.11 (s, 2H, C17H, C15H), 7.02 (s, 2H, C8H, C6H), 6.29 (s, 
1H, N22H), 5.50 (s, 1H, N30H), 4.77 (s, 1H, N32H), 4.49 (dd, J = 8.0, 4.5 Hz, 1H, C33H), 4.38 
(d, J = 6.0 Hz, 2H, C21H), 4.29 (dd, J = 7.9, 4.7 Hz, 1H, C29H), 4.01 (s, 4H, C2H2, C3H2), 3.17 
(td, J = 7.5 Hz, 4.4, 2H, C28H), 2.92 (m, 1H, C34H), 2.68 (t, J = 12.2 Hz, 1H, C34H), 2.37 (s, 
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3H, C20H3/C19H3), 2.36 (s, 3H, C19H3/C20H3), 2.34 (s, 6H, C10H3, C12H3), 2.33 (s, 3H, 
C11H3), 2.26 (td, J = 7.3, 2.2 Hz, 2H, C24H2), 1.70-1.63 (m, 4H, C25H2, C27H2), 1.44 (m, 2H, 
C26H2). 
13C NMR (101 MHz, CD2Cl2) δ 195.01 (C1), 173.78 (C23), 164.60 (C31), 140.70 (C16), 139.68 
(C4), 136.83 (C18, C14), 136.69 (C13), 136.27 (C5, C9), 135.24 (C7), 130.15 (C6, C8), 128.49 
(C15/C17), 128.47 (C17/C15), 62.21 (C29), 60.81 (C33), 56.13 (C28), 51.32 (C3/C2), 51.27 
(C2/C3), 43.15 (C21), 41.11 (C34), 36.40 (C24), 28.70 (C25, C26, C27), 21.42 (C11), 18.51 
(C20/C19), 18.47 (C19/C20), 18.35 (C10, C12). 
HR-MS (ESI, pos): m/z calcd. for C31H41AuN5O2S+ 744.2641 found 744.2651 [M-Cl]+. 
 
Synthesis of the gold complex biot-Au 2 
 
Imidazolium salt L3 was prepared according to the procedure of Grubbs and co-workers in 4 
steps by Boris Lozhkin.104 The gold complex L5 was prepared following the general procedure 
D1 yielding the product as a white solid (126 mg, 0.189 mmol, 94%): 
1H NMR (500 MHz, CD2Cl2) δ 7.05 (s, 1H), 7.04 (s, 1H), 7.02 (s, 2H), 4.53 (m, 1H), 4.49 (m, 
1H), 4.10 (t, J = 11.4 Hz, 1H), 3.94-3.81 (m, 1H), 3.47 (m, 1H), 3.26 (m, 1H), 2.41 (s, 3H), 2.36 
(s, 4H), 2.34 (s, 4H), 2.33 (s, 3H), 2.32 (s, 4H), 2.31 (s, 3H), 1.36 (s, 9H). 
13C NMR (126 MHz, CD2Cl2) δ 196.01, 139.81, 136.78, 136.16, 130.75, 130.53, 130.23, 
130.19, 63.81, 32.16, 28.47, 23.22, 21.43, 21.37, 19.53, 18.52, 18.38, 18.35, 14.44. 
HR-MS (ESI, neg): m/z calcd. for C27H36AuClN3O2- 666.2156 found 666.2177 [M-H]-; for 
C27H37AuClN3O2HCOO-  712.2211 found 712.2233 [M+HCOO]-. 
 
The biotinylated gold complex biot-Au 2 was prepared following the general procedure E1 
yielding the product as a white solid (18 mg, 0.023 mmol, 41%): 
1H NMR (500 MHz, CD2Cl2) δ 7.06 (s, 1H, C8H/C6H), 7.04 (s, 1H, C6H/C8H), 7.01 (s, 2H, 
C15H, C17H), 5.71 (d, J = 6.1 Hz, 1H, N23H), 5.38 (s, 1H, N31H), 4.76 (d, J = 5.3 Hz, 1H, 
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N33H), 4.53 (m, 1H, C3H), 4.45 (m, 1H, C34H), 4.24 (m, 1H, C30H), 4.11 (td, J = 11.3, 4.4 Hz, 
1H, C2H), 3.82 (ddd, J = 11.6, 8.6, 7.7 Hz, 1H, C2H), 3.74 (m, 1H, C22H), 3.24 (m, 1H, C22H), 
3.12 (m, 1H, C29H), 2.89 (dt, J = 12.9, 5.0 Hz, 1H, C35H), 2.65 (dd, J = 12.8, 7.5 Hz, 1H, 
C35H), 2.43 (s, 3H, C10H3/C11H3), 2.36 (s, 3H, C19H3/C20H3), 2.35 (s, 3H, C12H3), 2.33 (s, 
3H, C21H3), 2.31 (s, 6H, C11H3/C10H3, C20H3/C19H3), 2.01 (m, 2H, C25H2), 1.61 (s, 2H, 
C28H2), 1.47 (s, 2H, C26H2), 1.33 (s, 2H, C27H2). 
13C NMR (126 MHz, CD2Cl2) δ 196.04 (C1), 173.90 (C24), 163.61 (C32), 139.80 (C7, C16), 
136.82 (C4), 136.36 (C13), 135.13 (C14, C18), 134.41 (C9, C5), 130.76 (C8/C6), 130.53 
(C6/C8), 130.16 (C15, C17), 63.40 (C3), 62.25 (C30), 60.60 (C34), 55.91 (C29), 55.36 (C2), 
42.47 (C22), 41.15 (C35), 36.00 (C25), 28.58 (C27/C28), 28.51 (C28/C27), 25.68 (C26), 21.43 
(C12, C21), 19.59 (C10/C11), 18.53 (C19/C20), 18.38 (C11/C10), 18.34 (C20/C19). 
HR-MS (ESI, pos): m/z calcd. for C32H43AuN5O2S+ 758.2803 found 758.2794 [M-Cl]+; for 
C32H43AuClN5O2SNa+  816.2384 found 816.2384 [M+Na]+. 
 
Synthesis of the gold complex biot-Au 3 
 
The imidazolium salt L7 was prepared according to the procedure of Lavigne and co-workers 
in three steps.105 
The biotinylated imidazolium salt L9 was prepared following the general procedure E2 yielding 
the product as a pale orange solid (107 mg, 0.201 mmol, 54%): 
1H NMR (500 MHz, CD2Cl2) δ 8.92 (d, J = 1.9 Hz, 1H), 7.26 (d, J = 1.9 Hz, 1H), 7.12 (d, J = 
6.2 Hz, 4H), 5.01 (s, 1H), 4.74 (s, 1H), 4.52 – 4.44 (m, 1H), 4.31 (t, J = 6.6 Hz, 2H), 4.28 (m, 
1H), 3.41 (d, J = 4.3 Hz, 1H), 3.12 (ddd, J = 8.6, 6.1, 4.5 Hz, 1H), 2.90 (dd, J = 12.8, 5.0 Hz, 
1H), 2.70 (d, J = 12.8 Hz, 1H), 2.39 (d, J = 4.7 Hz, 6H), 2.24 (s, 6H), 2.17 (s, 6H), 1.77 (m, 2H), 
1.66 (m, 1H), 1.54 (m, 1H), 1.39 (m, 4H). 
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13C NMR (126 MHz, CD2Cl2) δ 163.53, 148.32, 142.42, 142.27, 135.59, 134.87, 131.44, 
131.23, 130.40, 130.36, 127.36, 102.73, 75.39, 62.28, 60.59, 56.08, 41.16, 29.10, 29.03, 
28.72, 25.98, 21.55, 21.50, 18.19, 18.13. 
HR-MS (ESI, pos): m/z calcd. for C31H41N4O2S+ 533.2945 found 533.2944 [M-Cl]+. 
 
Biotinylated gold complex biot-Au 3 was prepared following the general procedure D1 yielding 
the product as a golden solid (38 mg, 0.050 mmol, 50%): 
1H NMR (500 MHz, CD2Cl2) δ 7.06 (d, J = 6.4 Hz, 4H, C8H, C6H, C15H, C17H), 6.40 (s, 1H 
C2H), 4.63 (s, 2H, N29H, N31H), 4.48 (m, 1H, C32H), 4.25 (ddd, J = 7.7, 4.5, 1.6 Hz, 1H, 
C28H), 3.98 (t, J = 6.4 Hz, 2H, C22H2), 3.09 (ddd, J = 9.1, 5.9, 4.6 Hz, 1H, C27H), 2.90 (dd, J 
= 12.9, 5.0 Hz, 1H, C33H2), 2.69 (d, J = 12.8 Hz, 1H, C33H2), 2.38 (s, 3H, C21H3/C12H3), 2.37 
(s, 3H, C12H3/C21H3), 2.17 (s, 6H, C10H3, C11H3), 2.12 (s, 6H, C19H3, C20H3), 1.69 (m, 2H, 
C23H2), 1.59 (m, 2H, C26H2), 1.35 (m, 2H, C24H2), 1.26 (m, 2H, C25H2). 
13C NMR (126 MHz, CD2Cl2) δ 168.13 (C1), 163.01 (C30), 148.35 (C3), 140.51-140.40 (C7, 
C16), 136.16 (C14, C18), 136.01 (C4), 135.59 (C9, C5), 131.78 (C9), 129.84-129.80 (C8, C6, 
C15, C17), 99.21 (C2), 73.41 (C22), 62.39(C28), 60.59 (C32), 55.98 (C27), 41.16 (C33), 29.18-
29.14 (C25, C26), 28.89 (C23), 26.17 (C24), 21.59-21.50 (C12, C21), 18.28 (C19, C20), 18.03 
(C10, C11). 
HR-MS (ESI, neg): m/z calcd. for C31H39AuClN4O2S- 763.2142 found 763.2154 [M-H]-; for 
C31H40AuClN4O2SHCOO- 809.2197 found 809.2201 [M+HCOO]-. 
Synthesis of the gold complex biot-Au 4 
 
The imidazolium salt L8 was prepared according to the procedure of Lavigne and co-workers 
in 3 steps.105 
The biotinylated NHC salt L10 was prepared following the general procedure E2 yielding the 
product as a yellow solid (122 mg, 0.187 mmol, 55%): 
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1H NMR (500 MHz, CD2Cl2) δ 8.72 (d, J = 1.9 Hz, 1H), 7.65 (m, 1H), 7.62 (m, 2H), 7.41 (dd, J 
= 7.8, 2.4 Hz, 4H), 4.97 (s, 1H), 4.69 (s, 1H), 4.48 (m, 1H), 4.39 (t, J = 6.6 Hz, 2H), 4.29 (m, 
1H), 3.12 (m, 1H), 2.90 (dd, J = 12.8, 5.0 Hz, 1H), 2.69 (d, J = 12.8 Hz, 1H), 2.53 (dt, J = 12.7, 
6.6 Hz, 1H), 2.44 (pd, J = 6.8, 2.8 Hz, 2H), 2.00 (s, 1H), 1.78 (s, 2H), 1.65 (s, 1H), 1.53 (s, 1H), 
1.40 (s, 4H), 1.36 (d, J = 6.8 Hz, 6H), 1.28 (dd, J = 6.7, 1.0 Hz, 6H), 1.24 (dd, J = 6.9, 3.8 Hz, 
12H). 
13C NMR (126 MHz, CD2Cl2) δ 163.22, 149.20, 146.34, 145.74, 132.94, 132.84, 131.27, 
130.62, 126.50, 125.42, 104.13, 75.76, 62.24, 60.57, 55.98, 41.16, 30.02, 29.74, 29.08, 28.83, 
25.97, 25.26, 24.63, 24.31, 23.86. 
HR-MS (ESI, pos): m/z calcd. for C37H53N4O2S+ 617.3884 found 617.3893 [M-Cl]+. 
 
The biotinylated gold complex biot-Au 4 was prepared following the general procedure D1 
yielding the product as a white solid (24 mg, 0.028 mmol, 80%): 
1H NMR (600 MHz, CD2Cl2) δ 7.54 (q, J = 8.3 Hz, 2H, C7H, C19H), 7.33 (d, J = 2.8 Hz, 4H, 
C8H, C6H, C18H, C20H), 6.46 (s, 1H, C2H), 4.71 (s, 2H, N35H, N37H), 4.47 (t, J = 6.4 Hz, 
1H, C38H), 4.23 (t, J = 6.2 Hz, 1H, C34H), 4.01 (t, J = 6.4 Hz, 2H, C28H2), 3.06 (s, 1H, C33H), 
2.89 (dd, J = 13.0, 5.0 Hz, 1H, C39H), 2.69 (m, 1H, C39H), 2.67 (m, 2H, C22H, C25H), 2.61 
(p, J = 6.5, 6.0 Hz, 2H, C10H, C23H), 1.69 (t, J = 6.8 Hz, 2H, C29H2), 1.53 (m, 2H, C32H2), 
1.38 (m, 4H, C30H2, C31H2), 1.34 (d, J = 6.8 Hz, 6H, C24H3, C27H2), 1.32 (d, J = 7.0 Hz, 6H, 
C12H3, C14H3), 1.25 (d, J = 7.0 Hz, 6H, C26H3, C23H3), 1.21 (d, J = 6.9 Hz, 6H, C11H3, 
C15H3). 
13C NMR (151 MHz, CD2Cl2) δ 179.96 (C1), 163.10 (C36), 148.98 (C3), 146.94 (C5, C9), 
146.47 (C17, C21), 135.17 (C16), 131.11 (C7/C19), 131.02 (C19/C7), 130.89 (C4), 124.67-
124.55 (C6, C8, C18, C20), 99.83 (C2), 73.17 (C28), 62.33 (C34), 60.52 (C38), 55.94 (C33), 
41.16 (C39), 29.54 (C10, C23), 29.25 (C22, C25), 29.20-29.00 (C29, C31, C32), 26.19 (C30), 
24.96 (C26, C23), 24.39 (C11, C15), 23.95 (C12, C14). 
HR-MS (ESI, pos): m/z calcd. for C37H52AuN4O2S+ 813.3476 found 813.3458 [M-Cl]+; 







Synthesis of the gold complex biot-Au 5 
 
The imidazolium salt L4 was prepared according to the procedure of Ward and co-workers in 
four steps by Boris Lozhkin.218 
The gold complex L6 was prepared following the general procedure D1 yielding the product 
as a white solid (127 mg, 0.182 mmol, 91%): 
1H NMR (600 MHz, CD2Cl2) δ 7.48 (dd, J = 19.4, 7.7 Hz, 2H), 7.33 – 7.27 (m, 4H), 4.48 (t, J = 
6.4, 6.4 Hz, 1H), 4.44 – 4.33 (m, 1H), 4.17 (t, J = 11.4, 11.4 Hz, 1H), 3.90 (t, J = 10.8, 10.8 Hz, 
1H), 3.60 – 3.50 (m, 1H), 3.29 – 3.22 (m, 1H), 3.17 (dt, J = 12.5, 5.7, 5.7 Hz, 1H), 3.08 (p, J = 
7.0, 7.0, 6.9, 6.9 Hz, 1H), 3.02 (dt, J = 12.9, 6.3, 6.3 Hz, 1H), 2.95 (hept, J = 6.9, 6.9, 6.5, 6.5, 
6.5, 6.5 Hz, 1H), 1.46 (d, J = 6.8 Hz, 3H), 1.42 (d, J = 6.8 Hz, 3H), 1.39 – 1.36 (m, 12H), 1.35 
(s, 9H), 1.34 (s, 6H). 
13C NMR (151 MHz, CD2Cl2) δ 196.78, 155.86, 147.50, 146.68, 130.33, 130.16, 125.29, 
124.94, 124.84, 124.65, 80.19, 65.88, 57.61, 42.60, 31.73, 29.29, 29.09, 29.02, 28.90, 28.06, 
25.88, 25.24, 24.99, 24.85, 24.20, 23.80, 23.37, 22.80, 14.03. 
HR-MS (ESI, pos): m/z calcd. for C33H49AuClN3O2Na+ 774.3071 found 774.3057 [M+Na]+. 
 
The biotinylated gold complex biot-Au 5 was prepared following the general procedure E1 
yielding the product as a white solid (117 mg, 0.133 mmol, 74%): 
1H NMR (500 MHz, CD2Cl2) δ 7.52 (td, J = 7.8, 1.1 Hz, 1H, C7H/C19H), 7.47 (t, J = 7.8 Hz, 
1H, C19H/C7H), 7.33 (td, J = 7.6, 1.2 Hz, 2H, (C8H, C6H)/(C18H, C20H)), 7.28 (dd, J = 7.8, 
1.2 Hz, 2H, (C18H, C20H)/(C8H, C6H)), 5.56-5.47 (m, 1H, N29H), 5.23 (s, 1H, N37H), 4.70 
(d, J = 10.9 Hz, 1H, N39H), 4.52-4.42 (m, 2H, C40H, C3H), 4.24 (dd, J = 4.8, 2.3 Hz, 1H, 
C36H), 4.17 (t, J = 11.4 Hz, 1H, C2H), 3.92-3.82 (m, 1H, C2H), 3.85-3.76 (m, 1H, C28H), 3.25 
(m, 1H, C28H), 3.22 (m, 1H, C22H/C25H), 3.11 (m, 1H, C10H/C13H), 3.08 (m, 1H, C35H), 
3.04-2.99 (m, 1H, C25H/C22H), 2.98-2.92 (m, 1H, C13H/C10H), 2.88 (ddd, J = 12.9, 5.0, 2.8 
Hz, 1H, C41H), 2.66 (dd, J = 12.8, 2.4 Hz, 1H, C41H), 1.98 (m, 2H, C31H2), 1.65-1.60 (m, 2H, 
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C34H2), 1.53-1.49 (m, 2H, C32H2), 1.47 (d, J = 6.8 Hz, 3H, CH3), 1.43 (d, J = 6.8 Hz, 3H, CH3), 
1.35 (m, 18H, 4xCH3), 1.29-1.21 (m, 2H, C33H2). 
13C NMR (126 MHz, CD2Cl2) δ 197.24 (C1), 173.63 (C30), 163.35 (C38), 147.94-147.09 (C9, 
C5, C17, C21), 134.55 (C4/C16), 133.41 (C16/C4), 130.88-130.61 (C7, C19), 125.85-125.07 
(C8, C6, C18, C20), 65.84 (C3), 62.24 (C36), 60.59 (C40), 58.35 (C2), 55.87 (C35), 42.24 
(C28), 41.12 (C41), 36.06 (C31), 29.72-29.37 (C22, C25, C10, C13), 28.69-28.66 (C32, C34), 
26.38 (CH3), 25.66 (C33), 25.42(CH3), 25.31(CH3), 24.65 (CH3), 24.29 (CH3), 23.86 (CH3). 
HR-MS (ESI, pos): m/z calcd. for C38H55AuClN5O2SH+ 878.3503 found 878.3506 [M+H]+; 
C38H55AuClN5O2SNa+ 900.3323 found 900.3325 [M+Na]+. 
 
Synthesis of the gold complex Me2biot-Au 2 
 
The biotinylated gold complex Me2biot-Au 2 was prepared following the general procedure E1 
yielding the product as a white solid (11 mg, 0.013 mmol, 27%): 
1H NMR (500 MHz, CD2Cl2) δ 7.06 (s, 1H, C8H/C6H), 7.04 (s, 1H, C6H/C8H), 7.01 (s, 2H, 
C15H, C17H), 5.44 (t, J = 6.3 Hz, 1H, N23H), 4.51 (ddd, J = 12.9, 8.5, 6.0 Hz, 1H, C3H), 4.16 
– 4.10 (m, 1H, C34H), 4.11 (q, J = 12.0, 11.4 Hz, 1H,C2H), 3.88 (dd, J = 8.8, 5.1 Hz, 1H, 
C30H), 3.83 (ddd, J = 11.7, 8.7, 4.8 Hz, 1H, C2H), 3.81 – 3.72 (m, 1H, C22H), 3.23 (m, 1H, 
C22H), 3.20 (m, 1H, C29H), 2.82 (d, J = 4.1 Hz, 2H, C35H2), 2.79 (s, 3H, C31H), 2.71 (d, J = 
2.2 Hz, 3H, C33H), 2.43 (s, 3H, C10H3/C11H3), 2.37 (s, 3H, C19H3/C20H3), 2.35 (s, 3H, 
C12H3), 2.33 (s, 3H, C21H3), 2.31 (s, 6H, C11H3/C10H3, C20H3/C19H3), 2.07 – 1.89 (m, 2H, 
C25H2), 1.67 (m, 2H, C28H2), 1.45 (m, 2H, C26H2), 1.31 (s, 1H, C27H2). 
13C NMR (126 MHz, CD2Cl2) δ 196.10 (C1), 173.63 (C24), 162.10 (C32), 139.85-139.82 (C7, 
C16), 136.80 (C4), 136.33 (C13), 136.14 (C5/C9), 135.13 (C14, C18),, 134.39 (C9/C5),, 
130.78 (C8/C6), 130.54 (C6/C8), 130.22 (C15, C17), 130.17 (C15, C17), 67.18 (C3), 64.74 
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(C30), 63.52 (C34), 56.26 (C29), 55.33 (C2), 42.40 (C22), 36.48 (C25), 35.75 (C35), 33.14 
(C31), 32.15 (C27), 29.63 (C33), 29.56-29.33 (C26), 25.67 (C28), 21.42 (C12, C21), 19.57 
(C10/C11), 18.53 (C19/C20), 18.36 (C11/C10), 18.33  (C20/C19). 
HR-MS (ESI, pos): m/z calcd. for C34H47AuN5O2S+ 786.3116 found 786.3104 [M-Cl]+; 
C34H47AuClN5O2S Na+ 844.2697 found 844.2682 [M+Na]+. 
Synthesis of the gold complex biot-GlyAu2 
 
In a dried, nitrogen-flushed, two-headed flask equipped with a gas outlet and a septum, boc-
protected NHC L11 (100 mg, 0.212 mmol, 1 eq) was dissolved in dry CH2Cl2 (4 mL). The 
mixture was stirred at room temperature (2 h) under consistent HCl-gas flow. The HCl-gas was 
prepared through dropwise addition of concentrated sulfuric acid to ammonium chloride 
powder and introduced to the reaction mixture via cannula. After two hours, the cannula was 
removed and the mixture was stirred at room temperature (2 h) before evaporating the solvent 
(reaction control with ninhydrin-stained TLC). The crude was dissolved in dry DMF (3 mL) and 
transferred to a vial containing PFP Boc-glycinate (72.3 mg, 0.212 mmol, 1 eq) before adding 
trimethylamine (0.60 mL, 4.24 mmol, 20 eq). The mixture was stirred at room temperature (16. 
Silica was added to the mixture and the solvent was removed in vacuo. The crude was purified 
via flash column chromatography (KP-Sil 25 g, gradient of 3% to 25% methanol in CH2Cl2) to 
yield NHC L12 as a white solid (102 mg, 0.193 mmol, 91%): 
1H NMR (600 MHz, DMSO-d6) δ 9.10 (s, 1H), 8.16 (t, J = 6.0 Hz, 1H), 7.10 (m, 4H), 7.03 (t, J 
= 6.0 Hz, 1H), 4.96 – 4.86 (m, 1H), 4.59 (t, J = 11.7 Hz, 1H), 4.25 (dd, J = 12.1, 7.4 Hz, 1H), 
3.59 – 3.52 (m, 1H), 3.41 (d, J = 5.4 Hz, 2H), 3.26 (dt, J = 12.9, 5.0 Hz, 1H), 2.39 (s, 3H), 2.36 
(s, 3H), 2.31 (s, 3H), 2.31 – 2.27 (m, 9H), 1.34 (s, 9H). 
13C NMR (151 MHz, DMSO-d6) δ 170.54, 160.39, 155.79, 139.86, 139.54, 135.45, 135.40, 
135.36, 78.20, 61.92, 54.43, 45.43, 43.39, 28.13, 20.60, 20.54, 18.14, 17.78, 17.38, 17.14. 
HR-MS (ESI, pos): m/z calcd. for C29H41N4O3+ 493.3173 found 493.3169 [M-Cl-]+. 
 
Gold complex L13 was prepared following the general procedure D2 yielding the product as a 
golden solid (70 mg, 0.096 mmol, 99%): 
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1H NMR (500 MHz, Methylene Chloride-d2) δ 7.06 (d, J = 12.0 Hz, 2H), 7.01 (s, 2H), 6.09 (s, 
1H), 4.76 (s, 1H), 4.61 – 4.47 (m, 1H), 4.09 (t, J = 11.4 Hz, 1H), 3.81 (dd, J = 11.6, 8.7 Hz, 
1H), 3.79 – 3.71 (m, 1H), 3.58 (qd, J = 17.0, 6.1 Hz, 2H), 3.29 (dt, J = 13.8, 5.4 Hz, 1H), 2.43 
(s, 3H), 2.36 (d, J = 3.9 Hz, 6H), 2.33 (s, 3H), 2.31 (s, 6H), 1.42 (s, 9H). 
13C NMR (126 MHz, Methylene Chloride-d2) δ 196.28, 139.86, 136.87, 136.27, 136.23, 136.08, 
135.05, 134.41, 130.78, 130.62, 130.22, 130.19, 63.29, 55.25, 42.28, 28.54, 21.43, 21.41, 
19.55, 18.50, 18.36, 18.31. 
HR-MS (ESI, pos): m/z calcd. for C29H40AuN4O3NH3+ 706.3026 found 706.3033 [M+NH3-Cl-]+. 
 
Biotinylated gold complex biot-GlyAu 2 was prepared following the general procedure E1 
yielding the product as a white solid (8 mg, 0.018 mmol, 27%): 
1H NMR (500 MHz, Methylene Chloride-d2) δ 7.39 (d, J = 6.2 Hz, 1H, N23H), 7.21 (s, 1H, 
N26H), 7.02 (m, 2H, C6H, C8H), 7.00 (s, 2H, C15H, C17H), 6.54 (d, J = 5.1 Hz, 1H, N34H), 
5.22 (d, J = 40.6 Hz, 1H, N36H), 4.50 (m, 1H, C3H), 4.41 (q, J = 7.1 Hz, 1H, C37H), 4.22 (p, J 
= 4.6, 4.2 Hz, 1H, C33H), 4.10 (td, J = 11.3, 5.1 Hz, 1H, C2H2), 3.89 – 3.81 (m, 2H, C2H2, 
C25H2), 3.70 – 3.60 (m, 2H, C25H2, C22H2), 3.29 (d, J = 10.0 Hz, 1H, C22H2), 3.07 (q, J = 7.3, 
6.2 Hz, 1H, C32H), 2.85 (dt, J = 12.9, 4.5 Hz, 1H, C38H2), 2.57 (t, J = 13.6 Hz, 1H, C38H2), 
2.39 (s, 3H, C10H3/C11H3), 2.36 (s, 3H, C19H3/C20H3), 2.33 (s, 3H, C12H3), 2.32 (s, 3H, 
C21H3), 2.31 (s, 3H, C11H3/C10H3), 2.30 (m, 3H, C20H3/C19H3), 2.22 – 2.07 (m, 2H, C28H2), 
1.63 – 1.52 (m, 4H, C31H2, C29H2), 1.32 – 1.28 (m, 2H, C30H2). 
13C NMR (126 MHz, Methylene Chloride-d2) δ 195.87 (C1), 174.60 (C27), 171.14-171.05 
(C24), 164.42 (C35), 139.76-139.64 (C7, C16), 137.12 (C4), 136.41-136.18 (C13), 63.16 (C3), 
62.33 (C33), 60.68 (C37), 56.10-55.57 (C2), 46.59 (C32), 43.65 (C25), 42.13 (C22), 41.16-
41.01 (C38), 35.38 (C28), 28.58 (C29/C31), 28.25-28.13 (C30), 25.72-25.57 (C31/C29), 21.43 
(C12, C21), 19.64 (C10), 18.52 (C11/C19), 18.38 (C20). 
HR-MS (ESI, pos): m/z calcd. for C34H46AuN6O3S+ 815.3012, 816.3045, 817.3076 found 
815.3010, 816.3032, 817.3031 [M-Cl-]+, (C34H46AuN6O3S)22+ 815.3012, 815.8028, 816.3043, 










Tabulation of data displayed in SI Figure 2. 
 
All experiments were conducted as duplicates. An Eppendorf tube (1500 µL) was charged 
successively with MES-buffer (165 µL, 50 mM, pH 5), purified protein (20 µL of 1000 µM BBS 
in MQ-water) and cofactor (5 µL of 2 mM in DMSO). The tubes were incubated in a 
thermoshaker (20 min, 37 °C, 900 rpm). Afterwards, substrate 1 (10 µL of 100 mM in DMSO) 
was added and the tubes were shaken in a thermoshaker for 24 hours. The reaction was 
quenched by the addition of methanol (200 µL), followed by centrifugation (14’000 rpm, 10 °C, 
10 min). In UPLC vials, the reaction mixture (20 µL) was diluted in UPLC media (980 µL, 1:1 
MeCN:MQ-Water containing 20.4 µM of phthalane) before UPLC-MS analysis. 
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SI Figure 2 Cofactor screening using purified Sav samples: [biot-Au 2] = 1 mol%, [Sav] = 2 mol%, MES-
buffer pH = 5, 37 °C and 24 h reaction time. All reactions were performed in duplicate. 
Control experiments and reaction optimization 
An Eppendorf tubes (1500 µL) was charged successively with MES-buffer (165 µL, 50 mM, 
pH 5) or a mixture of MES-buffer and cell lysate (BL21 E.coli with DNAse and lysozyme in MQ 
water), purified protein (20 µL of 1000 µM BBS in MQ-water), additives (dissolved either in 
DMSO or MQ water) and cofactor (5 µL of 2 mM in DMSO). All additives were freshly prepared 
prior to each run. The tubes were incubated in a thermoshaker (20 min, 37 °C, 900 rpm). 
Afterwards, substrate 1 (10 µL of 100 mM in DMSO) was added and the tubes were shaken in 
a thermoshaker for the indicated reaction time at 37 °C. The reaction was quenched by the 
addition of methanol (200 µL) followed by centrifugation (14’000 rpm, 10 °C, 10 min). In UPLC 
vials, the reaction mixture (20 µL) was diluted in UPLC media (980 µL, 1:1 MeCN:MQ-Water 




SI Figure 3 HABA displacement titration of biotin and biotinylated cofactors biot-Au 2 and Me2biot-
Au 2 in the presence of Sav-SOD K121A, Sav-SOD S112N T114S T115N N118G K121G S122G and 
Sav-SOD S112T T114T T115A N118S K121F S122G. For procedure see.219  
 
SI Figure 4 Timecourse of the HAMase conversion using biot-Au 2 · Sav-SOD K121A: [biot-Au 2] 
1 mol%, [Sav] = 2 mol%, MES-buffer pH 5, 37 °C. 
 
 
SI Figure 5 Reactivity of biot-Au 2 · Sav-SOD K121A in different aqueous buffer: [biot-Au 2] 1 mol%, 
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1 3.7 ± 0.1 0.8 ± 0.0 
3 8.0 ± 0.5 3.0 ± 0.1 
6 11.9 ± 0.2 6.6 ± 0.2 
24 22.1 ± 1.6 14.3 ± 3.1 




TON indole 2 
Acetate 15.5 ± 0.5 12.0 ± 1.2 
Tris HCl 9.5 ± 0.9 6.1 ± 0.5 
PBS 13.5 ± 1.5 7.3 ± 0.7 
MQ H2O 8.5 ± 1.0 3.9 ± 0.5 
MES 21.7 ± 1.2 10.4 ± 1.4 








SI Figure 7 Performance of chimeric streptavidin with different substrate concentrations. Reaction 
conditions: [biot-Au 2] = 1 mol%, [Sav] = 2 mol%, MES-buffer pH = 5, 37 °C and 28 h reaction time. All 
reactions were performed in duplicates. 
 
SI Figure 8 Reactivity of biot-Au 2 · Sav-SOD K121A with varying cofactor concentrations. Reaction 
conditions: [Sav] = 2x[biot-Au 2], MES-buffer pH = 5, 37 °C and 24 h reaction time. All reactions were 












































































2 17.8 ± 0.9 1.0 ± 0.0 1.4 ± 0.1 
3 12.5 ± 1.1 8.6 ± 1.4 7.1 ± 1.7 
4 18.3 ± 1.3 10.9 ± 2.0 5.3 ± 0.6 
5 32.8 ± 8.0 11.0 ± 2.6 7.1 ± 2.0 
6 28.4 ± 3.0 20.7 ± 2.2 16.7 ± 2.8 
7 16.0 ± 0.9 5.8 ± 0.0 6.8 ± 0.4 
8 4.1 ± 0.3 0.7 ± 0.0 0.5 ± 0.0 
9 1.2 ± 0.1 0.2 ± 0.0 0.2 ± 0.0 
10 0.5 ± 0.0 0.1 ± 0.0 0.2 ± 0.0 






5 25.5 ± 1.1 20.3 ± 3.8 
2.5 20.7 ± 0.2 19.0 ± 3.3 
1.5 16.6 ± 0.5 8.1 ± 1.1 







1.00 22.1 ± 1.6 14.3 ± 3.1 
0.50 34.0 ± 0.7 8.6 ± 0.6 
0.25 10.9 ± 0.4 1.0 ± 0.1 
0.10 8.4± 0.8 0 
SI Figure 6 Reactivity of biot-Au 2 · Sav-SOD K121A at different pH in MES-Buffer: [biot-Au 2] 1 mol%, 
[Sav] 2 mol%, 37 °C and 72 h reaction time. All reactions were performed in duplicates. 




SI Figure 9 Screening Sav mutants bearing mutations on position K121 or S112: [biot-Au 2] 1 mol%, 
[Sav] 2 mol%, MES-buffer pH 5, 37 °C and 5 days reaction time. All reactions were performed in 
duplicates. 
SI Table 2 Summary of the HAMAse activity screening using Sav mutants: [biot-Au 2] 1 mol%, [Sav] 
2 mol%, MES-buffer pH 5, 37 °C and 5 days reaction time. All reactions were performed in duplicates. 
Sav Mutants TON quinazolinone 3 TON indole 2 
K121L 72.4 ± 2.0 0.8 ± 0.1 
K121M 67.0 ± 0.4 0.8 ± 0.1 
K121F 62.5 ± 0.7 0 
K121I 60.8 ± 1.3 0.8 ± 0.1 
K121T 60.6 ± 0.8 0.9 ± 0.2 
K121V 60.1 ± 0.9 0.8 ± 0.1 
K121E 60.1 ± 4.4 0 
K121W 56.4 ± 0.7 0.4 ± 0.1 
K121D 52.3 ± 0.8 0 
K121N 52.1 ± 1.7 0 
K121S 50.1 ± 0.8 0.4 ± 0.1 
K121C 47.0 ± 1.2 0.2 ± 0.1 
K121P 44.3 ± 0.9 0.9 ± 0.1 
K121Q 39.2 ± 0.6 0 
K121A 33.1 ± 0.5 0.9 ± 0.1 
K121H 27.3 ± 0.8 0 
K121G 25.5 ± 0.3 1.9 ± 0.1 
S112E 17.7 ± 0.4 0 
S112T 12.3 ± 0.2 0.4 ± 0.1 
S112G 10.6 ± 0.4 0 
S112D 10.5 ± 0.0 0.5 ± 0.1 
S112F 9.6 ± 0.1 0 
S112Y 9.5 ± 0.0 0.5 ± 0.1 
S112C 8.0 ± 0.2 0 
K121R 7.6 ± 0.9 0 
S112H 7.2 ± 0.4 0.2 ± 0.1 
S112N 7.2 ± 0.0 0.6 ± 0.1 
WT 6.9 ± 0.1 0 
S112M 6.7 ± 0.2 0.3 ± 0.1 
S112P 6.0 ± 0.1 0.4 ± 0.1 
S112L 4.2 ± 0.2 0.2 ± 0.1 
S112A 4.2 ± 0.1 0 
biot-Au 2 only 2.8 ± 0.1 0.6 ± 0.1 
S112K 2.0 ± 0.0 0.1 ± 0.1 
S112R 1.3 ± 0.2 0.1 ± 0.1 
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SI Table 3 Evaluation of the reactivity and stability of various gold-complexes and gold-based ArM 





(CH3)2SAuCl - none 0 0.2 ± 0.0 
AuSIMes - none 1.3 ± 0.5 0.6 ± 0.0 
AuIMes - none 0.3 ± 0.3 0.2 ± 0.1 
AuSIPr - none 0.2 ± 0.2 0.0 ± 0.0 
AuIPr - none 0.3 ± 0.3 0.0 ± 0.0 
biot-Au 2 - none 1.3 ± 0.1 0.2 ± 0.0 
AuSIMes Sav K121L none 0 0.3 ± 0.1 
biot-Au 2 Sav K121L none 47.5 ± 1.4 2.1 ± 0.0 
biot-Au 2 Sav-SOD K121A none 33.1 ± 0.3 20.5 ± 0.1 
biot-Au 2 Sav-SOD K121A 10% cell lysate 14.7 ± 0.3 5.1 ± 0.1 
biot-Au 2 Sav-SOD K121A 50% cell lysate 12.9 ± 0.3 2.3 ± 0.0 
biot-Au 2 Sav-SOD K121A 2 mol% GSH redc 28.7 ± 0.7 9.5 ± 0.4 
biot-Au 2 Sav-SOD K121A 20 mol% GSH redc 22.3 ± 1.1 6.2 ± 0.3 
biot-Au 2 Sav-SOD K121A 100 mol% GSH redc 7.4 ± 0.1 1.2 ± 0.1 
biot-Au 2 Sav-SOD K121A 100 mol% GSH redd 7.4 ± 0.5 1.4 ± 0.0 
biot-Au 2 Sav-SOD K121A 100 mol% GSH oxd 33.6 ± 0.4 12.8 ± 0.4 
biot-Au 2 Sav-SOD K121A 1 mol% biotind 19.0 ± 0.5 10.2 ± 1.3 
biot-Au 2 Sav-SOD K121A 2 mol% biotind 12.0 ± 0.6 3.8 ± 0.3 
biot-Au 2 Sav-SOD K121A 2 mol% biotinc 15.9 ± 0.3 3.7 ± 0.2 
biot-Au 2 Sav-SOD K121A 4 mol% biotind 6.7 ± 0.6 1.8 ± 0.2 
biot-Au 2 Sav-SOD K121A 100 mol% Diamided 20.2 ± 0.4 34.2 ± 0.0 
biot-Au 2 - 100 mol% Diamided 10.0 ± 0.8 3.4 ± 0.3 
aReaction conditions: Vtot 200 μL (VDMSO 15 μL), [Sub] 5 mM, [biot-Au 2] 50 µM, [Sav] 100 µM, 
MES-buffer pH 5 + cell lysate, 37 °C for 72 h. The reactions were carried out in duplicates. 















Catalysis in cell-free extracts 
Each pipetting operation was followed by five mixing steps. In a glass 96-well plate, cell-free 
extracts (190 L) were mixed with MES buffer (190 L, pH 5, 50 mM). To the mixture, biot-
Au 2 (10 L, 0.25 mM in DMSO) was added, the plate was sealed with aluminum foil and 
shaken (30 min at 37 °C). Afterwards, the substrate (10 L, 100 mM in DMSO) was added, the 
plate was sealed and the mixture was shaken (4 days at 37 °C). The reaction was quenched 
by addition of MeOH (400 L, HPLC grade). In UPLC vials, the reaction mixture (150 L) was 
diluted in UPLC media (850 L, 1:1 MeCN:MQ-Water containing 40 M of phthalane and 0.1% 
formic acid) prior to UPLC-MS analysis. For the first round of directed evolution on position 
N118, K121 and S122, our hit selection was based on the measured activity and selectivity in 
relation to the B4F assay as the expression levels varied. Expression was optimized, thus for 
next rounds of directed evolution, hit selection was based solely on activity and selectivity.  
SI Table 4 Investigation of E. coli strains for cell-free extract catalysis with various ratios of MES buffer 
(pH 5, 50 mM) to cell-free extract (cfe) before directed evolution. 
E.Coli Strain Mutant Amount of cfe (%) 
TON quinazo-
linone 3 TON indole 2 
BL21(DE3) emptyV 100 0 0 
BL21(DE3) Sav_WT 100 0 0 
BL21(DE3) Sav_K121L 100 0 0 
BL21(DE3) emptyV 50 0 0 
BL21(DE3) Sav_WT 50 1 0 
BL21(DE3) Sav_K121L 50 11 0 
BL21(DE3) emptyV 30 0 0 
BL21(DE3) Sav_WT 30 2 0 
BL21(DE3) Sav_K121L 30 15 0 
SHuffle-T7 emptyV 50 0 0 
SHuffle-T7 Sav_WT 50 0 0 
SHuffle-T7 Sav_K121L 50 0 0 
SHuffle-T7 emptyV 30 0 0 
SHuffle-T7 Sav_WT 30 0 0 





SI Figure 10 Scatterplot of 2500 cell-free-extract experiments covering 4 Generations of chimeric 
streptavidin analyzed via UPLC-MS after preselection via B4F-assay displaying the two evolution 
trajectories of HAMase. 
 




Determination of the biotin-binding sites 
First, a solution of B4F (1 M) in MOPS (50 mM, pH = 7.4) was prepared. Then, 200 L of this 
B4F solution was added to a clear micro wellplate, followed by 10 L of cell-free extract (cfe). 
The negative control contained 10 L of lysis buffer (LB). The positive control (SavSTD) 
contained 10 L of 40 M Sav as 100% saturation point. It should be noted that, the lysis buffer 
and protein components can alter the B4F fluorescence up to 10-20%. The fluorescence of 
each well was measured using a Tecan fluorimeter Infinite M1000Pro. The total concentration 
of Sav should be linear within this region and calculated using the following equation: 
[SAVCFE]( µM) =[(FCFE-FSAVSTD)- (FLB-FSAVSTD)]/(-FLB-FSAVSTD)*20 
       FCFE = Fluorescence intensity of Cell free extract 
  FSAVSTD = Fluorescence intensity of Sav Standard to bind all free BF4 
FLB = Fluorescence intensity of Lysis buffer  
Summary of key experiments using purified Sav 
Under the general UPLC-conditions (General Information), the following retention times were 
obtained internal standard (phthalane) at ~2.11 min, the quinazolinone 3 at ~2.64 min, the urea 
1 at ~4.19 min, the indole 2 at ~5.05 min and a dimeric side product at 6.40 min. Higher MeOH 
content changes the retention times (see optimized conditions SI Table 5). Standard reaction 
conditions: Vtot 200 L (VDMSO 15 L), [Sub] 5 mM, [biot-Au 2] 50 M, [Sav] 100 M, MES-
buffer pH 5, 37 °C for 24 h. The reactions were carried out in two sets of duplicates; The 
reactions were quenched with MeOH to a total volume of 800 L followed by centrifugation 
(14’000 rpm, 10 °C, 10 min). In UPLC vials, the reaction mixture (40 L) was diluted in UPLC 
media (960 L, 1:1 MeCN:MQ-Water containing 40.8 M of phthalane) before UPLC-MS 
analysis 








for indole 2 
Sav K121A 17.95 3.52 21.48 16.4% 
Sav K121A 17.00 3.91 20.91 18.7% 
Sav K121A 18.72 3.99 22.71 17.6% 
Sav K121A 17.60 3.29 20.89 15.8% 
Sav-SOD K121A 25.49 16.18 41.67 38.8% 
Sav-SOD K121A 24.08 16.09 40.17 40.1% 
Sav-SOD K121A 24.73 12.38 37.11 33.4% 
Sav-SOD K121A 23.64 15.48 39.12 39.6% 
Sav-SOD N118G K121G S122G 27.52 33.92 61.44 55.2% 
Sav-SOD N118G K121G S122G 25.50 30.19 55.68 54.2% 
Sav-SOD N118G K121G S122G 26.97 34.72 61.68 56.3% 
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Sav-SOD N118G K121G S122G 23.95 28.01 51.96 53.9% 
Sav-SOD N118S K121F S122G 38.59 0.38 38.97 1.0% 
Sav-SOD N118S K121F S122G 37.89 0.45 38.34 1.2% 
Sav-SOD N118S K121F S122G 37.34 0.36 37.70 1.0% 
Sav-SOD N118S K121F S122G 39.64 0.45 40.10 1.1% 
Sav_SOD S112N N118G K121G S122G 21.90 44.78 66.68 67.2% 
Sav_SOD S112N N118G K121G S122G 20.92 44.67 65.59 68.1% 
Sav_SOD S112N N118G K121G S122G 21.13 44.51 65.64 67.8% 
Sav_SOD S112N N118G K121G S122G 20.19 41.77 61.96 67.4% 
Sav_SOD S112T N118S K121F S122G 40.42 1.07 41.49 2.6% 
Sav_SOD S112T N118S K121F S122G 42.50 1.23 43.73 2.8% 
Sav_SOD S112T N118S K121F S122G 40.24 1.03 41.27 2.5% 
Sav_SOD S112T N118S K121F S122G 40.80 1.14 41.94 2.7% 
Sav_SOD S112N T114S T115N N118G 
K121G S122G 
18.14 55.07 73.21 75.2% 
Sav_SOD S112N T114S T115N N118G 
K121G S122G 
17.59 46.04 63.63 72.3% 
Sav_SOD S112N T114S T115N N118G 
K121G S122G 
18.54 52.31 70.85 73.8% 
Sav_SOD S112N T114S T115N N118G 
K121G S122G 
17.61 46.49 64.10 72.5% 
Sav_SOD S112T T115A N118S K121F 
S122G 
41.48 2.90 44.38 6.5% 
Sav_SOD S112T T115A N118S K121F 
S122G 
41.69 3.08 44.77 6.9% 
Sav_SOD S112T T115A N118S K121F 
S122G 
42.98 3.53 46.51 7.6% 
Sav_SOD S112T T115A N118S K121F 
S122G 
















Sav-SOD N118G K121G S122G 
 
Sav-SOD N118G K121G S122G 
 







Sav-SOD N118S K121F S122G 
 
Sav-SOD S112N N118G K121G 
S122G 
 








Sav-SOD S112T N118S K121F 
S122G 
 
Sav-SOD S112T N118S K121F 
S122G 
 
Sav-SOD S112N T114S T115N 
N118G K121G S122G 
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for indole 2 
Sav-SOD S112N T114S T115N 
N118G K121G S122G 
Sav-SOD S112T T115A N118S 
K121F S122G 
 







Sav-SOD S112N T114S T115N N118G 
K121G S122G – OPTIMIZED 1 
1.78 46.51 48.30 96.3% 
Sav-SOD S112N T114S T115N N118G 
K121G S122G – OPTIMIZED 2 
1.65 47.17 48.83 96.6% 
Sav-SOD S112N T114S T115N N118G 
K121G S122G – OPTIMIZED 3 
2.07 53.86 55.86 96.3% 
Sav-SOD S112N T114S T115N N118G 
K121G S122G – OPTIMIZED 4 
1.93 49.84 51.77 96.3% 
Sav-SOD S112T T115A N118S K121F 
S122G – OPTIMIZED 1 
264.98 2.40 267.38 0.9% 
Sav-SOD S112T T115A N118S K121F 
S122G – OPTIMIZED 2 
308.30 2.73 311.03 0.9% 
Sav-SOD S112T T115A N118S K121F 
S122G – OPTIMIZED 3 
349.21 2.22 351.43 1.0% 
Sav-SOD S112T T115A N118S K121F 
S122G – OPTIMIZED 4 
397.26 3.83 401.09 0.6% 
Optimized reaction conditions for quinazolinone 3: Vtot 400 L (365 L MES-buffer pH 5) [Sub] 2.5 mM, [biot-Au2] 
2.5 M, [Sav] 5 M, 39 °C for 72 h and for indole 2: Vtot 100 L (VMES 45 L, VDMSO 20 L), [Sub] 15 mM, [Diamide] 
15 mM, [biot-Au 2] 100 M, [SAV] 200 M, 37 °C for 72 h. Both sets of experiments were quenched with MeOH to 





Sav-SOD S112N T114S T115N N118G 
K121G S122G – OPTIMIZED 1 
Sav-SOD S112N T114S T115N N118G 







       
 
 
Sav-SOD S112N T114S T115N N118G 
K121G S122G – OPTIMIZED 3 
Sav-SOD S112N T114S T115N N118G 
K121G S122G – OPTIMIZED 4 
Sav-SOD S112T T115A N118S 












Sav-SOD S112T T115A N118S 
K121F S122G – OPTIMIZED 2 
Sav-SOD S112T T115A N118S 
K121F S122G – OPTIMIZED 3 
Sav-SOD S112T T115A N118S 
K121F S122G – OPTIMIZED 4 
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Preparative reaction with purified Sav-SOD hits 
Preparative reaction using Sav-SOD N-SN-GGG 
To a 50 mL Falcon tube were added successively MES buffer (15 mL, 50 mM, pH 5), Sav-
SOD S112N T114S T115N N118G K121G S122G (188 mg, 8 mol, 0.04 mol%), biot-Au 2 
(2 mL of 2 mM solution in DMSO, 4 mol, 0.02 mol%) and diamide (0.5 mL of 100 mM solution 
in H2O, 0.1 mmol, 50 mol%). The tube was closed, wrapped in aluminum foil and shaken 
(30 min at 37 °C in an incubator). Then, the substrate 1 (2 mL of 100 mM solution in DMSO, 
0.2 mmol) was added, the tube was closed, sealed with parafilm, wrapped in aluminum foil and 
shaken (4 days at 37 °C in an incubator). The reaction mixture was diluted (80 mL) with a 1:1:1 
mixture of brine, MQ water and sat. NH4Cl. The aqueous phase was extracted with EtOAc 
(5x50 mL), washed with brine (20 mL), dried over MgSO4 and filtrated. The crude was taken 
up in silica and purified via flash column chromatography with a cyclohexane/EtOAc gradient 
to yield the following products in three fractions: indole 2 (34 mg, 0.14 mmol, 72%); 
quinazolinone 3 (3 mg, 13 mol, 6%); and sideproducts (10 mg, uncharacterisable). 
The isolated ratio of indole 2 and quinazolinone 3 is 92:8 at a combined yield of 78%. 
 




SI Figure 13 UPLC-MS DAD (100-500 nm) and PDA (254 nm) Chromatogram of isolated indole 2 (5.37 
min). 
 
Preparative reaction using Sav-SOD T-A-SFG 
To a 100 mL tube were added successively MES buffer (80 mL, 50 mM, pH 5), Sav-SOD 
S112T T114T T115A N118S K121F S122G (47 mg, 2 mol, 0.01 mol%) and biot-Au 2 (1 mL 
of 2 mM solution in DMSO, 1 mol, 0.005 mol%). The tube was closed, wrapped in aluminum 
foil and shaken (30 min at 37 °C in an incubator). Then, substrate 1 (1 mL of 100 mM solution 
in DMSO, 0.1 mmol) was added, the tube was closed, sealed with parafilm, wrapped in 
aluminum foil and shaken (4 days at 37 °C in an incubator). The reaction mixture was then 
diluted (80 mL) with a 1:1:1 mixture of brine, MQ water and sat. NH4Cl. The aqueous phase 
was extracted with EtOAc (5x50 mL), washed with brine (20 mL), dried over MgSO4 and 
filtered. The crude was taken up in silica and purified via flash column chromatography with a 
cyclohexane/EtOAc gradient to yield the following products in three fractions: urea 1 (<1 mg, 
<4 mol, <4%); quinazolinone 3 (11 mg, 47 mol, 47%); and sideproducts (<1 mg, 
uncharactarisable). 
The isolated ratio of quinazolinone 3 to indole 2 is >99:1 at a combined yield of 47% which 
corresponds to a total TON of 94. Indole 2 could not be isolated and is inferred from the 





SI Figure 14 Stacked 1H NMR spectra of isolated and the reference quinazolinone 3 in DMSO-d6. 
  
SI Figure 15 UPLC-MS DAD (100-500 nm) and DAD (300 nm) Chromatogram of isolated quinazolinone 









SI Figure 16 Isotopic product-distribution of the HAMase biot-Au 2 · Sav-SOD N-SN-GGG carried 
out in D2O. a Deuteration profile of quinazolinone 3 and indole 2 resulting from the gold-catalyzed 
hydroamination. For the quinazolinone 3, all highlighted protons/deuterons are readily exchanged in 
D2O/H2O; b 1H NMR analysis of the indole 2-d2 isolated from preparative reactions in H2O (top) and D2O 
(bottom, the urea N–H is readily exchanged in the presence of traces of H2O) and c HR-MS analysis of 





SI Figure 17 Stacked 1H NMR spectrum confirming the inertness of indole 2 and 2-d2 towards 
deuterium-proton exchange at the indole’s C2 and C3 positions (highlighted in red). In contrast, the urea 
proton (blue) is readily exchanged. 
 
Preparative deuterium incorporation experiments Sav-SOD N-SN-GGG 
To a 50 mL Falcon tube were added successively MES buffer (15 mL, 50 mM in D2O, pH 5), 
Sav-SOD S112N T114S T115N N118G K121G S122G (188 mg, 8 mol, 0.04 mol%), biot-
Au 2 (2 mL of 2 mM solution in DMSO-d6, 4 mol, 0.02 mol%) and diamide (0.5 mL of 100 mM 
solution in D2O, 0.1 mmol, 50 mol%). The tube was closed, wrapped in aluminum foil and 
shaken (30 min at 37 °C in an incubator). Urea 1 (2 mL of 100 mM solution in DMSO-d6, 
0.2 mmol) was added, the tube was closed, sealed with parafilm, wrapped in aluminum foil and 
shaken (3 days at 37 °C in an incubator). Afterwards, the reaction mixture was diluted with 
D2O (50 mL). The aqueous phase was extracted with EtOAc (5x50 mL), washed with NaCl in 
D2O (20 mL), dried over MgSO4 and filtrated. The crude was taken up in silica and purified via 
flash column chromatography with a cyclohexane/EtOAc gradient to yield the following 
products in four fractions: deuterated indole 2-d2 (26 mg, 0.10 mmol, 53%); urea 1 (21 mg, 
91 mol, 42%); traced of quinazolinone 3 (<1mg); and sideproducts (3 mg, uncharacterisable). 
Deuterated Indole 2-d2 was isolated with twice >98% Deuterium intake in both the C2 and C3 
position of the indole moiety.  
reference indole 2  
recorded in DMSO-d6 
indole 2 isolated from the HAMase 
carried out in H2O stirred at 37 °C for 
16 h in D2O prior to 1H NMR, 
recorded in D2O:DMSO-d6 (2:1) 
Following purification, 2-d2 was 
dissolved in H2O:DMSO-d6 and 
stirred at 37 °C for 16 h prior to  
1H NMR, spectra recorded in 
H2O:DMSO-d6 (2:1) 
indole 2-d2 isolated from the 
HAMase carried out in D2O 
recorded in D2O:DMSO-d6 (2:1) 
116 
 
Preparative deuterium incorporation experiments Sav-SOD T-A-SFG 
To a 100 mL tube were added successively MES buffer (80 mL, 50 mM in D2O, pH 5), Sav-
SOD S112T T114T T115A N118S K121F S122G (47 mg, 2 mol, 0.01 mol%) and biot-Au 2 
(1 mL  of 2 mM solution in DMSO-d6, 1 mol, 0.005 mol%). The tube was closed, wrapped in 
aluminum foil and shaken (30 min at 37 °C in an incubator). Urea 1 (1 mL of 100 mM solution 
in DMSO-d6, 0.1 mmol) was added, the tube was closed, sealed with parafilm, wrapped in 
aluminum foil and shaken (4 days at 37 °C in an incubator). Afterwards, the reaction mixture 
was diluted with D2O (50 mL). The aqueous phase was extracted with EtOAc (5x50 mL), 
washed with NaCl in D2O (20 mL), dried over MgSO4 and filtrated. The crude was taken up in 
silica and purified via flash column chromatography with a cyclohexane/EtOAc gradient to yield 
the following products in four fractions: indole 2-d2 (<1 mg, <4 mol, <4%); urea 1 (11 mg, 
40 mol, 40%); quinazolinone 3 (4 mg, 17 mol, 17%); and sideproducts(<1 mg, 
uncharactarisable). 
Deuterated Indole 2-d2 was isolated with twice >99% Deuterium intake in both the C2 and C3 




Procedure: An Eppendorf tube (1500 L) was charged successively with MES-buffer (50 mM, 
pH 5), purified protein (1000 M BBS in MQ-water), additives (100 mM, diamide dissolved in 
MQ water) and cofactor (2 mM in DMSO) were added. The tube was incubated in a 
thermoshaker (20 min, 37 °C, 900 rpm). Afterwards, urea 1 (100 mM in DMSO) was added 
and the tube was shaken in a thermoshaker. The reaction was quenched by the addition of 
methanol to a total volume of 800 L, followed by centrifugation (14’000 rpm, 10 °C, 10 min). 
In UPLC vials, the reaction mixture (40 L) was diluted in UPLC media (960 L, 1:1 MeCN:MQ-
Water containing 40.8 M of phthalane) before UPLC-MS analysis. 
Under optimized conditions, Sav-SOD NSNGGGb predominantly produces the 5-endo-dig 
product (indole) product most cases (1a-1e), while Sav-SOD TASFGc predominantly produces 
the quinazolinone products (1a-1f). Comparing the two mutants under standard reaction 
conditionsa highlights the marked influence of the mutations on the regioselectivity for all 
substrates tested. 
 
SI Table 7 Substrate scope using the evolved biot-Au 2 · Sav-SOD chimeras under standard reaction 

































































The experiments were carried out in duplicate. The combined turnover for both products is displayed as well 
as the quinazolinone:indole ratio (3:2). aStandard Reaction conditions for directed evolution see SI Table 5; 
b Reaction conditions optimized for 5-endo-dig product: Vtot 100 L (VMES 45 L, VDMSO 20 L), [Sub] 15 mM, 
[Diamide] 15 mM, [biot-Au 2] 100 M, [Sav] 200 M, [MES-buffer] 50 mM, pH 5, 37 °C for 24 h; c Reaction 
conditions optimized for 6-exo-dig product: Vtot 400 L (VMES 365 L, VDMSO 12 L) [Sub] 2.5 mM, [biot-Au 2] 
6.25 M, [Sav] 12.5 M, [MES-buffer] 50 mM, pH 5, 39 °C for 48 h; d with following changes: [biot-Au 2] 








Spectrum 1 1H NMR Spectrum of urea 1 in DMSO-d6. 
 




Spectrum 3 1H NMR Spectrum of urea 1a in DMSO-d6. 
 





Spectrum 5 1H NMR Spectrum of urea 1b in DMSO-d6. 
  




Spectrum 7 1H NMR Spectrum of urea 1c in DMSO-d6. 
 





Spectrum 9 1H NMR Spectrum of urea 1d in DMSO-d6. 
 





Spectrum 11 1H NMR Spectrum of urea 1e in DMSO-d6. 
 




Spectrum 13 1H NMR Spectrum of urea 1f in DMSO-d6. 
  




Spectrum 15 1H NMR Spectrum of indole 2 in DMSO-d6. 
 
 




Spectrum 17 1H NMR Spectrum of indole 2a in DMSO-d6. 
  




Spectrum 19 1H NMR Spectrum of indole 2b in DMSO-d6. 
  




Spectrum 21 1H NMR Spectrum of indole 2c in DMSO-d6. 
 





Spectrum 23 1H NMR Spectrum of indole 2d in DMSO-d6. 
 





Spectrum 25 1H NMR Spectrum of indole 2e in DMSO-d6. 
  




Spectrum 27 1H NMR Spectrum of indole 2f in DMSO-d6.  
 
Spectrum 28 19F NMR Spectrum of indole 2f in DMSO-d6. 
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Spectrum 30 1H NMR Spectrum of quinazolinone 3 in DMSO-d6. 
 




Spectrum 32 1H NMR Spectrum of quinazolinone 3a in DMSO-d6. 
  




Spectrum 34 1H NMR Spectrum of quinazolinone 3b in DMSO-d6. 
  




Spectrum 36 1H NMR Spectrum of quinazolinone 3c in DMSO-d6. 
  




Spectrum 38 1H NMR Spectrum of quinazolinone 3d in DMSO-d6. 
 
 




Spectrum 40 1H NMR Spectrum of quinazolinone 3e in DMSO-d6. 
 





Spectrum 42 1H NMR Spectrum of quinazolinone 3f in DMSO-d6.  
 




   
Spectrum 44 13C NMR Spectrum of quinazolinone 3f in DMSO-d6. 
 




Spectrum 46 13C NMR Spectrum of BiotMS in DMSO-d6. 
 




Spectrum 48 19F NMR Spectrum of Me2BiotPFP in DMSO-d6. 
   




Spectrum 50  1H NMR spectrum of acid 17 in CDCl3. 
  




Spectrum 52  1H NMR spectrum of aldehyde 19 in CDCl3. 
  




Spectrum 54  13C NMR spectrum of amine 13 in DMSO-d6. 
  




Spectrum 56  1H NMR Spectrum of biot-Au 1 in CD2Cl2. 
 
 




Spectrum 58 1H NMR Spectrum of gold complex L2 in CD2Cl2. 
 





Spectrum 60  1H NMR Spectrum of biot-Au 2 in CD2Cl2. 
 





Spectrum 62 1H NMR Spectrum of gold complex L5 in CD2Cl2. 
 





Spectrum 64 1H NMR Spectrum of biot-Au 3 in CD2Cl2. 
 





Spectrum 66 1H NMR Spectrum of NHC salt L9 in CD2Cl2. 
 





Spectrum 68 1H NMR Spectrum of biot-Au 4 in CD2Cl2. 
 





Spectrum 70 1H NMR Spectrum of NHC salt L10 in CD2Cl2. 
 





Spectrum 72 1H NMR Spectrum of biot-Au 5 in CD2Cl2. 
 





Spectrum 74 1H NMR Spectrum of gold complex L6 in CD2Cl2. 
 




Spectrum 76 1H NMR Spectrum of Me2biot-Au 2 in CD2Cl2. 
 





Spectrum 78 1H NMR Spectrum of NHC 5 in DMSO-d6. 
 





Spectrum 80 1H NMR Spectrum of Gold complex 8 in Methylene chloride-d2. 
 





Spectrum 82 1H NMR Spectrum of biot-GlyAu 2 in Methylene chloride-d2. 
  




Diffusion Ordered Spectroscopy (DOSY) Data 
 
Summary: 






Diffusion ordered spectroscopy (DOSY) of the biotinylated gold complex biot-Au 2 revealed a 
significantly lower diffusion constant compared to the boc-protected gold complex boc-Au 2 
even taking into account the molecular weight difference. Rough calculations from the diffusion 
coefficients (7.9x10-10m2/s for biot-Au 2 and 10.1x10-10m2/s for boc-Au 2) suggest a 
predominantly dimeric nature for biot-Au 2. Further investigations under mild HR MS 
conditions allowed to record accurate mass spectra of dimeric biot-Au 2 and other dimers of 
biotinylated gold complexes (see HR-MS spectra). While recording native MS spectra of biot-
Au 2 in Sav at high cone voltages a large peak at m/z=1551 arouse indicating the release of 
dimeric biot-Au 2 under this harsh conditions (see SI Native MS spectrum 4). All these results 
lead us to the conclusions that biotinylated gold complexes have the tendency to dimerize 
and/or agglomerate. The increased diffusion constant of methylated Me2biot-Au 2 compared 






























= 𝟐. 𝟏𝟏 
Gold Complex Diff. Coef. ( 10-10 m2/s)a mass (g/mol) 
boc-Au 2 10.08 667.22 
biot-Au 2 7.857 793.25 
Me2biot-Au 2 8.475 821.28 




SI Figure 18 Aggregation of biotinylated gold complexes. (a) Overlay of recorded DOSY spectra for 
boc protected gold complex boc-Au 2 and biotinylated gold complexes biot-Au 2 (b) HR MS spectrum 




SIMFIT RESULTS for Aryl Peak (s) at 7.054 ppm 
INTENSITY fit : Diffusion : Variable Gradient : 
I=I[0]*exp(-D*SQR(2*PI*gamma*Gi*LD)*(BD-LD/3)*1e4) 
16 points for Peak 1,  Peak Point = 7.054 ppm 
Converged after 35 iterations! 
Results     Comp. 1     
I[0]           =  1.005e+000   
Diff Con.      =  9.994e-010 m2/s 
Gamma          =  4.258e+003 Hz/G 
Little Delta   =      2.800m 
Big Delta      =     24.900m 
RSS   =   6.508e-005 
SD    =   2.017e-003 




Diff Con  
(10-10 m2/s) 
Aryl-H 7.05 9.994 
NHC-H 4.13 10.11 
Methyl-H 2.44 10.07 
   
Mean Diff Con 10.058 




SIMFIT RESULTS for NHC-H (triplet) at 4.132 ppm 
INTENSITY fit : Diffusion : Variable Gradient : 
I=I[0]*exp(-D*SQR(2*PI*gamma*Gi*LD)*(BD-LD/3)*1e4) 
16 points for Peak 1,  Peak Point = 4.132 ppm 
Converged after 24 iterations! 
Results     Comp. 1     
I[0]           =  1.011e+000   
Diff Con.      =  1.005e-009 m2/s 
Gamma          =  4.258e+003 Hz/G 
Little Delta   =      2.800m 
Big Delta      =     24.900m 
RSS   =   4.946e-004 
SD    =   5.560e-003 
 
============================================================ 
SIMFIT RESULTS for methyl-H (s) at 2.444 ppm 
INTENSITY fit : Diffusion : Variable Gradient : 
I=I[0]*exp(-D*SQR(2*PI*gamma*Gi*LD)*(BD-LD/3)*1e4) 
16 points for Peak 1,  Peak Point = 2.444 ppm 
Converged after 27 iterations! 
Results     Comp. 1     
I[0]           =  1.007e+000   
Diff Con.      =  1.007e-009 m2/s 
Gamma          =  4.258e+003 Hz/G 
Little Delta   =      2.800m 
Big Delta      =     24.900m 
RSS   =   4.359e-004 







SIMFIT RESULTS for Aryl-H (s) at 7.050 ppm 
INTENSITY fit : Diffusion : Variable Gradient : 
I=I[0]*exp(-D*SQR(2*PI*gamma*Gi*LD)*(BD-LD/3)*1e4) 
16 points for Peak 1,  Peak Point = 7.050 ppm 
Converged after 32 iterations! 
Results     Comp. 1     
I[0]           =  1.010e+000   
Diff Con.      =  7.833e-010 m2/s 
Gamma          =  4.258e+003 Hz/G 
Little Delta   =      2.800m 
Big Delta      =     24.900m 
RSS   =   6.744e-005 
SD    =   2.053e-003 
 
============================================================ 
SIMFIT RESULTS for NHC-H (td) at 4.156 ppm 
INTENSITY fit : Diffusion : Variable Gradient : 
I=I[0]*exp(-D*SQR(2*PI*gamma*Gi*LD)*(BD-LD/3)*1e4) 
16 points for Peak 1,  Peak Point = 4.156 ppm 
Converged after 31 iterations! 
Results     Comp. 1     
I[0]           =  1.017e+000   
Diff Con.      =  7.855e-010 m2/s 
Gamma          =  4.258e+003 Hz/G 
Little Delta   =      2.800m 
Big Delta      =     24.900m 
RSS   =   1.084e-003 
SD    =   8.229e-003 
Au Complex: biot-Au 2 
Proton  peak (ppm) 
Diff Con  
(10-10 m2/s) 
Aryl-H 7.05 7.833 
NHC-H 4.16 7.855 
Methyl-H 2.46 7.824 
   
Mean Diff Con 7.837 




SIMFIT RESULTS for methyl-H (s) at 2.462 ppm 
INTENSITY fit : Diffusion : Variable Gradient : 
I=I[0]*exp(-D*SQR(2*PI*gamma*Gi*LD)*(BD-LD/3)*1e4) 
16 points for Peak 1,  Peak Point = 2.462 ppm 
Converged after 32 iterations! 
Results     Comp. 1     
I[0]           =  9.993e-001   
Diff Con.      =  7.824e-010 m2/s 
Gamma          =  4.258e+003 Hz/G 
Little Delta   =      2.800m 
Big Delta      =     24.900m 
RSS   =   5.208e-004 




SIMFIT RESULTS for Aryl-H (s) at 7.050 ppm 
INTENSITY fit : Diffusion : Variable Gradient : 
I=I[0]*exp(-D*SQR(2*PI*gamma*Gi*LD)*(BD-LD/3)*1e4) 
16 points for Peak 1,  Peak Point = 7.050 ppm 
Converged after 31 iterations! 
Results     Comp. 1     
I[0]           =  1.008e+000   
Diff Con.      =  8.345e-010 m2/s 
Gamma          =  4.258e+003 Hz/G 
Little Delta   =      2.800m 
Big Delta      =     24.900m 
RSS   =   1.493e-004 




Proton  peak (ppm) 
Diff Con  
(10-10 m2/s) 
Aryl-H 7.05 8.345 
NHC-H 4.14 8.392 
Methyl-H 2.46 8.379 
   
Mean Diff Con   8.372 




SIMFIT RESULTS for NHC-H (t) at 4.139 ppm 
INTENSITY fit : Diffusion : Variable Gradient : 
I=I[0]*exp(-D*SQR(2*PI*gamma*Gi*LD)*(BD-LD/3)*1e4) 
16 points for Peak 1,  Peak Point = 4.139 ppm 
Converged after 32 iterations! 
Results     Comp. 1     
I[0]           =  1.007e+000   
Diff Con.      =  8.392e-010 m2/s 
Gamma          =  4.258e+003 Hz/G 
Little Delta   =      2.800m 
Big Delta      =     24.900m 
RSS   =   3.694e-003 
SD    =   1.520e-002 
 
============================================================ 
SIMFIT RESULTS for Methyl-H (s) at 2.462 ppm 
INTENSITY fit : Diffusion : Variable Gradient : 
I=I[0]*exp(-D*SQR(2*PI*gamma*Gi*LD)*(BD-LD/3)*1e4) 
16 points for Peak 1,  Peak Point = 2.462 ppm 
Converged after 28 iterations! 
Results     Comp. 1     
I[0]           =  1.007e+000   
Diff Con.      =  8.379e-010 m2/s 
Gamma          =  4.258e+003 Hz/G 
Little Delta   =      2.800m 
Big Delta      =     24.900m 
RSS   =   6.496e-003 





Selected HR-MS spectra 
HR-MS spectra of biotinylated gold complexes recorded from MeOH 
 












































Spectrum 93 HR-MS Spectrum of biot-GlyAu 2 
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8.3 Chapter 2: Systematic Screening of Gold-based ArMs 
Substrate Synthesis 
 
3-(diethylamino)phenyl 3-phenylpropiolate (1): Prepared according to a modified procedure 
of Do et al 220. To a solution of 3-diethylaminophenol (826 mg, 5.00 mmol, 1.0 eq) in dry CH2Cl2 
(20 mL) was added a solution of 3-phenylpropiolic acid (804 mg, 5.50 mmol, 1.1 eq) in dry 
CH2Cl2 (10 mL). The solution was cooled to 0 °C before the dropwise addition of a solution of 
DMAP (305 mg, 2.50 mmol, 0.5 eq) and DCC (1.55 g, 7.50 mmol, 1.5 eq) in dry CH2Cl2 
(10 mL). The solution was stirred at room temperature for 16 h, then cooled to 0 °C and filtered 
to remove most of the formed dicyclohexylurea. The crude mixture was concentrated in vacuo 
and purified via automated flash column chromatography (KP-Sil 50g) to yield ester 1 as an 
orange oil (622 mg, 2.12 mmol, 42%). 
1H NMR (500 MHz, DMSO-d6) δ 7.71 – 7.66 (m, 2H), 7.63 – 7.58 (m, 1H), 7.52 (t, J = 7.7 Hz, 
2H), 7.19 (t, J = 8.2 Hz, 1H), 6.58 (dd, J = 8.4, 2.5 Hz, 1H), 6.50 (t, J = 2.3 Hz, 1H), 6.40 (dd, 
J = 7.8, 2.1 Hz, 1H), 3.32 (q, J = 7.2 Hz, 4H), 1.07 (t, J = 7.0 Hz, 6H). 
13C NMR (126 MHz, DMSO-d6) δ 151.74, 151.17, 148.70, 132.95, 131.62, 129.96, 129.17, 
118.15, 109.43, 107.36, 104.27, 87.95, 80.26, 43.73, 12.27. 
HR-MS (ESI, pos): m/z calcd. for C19H19NO2H+ 294.1489 found 294.1487 [M+H+]+; m/z calcd. 
for C19H19NO2Na+ 316.1308 found 316.1306 [M+Na+]+. 
 
 
7-(diethylamino)-4-phenyl-2H-chromen-2-one (2): Prepared according to a modified 
procedure of Do et al 220. In a reaction tube, ester 1 (96.8 mg, 0.33 mmol, 1.0 eq) was diluted 
with dry CH2Cl2 (1.6 mL) and dry EtOH (0.4 mL) before adding hydrogen tetrachloroaurate(III) 
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hydrate (23.6 mg, 0.07 mmol, 0.2 eq). The reaction mixture was stirred at room temperature 
for 16 h in the dark. The solvents were removed in vacuo and the crude was purified via 
automated flash column chromatography (KP-Sil25g, ) to yield coumarin 2 as a yellow oil 
(43 mg, 0.15 mmol, 44%). 
1H NMR (500 MHz, DMSO-d6) δ 7.54 (dt, J = 5.0, 2.2 Hz, 3H), 7.51 – 7.46 (m, 2H), 7.18 (d, J 
= 9.1 Hz, 1H), 6.68 (dd, J = 9.1, 2.6 Hz, 1H), 6.61 (d, J = 2.5 Hz, 1H), 5.93 (s, 1H), 3.43 (q, J 
= 7.0 Hz, 4H), 1.12 (t, J = 7.0 Hz, 6H). 
13C NMR (126 MHz, DMSO-d6) δ 160.62, 156.37, 155.59, 150.50, 135.61, 129.42, 128.77, 
128.30, 127.67, 108.91, 107.26, 106.77, 97.13, 44.02, 12.32. 
HR-MS (ESI, pos): m/z calcd. for C19H19NO2H+ 294.1489 found 294.1491 [M+H+]+; m/z calcd. 
for C19H19NO2Na+ 316.1308 found 316.1310 [M+Na+]+.  
 
 
Protected indole 7: Indole (351 mg, 3 mmol, 1 eq), di-tert-butyl dicarbonate (Boc2O) (0.77 mL, 
3.6 mmol, 1.2 eq) and DMAP (73 mg, 0.6 mmol, 0.2 eq) were dissolved in dry THF (5 mL). The 
mixture was stirred (2 h, rt) before removing the solven in vacuo. The product was purified by 
flash column chromatography (20% EtOAc/cyclohexane) to yield the product as a colourless 
oil (558 mg, 2.57 mmol, 86%). 
1H NMR (500 MHz, DMSO-d6) δ 8.06 (dd, J = 8.2, 1.1 Hz, 1H), 7.67 (d, J = 3.7 Hz, 1H), 7.65 







The synthesis of substrate 9 was performed according to the procedure of Kent and co-
workers.136 The spectra were in agreement with literature data. 
Amide 13: 1H NMR (500 MHz, CD3OD) δ 9.80 (s, 1H), 8.69 – 8.65 (m, 2H), 8.56 – 8.51 (m, 
1H), 8.51 – 8.44 (m, 2H), 8.43 – 8.38 (m, 2H), 8.38 – 8.34 (m, 2H), 8.33 – 8.22 (m, 5H), 5.28 
– 5.20 (m, 2H), 5.21 – 5.17 (m, 1H), 4.46 (ddd, J = 11.2, 7.5, 3.8 Hz, 1H), 4.28 – 4.23 (m, 1H), 
3.29 (dddd, J = 13.3, 9.4, 8.3, 7.1 Hz, 1H), 3.12 – 2.96 (m, 1H), 2.84 – 2.70 (m, 1H), 2.53 (dtd, 
J = 13.6, 8.0, 5.5 Hz, 1H). 
Substrate 9: 1H NMR (500 MHz, D2O) δ 3.92 (t, J = 5.5 Hz, 1H), 2.87 (d, J = 1.3 Hz, 2H), 2.53 
(t, J = 2.7 Hz, 1H). 
MS-Direct Injection (ESI, pos) m/z: 114.23 [100%, M+H]+. 
Catalysis Protocol 
Pre-screening conditions: To a GC-MS vial (1.5 mL) was added MES-buffer (185 µL, 50 mM, 
pH 5.1), purified protein (4 µL of 1000 µM FBS in MQ-water) and cofactor (1 µL of 2 mM in 
DMSO). The tubes were incubated in a thermoshaker (20 min, 37 °C, 900 rpm). Afterwards, 
substrate (1 µL of 100 mM in DMSO) was added and the tubes were shaken in a thermoshaker 
for the corresponding reaction time. The reaction was quenched by the addition of methanol 
(200 µL) followed by centrifugation (14’000 rpm, 10 °C, 10 min). In UPLC vials, the reaction 





NMR & Mass Spectra 
 
Spectrum 94  1H-NMR spectrum of ester 1 in DMSO-d6. 
 




Spectrum 96  1H-NMR spectrum of coumarin 2 in DMSO-d6. 
 











Spectrum 99  HR-MS Spectrum of ester 1. 
 
 




Spectrum 101  1H-NMR spectrum of amide 13 in MeOD. 
 




8.4 Chapter 3: Palladium-based ArMs 
Substrate Synthesis 
 
Tosyl amine 7: Under inert atmosphere, a schlenk flask was charged with 2-Iodoaniline 1 
(2.2 g, 10 mmol, 1 eq) and dry CH2Cl2 (15 mL). The solution was cooled (0 °C) before 
adding  TosCl (2.1 g, 10.9 mmol, 1.09 eq) and pyridine (24 mL, 30 mmol, 30 eq). After 
addition, the mixture was stirred (rt, colour change green, yellow then grey) and monitored by 
TLC. After consumption of the starting material, ethylendiamine (60 mg, 1.0 mmol, 0.1 eq) was 
added to quench the remaining TosCl. The mixture was stirred (rt, 2 h) before the addition of 
aq. HCl (10 mL, 0.1 M). The crude was extracted with CH2Cl2 (3x20 mL), washed with brine 
(10 mL) and dried over MgSO4. The solvent was removed in vacuo. The crude was purified via 
flash column chromatography (20% EtOAc/cyclohexane) to yield the product as a slight yellow 
oil. Recrystallization (5% EtOAc/cyclohexane) gave the product as white crystals (3.4 g, 
9.1 mmol, 91%). The mother liquor can be treated with drops of pentane to provoce further 
precipitation of the product. As an alternative, Kugelrohr destillation can be used (210 °C at 
0.2 mbar). Spectra in agreement with literature data.221 
1H NMR (500 MHz, DMSO-d6) δ 9.66 (s, 1H), 7.82 (dd, J = 7.9, 1.5 Hz, 1H), 7.63 – 7.55 (m, 
2H), 7.37 (d, J = 8.0 Hz, 2H), 7.29 (td, J = 7.7, 1.5 Hz, 1H), 6.99 (dd, J = 8.0, 1.6 Hz, 1H), 6.96 
(td, J = 7.6, 1.6 Hz, 1H), 2.38 (s, 3H). 
Tosyl amine 17: A dried Schlenk flask was charged with NaH (43 mg, 1.1 mmol, 60%, 2 eq) 
and dry DMF (3 mL) and cooled (0 °C).The amine 7 (200 mg, 0.53 mmol, 1 eq) in dry DMF 
(3 mL) was slowly added to the NaH-solution. The mixture was stirred (1 h, rt) before the 
addition dibromoethane (503 mg, 2.7 mmol, 5 eq).The mixture was heated (3.5 h, 80 °C). 
Reaction control via HPLC-MS revealed partial conversion. Thus, more NaH (43 mg, 
1.1 mmol, 60%, 2 eq) and dibromoethane (503 mg, 2.7 mmol, 5 eq) were added and the 
mixture was heated again (3.5 h, 80 °C). After full conversion, the mixture was cooled (0 °C) 
and quenched by the slow addition of aq. NH4Cl (10 mL). The crude was extracted with EtOAc 
(3x50 mL), washed over brine (15 mL), dried over NaSO4 and concentrated in vacuo. 
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Purification via flash column chromatography (10% EtOAc/cyclohexane) yielded the product 
as a colourless oil (237 mg, 0.49 mmol, 92%). 
1H NMR (500 MHz, DMSO-d6) δ 7.96 (dd, J = 7.9, 1.5 Hz, 1H), 7.63 – 7.55 (m, 2H), 7.46 – 
7.42 (m, 2H), 7.40 (td, J = 7.6, 1.5 Hz, 1H), 7.15 (td, J = 7.6, 1.6 Hz, 1H), 7.00 (dd, J = 7.9, 1.6 
Hz, 1H), 3.95 (ddd, J = 14.3, 8.3, 5.8 Hz, 1H), 3.84 (ddd, J = 14.6, 8.1, 6.1 Hz, 1H), 3.53 (ddd, 
J = 10.1, 8.1, 5.8 Hz, 1H), 3.38 (ddd, J = 10.1, 8.3, 6.1 Hz, 1H), 2.42 (s, 3H). 
Tosy-vinyl amine 18: To a solution of amine 17 (101 mg, 0.21 mmol, 1 eq) in dry DMSO (5 mL) 
was added tBuOK (31 mg, 0.28 mmol, 1.33 eq). The mixture was stirred (rt, colour change 
green to yellow then red). The reaction progess (every 30 min) was monitored via HPLC-MS. 
After full consumption of the substrate (2 h) the reaction was quenched with water (5 mL, 0 °C), 
extracted with EtOAc (3x5mL), washed with cold brine (3x1.5 mL) and dried over NaSO4. The 
crude was concentrated in vacuo (<30 °C). Purification via flash column chromatography (10% 
EtOAc/cyclohexane) yielded the product as a white solid (61 mg, 0.15 mmol, 73%). 
1H NMR (500 MHz, DMSO-d6) δ = 8.04 (dd, J=7.9, 1.5, 1H, C1H), 7.69 – 7.64 (m, 2H, C13H, 
C17H), 7.50 – 7.46 (m, 2H, C14H, C16H), 7.42 (td, J=7.6, 1.5, 1H, C2H), 7.21 (td, J=7.6, 1.6, 
1H, C3H), 7.15 (dd, J=15.3, 8.8, 1H, C19H), 6.61 (dd, J=7.8, 1.5, 1H, C4H), 4.34 (dd, J=8.8, 
1.0, 1H, C20H), 3.52 (dd, J=15.3, 1.0, 1H, C20H), 2.43 (s, 3H, C18H3). 
13C NMR (126 MHz, DMSO-d6) δ = 144.42 (C10), 140.51 (C1), 138.14 (C6), 135.81 (C15), 
133.46 (C19), 131.04 (C3), 130.13 (C14/C16), 129.64 (C4), 129.62 (C2), 127.24 (C13/C17), 
102.90 (C5), 94.79 (C20), 21.10 (C18). 
HR-MS (ESI, pos): m/z calcd. for C15H14INO2SH+ 399.9863 found 399.9862 [M+H+]+; m/z calcd. 





Nosyl amine 8: To a cold solution (0 °C) of 2-Iodoaniline 1 (241 mg, 1.1 mmol, 1.1 eq) in 
pyridine (15 mL) was added nosyl chloride (222 mg, 1 mmol, 1 eq). The mixture was stirred 
(3 h, 0-25 °C) before pyridine was removed in vacuo. The reaction mixture was poured into 
water and the crude was extracted with CH2Cl2 (3x25 mL), dried over MgSO4, and 
concentrated in vacuo. Purification by column chromatography (15% EtOAc/cyclohexane) 
yielded nosyl-amine 8 as a pale yellow solid (321 mg, 0.79 mmol, 79%). Spectra in agreement 
with literature data.221 
1H NMR (500 MHz, DMSO-d6) δ 10.27 (s, 1H), 8.46 – 8.35 (m, 2H), 7.96 – 7.90 (m, 2H), 7.87 
– 7.81 (m, 1H), 7.38 – 7.28 (m, 1H), 7.07 – 6.98 (m, 2H). 
Nosyl amine 19: In a sealed tube, amine 8 (243 mg, 0.6 mmol, 1 eq) and K2CO3 (249 mg, 
1.8 mmol, 3 eq) were dried and diluted with dry acetonitrile (2 mL). The mixture was heated 
(1 h, 50 °C) before adding dibromoethane (451 mg, 2.4 mmol, 4 eq) under continued stirring 
(2 h, 50 °C). No full conversion was observed (HPLC-MS), thus more dibromoethane 
(1127 mg, 6 mmol, 10 eq) and K2CO3 (415 mg, 3 mmol, 5 eq) were added and the mixture was 
heated again (24 h, 60 °C). The mixture was quenched with brine (20 mL), extracted with 
EtOAc (3x40 mL) and dried over NaSO4. Purification via flash column chromatography (15% 
EtOAc/cyclohexane) yielded amine 19 as a pale yellow solid (264 mg, 0.52 mmol, 86%). 
1H NMR (500 MHz, DMSO-d6) δ 8.47 – 8.37 (m, 2H), 7.99 – 7.93 (m, 3H), 7.44 (td, J = 7.7, 1.5 
Hz, 1H), 7.21 – 7.12 (m, 2H), 4.08 – 3.91 (m, 2H), 3.57 (ddd, J = 10.3, 7.5, 5.6 Hz, 1H), 3.39 
(dt, J = 10.2, 7.2 Hz, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 150.15, 144.12, 140.47, 139.74, 131.70, 130.90, 129.37, 
129.29, 124.80, 102.26, 52.62, 29.69. 
Nosy-vinyl amine 20: To a solution of amine 19 (102 mg, 0.2 mmol, 1 eq) in dry DMSO (5 mL) 
was added tBuOK (30 mg, 0.27 mmol, 1.33 eq). The mixture was stirred (rt, colour change 
green to yellow then red). The reaction progess (every 30 min) was monitored via HPLC-MS. 
After full consumption of the substrate (2 h) the reaction was quenched with water (5 mL, 0 °C), 
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extracted with EtOAc (3x5mL), washed with cold brine (3x1.5 mL) and dried over NaSO4. The 
crude was concentrated in vacuo (<30 °C). Purification via flash column chromatography (10% 
EtOAc/cyclohexane) yielded the product as a white solid (46 mg, 0.107 mmol, 54%). 
1H NMR (500 MHz, DMSO-d6) δ 8.51 – 8.41 (m, 2H), 8.10 – 8.01 (m, 3H), 7.43 (td, J = 7.7, 1.5 
Hz, 1H), 7.26 – 7.18 (m, 2H), 6.73 (dd, J = 7.8, 1.6 Hz, 1H), 4.44 (dd, J = 8.8, 1.2 Hz, 1H), 3.61 
(dd, J = 15.3, 1.2 Hz, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 150.37, 143.74, 140.70, 137.51, 132.94, 131.36, 130.19, 
129.90, 128.88, 125.10, 102.48, 96.25. 
 
 
Tosy-indole 21 was prepared according to a modified procedure of Gagnon and co-workers.222 
Indole (250 mg, 2.1 mmol, 1 eq) was dissolved in dry THF (15 mL) and slowly added to a ice-
cold mixture of sodium hydride (130 mg, 3.2 mmol, 60%) in dry THF (15 mL). The mixture was 
stirred until no gas formation was observed (ca. 90 min). To the mixture was slowly added tosyl 
chloride (447 mg, 2.34 mmol, 1.1 eq) in dry THF (5 mL). The mixture was stirred (16 h, rt) 
before quenching it with aq. NH4Cl (20 mL). The product was extracted with EtOAc (3x50 mL), 
washed with brine (20 mL) and dried over MgSO4. Purification via flash column 
chromatography (15% EtOAc/cyclohexane) yielded the product as a white solid (553 mg, 
2.04 mmol, 96%). 
1H NMR (500 MHz, DMSO-d6) δ = 7.92 (dd, J=8.4, 0.9, 1H, C8H), 7.85 (d, J=8.4, 2H, 
C15H/C17H), 7.78 (d, J=3.7, 1H, C2H), 7.62 – 7.57 (m, 1H, C5H), 7.38 (d, J=8.1, 2H, 
C14H/C18H), 7.33 (ddd, J=8.5, 7.2, 1.3, 1H, C7H), 7.24 (td, J=7.6, 1.0, 1H, C6H), 6.83 (dd, 
J=3.6, 0.8, 1H, C3H), 2.31 (s, 3H, C19H3). 
13C NMR (126 MHz, DMSO-d6) δ 145.45 (C16), 134.16 (C11), 134.08 (C9), 130.44 (C4), 
130.21 (C14/C18), 126.91 (C2), 126.68 (C15/C17), 124.62 (C7), 123.41 (C6), 121.58 (C5), 






Nos-indole 22 was prepared according to a modified procedure of Carretero and co-workers.223 
Indole (900 mg, 7.68 mmol, 1 eq) was dissolved in dry THF (15 mL) and cooled (0 °C). To the 
mixture was added sodium hydride (258 mg, 10.8 mmol, 1.4 eq). The mixture was stirred until 
no gas formation was observed (ca. 90 min). To the mixture was slowly added nosyl chloride 
(2.38 g, 10.8 mmol, 1.4 eq) in dry THF (5 mL). The mixture was stirred (16 h, rt) before 
quenching it with aq. NH4Cl (20 mL). The product was extracted with EtOAc (3x50 mL), 
washed with brine (20 mL) and dried over MgSO4. Purification via flash column 
chromatography (15% EtOAc/cyclohexane) yielded the product as a white solid (1.34 g, 
4.45 mmol, 58%). 
1H NMR (500 MHz, DMSO-d6) δ 8.38 – 8.32 (m, 2H), 8.27 – 8.22 (m, 2H), 7.96 (dq, J = 8.4, 
0.8 Hz, 1H), 7.86 (d, J = 3.7 Hz, 1H), 7.62 (dt, J = 7.7, 1.0 Hz, 1H), 7.38 (ddd, J = 8.5, 7.3, 1.3 






Synthesis of Palladium Complexes 
 
Pd1 was prepared according to the procedure of Davis and co-workers and following their 
procedure without further isolation an characterization directly used for the catalysis after 
colour change of the aqueous mixture.161  
 
Pd2 was prepared according a modified procedure of Wang and co-workers. 159  
Ligand 26: Imidazole 25 (93 mg, 0.5 mmol, 1 eq) and 2-chloro pyrimidine (63 mg, 0.55 mmol, 
1.1 eq) were mixed in DMF and heated (reflux, 16 h). The cooled mixture was partioned 
between EtOAc/brine (1:1, 50 mL). The aqueous phase was extracted with EtOAc (5x10 mL) 
and the organic solution was discarted. The aqueous phase was then transfered to an 
erlenmeyer. During vigurous stirring, a saturated solution of NH4PF6 was added until no more 
precipitation took place. The mixture was stirred (1 h) before filtration. The filtercake was 
washed with cold water and extracted with CH2Cl2 from the filter into a flask. The solvent was 
removed in vacuo to yield the product 26 as a white solid (63 mg, 0.24 mmol, 48%). 
1H NMR (500 MHz, DMSO-d6) δ 10.47 (d, J = 1.9 Hz, 1H), 9.09 (d, J = 4.9 Hz, 2H), 8.78 (d, J 





Complex Pd2: In a sealed tube, ligand 26 (53 mg, 0.2 mmol, 1 eq) and Ag2O (23 mg, 0.1 mmol, 
0.5 eq) were dissolved in dry acetonitrile (3 mL) and heated (50 °C, 4 h). After the mixture was 
cooled to room temperature, [Pd(CH3CN)2]Cl2 (53 mg, 0.2 mmol, 1 eq) was added to the 
solution, and the solution was stirred (rt, 2 h). Afterwards, the mixture was filtered through 
celite, and all volatiles removed in vacuo. The yellow residue was dissolved in dry acetonitrile 
and recrystallization by slow addition of diethyl ether to yield the product as a yellow solid 
(65.3 mg, 0.11 mmol, 55%).  
1H NMR (500 MHz, CD2Cl2) δ 9.58 (s, 1H), 9.06 (dd, J = 5.0, 2.2 Hz, 1H), 8.28 (d, J = 5.6 Hz, 
1H), 8.12 (s, 1H), 7.69 (d, J = 7.7 Hz, 1H), 7.66 – 7.61 (m, 1H), 7.19 (s, 1H), 7.17 – 7.10 (m, 
2H), 6.64 (s, 1H), 2.37 (s, 3H), 2.19 (s, 3H), 2.16 (s, 1H), 2.09 (s, 1H), 2.05 (s, 3H), 1.91 (s, 
3H). 
19F NMR (471 MHz, CD2Cl2) δ -72.45, -73.96. 
 
 
Pd3 was prepared according to a modified procedure of Ananikov and co-workers.224 The 
azolium salt (0.55 mmol), anhydrous K2CO3 (345 mg, 2.5 mmol), and PdCl2 (89 mg, 0.5 mmol) 
were charged in a glass tube. Dry pyridine was added (4 mL), the tube was capped with a 
screw cap, and the mixture was heated with vigorous stirring for 16 h at 80 °C. After it was 
cooled to 20 °C, the reaction mixture was diluted with CH2Cl2 (5 mL) and passed through a 
short pad of silica gel with CH2Cl2 as eluent until the product was completely recovered. The 
solvent was removed under vacuum (rotary evaporator) at room temperature. The residue that 
formed was treated with a small volume of hexane (∼5 mL); the precipitate that formed was 
separated by filtration, washed with hexane (5 mL), and dried under vacuum at 20 °C. The 
crude was purified via flash column chromatography (15% EtOAc/cyclohexane) to give the 
complex Pd3 as white solid (96 mg, 0.18 mmol, 36%). 
1H NMR (500 MHz, CD2Cl2) δ 8.55 (dt, J = 5.0, 1.6 Hz, 2H, C38H), 7.62 (tt, J = 7.7, 1.7 Hz, 1H, 
C36H), 7.51 (t, J = 7.8 Hz, 2H, C15H, C10H), 7.37 (d, J = 7.8 Hz, 4H, C16H, C14H, C9H, 
C11H), 7.16 (m, 4H, C37H, C35H, C2H, C3H), 3.16 (p, J = 6.7 Hz, 4H, C18H, C19H, C24H, 
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C27H), 1.45 (d, J = 6.6 Hz, 12H, C22H3, C21H3, C28H3, C25H3), 1.11 (d, J = 6.9 Hz, 12H, 
C23H3, C20H3, C26H3, C29H3). 
13C NMR (126 MHz, CD2Cl2) δ 151.79 (C38, C34), 147.44 (C8, C12, C13, C17), 138.22 (C36), 
135.88 (C6, C7), 130.55 (C10, C15), 125.79 (J = 198, 12.6 Hz, C2, C3), 124.54 (C35, C37), 
124.53 (C9, C11, C14, C16), 29.24 (C18, C19, C24, 27), 26.52 (C20, C23, C26, C29), 23.53 
(C21, C22, C25, C28). 





The complex Pd4 was prepared according to the procedure of Ward and co-workers and 
purified via PräpHPLC with additional recristallization from CH2Cl2/hexane to yield the product 
as a white solid (11 mg, 0.014 mmol, 30%).149 The spectra is difficult to assign but in agreement 
with literature data. As the catalyst did not prove efficient in catalysis, it was not characterized 
further. 
1H NMR (500 MHz, CD2Cl2) δ 7.27 – 6.81 (m, 9H), 5.88 (s, 1H), 5.23 (td, J = 12.2, 6.8 Hz, 1H), 
4.88 (d, J = 7.1 Hz, 1H), 4.72 (d, J = 11.9 Hz, 1H), 4.52 – 4.40 (m, 2H), 4.33 – 4.13 (m, 1H), 
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4.06 (t, J = 11.1 Hz, 1H), 3.81 (dd, J = 11.3, 6.8 Hz, 1H), 3.57 (d, J = 35.5 Hz, 1H), 3.28 (s, 
1H), 3.13 (t, J = 11.9 Hz, 1H), 2.91 (s, 1H), 2.66 (s, 1H), 2.57 – 2.21 (m, 16H), 2.07 (s, 1H), 
1.46 – 1.18 (m, 2H). 
 
Ligand 30: The ligand was prepared by Dr. Isabel T. Alt according to the procedure of 
Shaughnessy and co-workers.163 The spectra are in agreement with literature data. 
1H NMR (500 MHz, DMSO-d6) δ 9.37 (t, J = 1.6 Hz, 1H), 8.11 (t, J = 1.8 Hz, 1H), 7.92 (t, J = 
1.8 Hz, 1H), 7.14 (d, J = 1.1 Hz, 2H), 4.42 (t, J = 7.0 Hz, 2H), 2.44 (t, J = 7.1 Hz, 2H), 2.33 (s, 
3H), 2.20 (p, J = 7.1 Hz, 2H), 2.02 (s, 6H). 
 
Complex Pd5: In a sealed tube, ligand 30 (50 mg, 0.15 mmol, 1 eq), Pd(cymene)Cl-dimer 
(39 mg, 0.073 mmol, 0.5 eq) and tBuOK (21 mg, 0.19 mmol, 1.3 eq) were dissolved in dry 
DMF (3 mL). The pressure tube was heated (130 °C, 16 h). After the reaction, the solvent was 
removed in vacuo. EtOAc was added to dissolve the crude. The mixture was filtered and 
hexane was added to precipitate the product Pd5 as a white solid (63 mg, 0.11 mmol, 76%).  
1H NMR (500 MHz, DMSO-d6) δ 7.62 (d, J = 1.9 Hz, 1H), 7.38 – 7.29 (m, 3H), 7.26 – 7.15 (m, 
3H), 7.03 (s, 2H), 5.60 (q, J = 10.4, 9.9 Hz, 1H), 4.42 (d, J = 12.7 Hz, 1H), 4.35 (t, J = 6.9 Hz, 
2H), 2.40 (dd, J = 8.9, 6.3 Hz, 3H), 2.31 (s, 3H), 2.16 (t, J = 7.6 Hz, 3H), 2.04 (s, 6H). 





NMR & Mass Spectra 
 
Spectrum 103 1H NMR spectrum of tosy amine 7 in DMSO-d6. 
 




Spectrum 105  1H NMR spectrum of tosy-vinyl amine 18 in DMSO-d6. 
 




Spectrum 107  1H NMR spectrum of nosyl amine 8 in DMSO-d6. 
 




Spectrum 109 13C NMR spectrum of nosyl amine 19 DMSO-d6. 
 




Spectrum 111 13C NMR spectrum of nosyl vinyl amine 20 DMSO-d6. 
 




Spectrum 113  13C NMR spectrum of tosyl-indole 21 in DMSO-d6. 
 





Spectrum 115  1H NMR spectrum of ligand 26 in DMSO-d6. 
 




Spectrum 117 19F NMR spectrum of complex Pd2 in CD2Cl2. 
 




Spectrum 119  13C NMR spectrum of complex Pd3 in DMSO-d6. 
 




Spectrum 121 1H NMR spectrum of ligand 30 in DMSO-d6. 
 







Spectrum 124  UPLC-MS spectrum of Pd3 from MeCN.  
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TMS-protected aldehyde 2 was prepared from glycerol 1 according to the procedure of 
Paterson and co-workers.225 The product was obtained quantitatively as a clear, colorless oil, 
the spectra were in agreement with literature data. 
Butynol 3 was prepared via Grignard reaction with ethynylmagnesium bromide. The aldehyde 
2 (2.00 g, 11.5 mmol, 1 eq) was added to a cold solution of dry THF (40 mL, 0 °C) followed by 
the dropwise addition of ethynylmagnesium bromide (27.6 mL, 13.8 mmol, 1.2 eq). The 
mixture was stirred (0 °C, ~4 h) until TLC stained with KMnO4 revealed full conversion. The 
reaction mixture was quenched cold (0 °C) by the dropwise addition of aq. NH4Cl (40 mL). The 
crude was extracted with Et2O (3x50 mL), washed with brine (15 mL), dried with MgSO4, and 
gently reduced in vacuo (>100 mbar!). Purification by flash column chromatography (KP-Sil 
50g, 10-20% Et2O/pentane) yielded butynol 3 as a colorless oil (1.83 g, 9.16 mmol, 80%). 
1H NMR (500 MHz, DMSO-d6) δ 5.45 (d, J = 6.0 Hz, 1H), 4.17 (dd, J = 6.1, 2.2 Hz, 1H), 3.56 
(dd, J = 6.2, 1.0 Hz, 2H), 0.87 (s, 9H), 0.05 (d, J = 1.1 Hz, 6H). 
TMS-protected substrate 4 was prepared via Mitsunobu reaction. To a solution of butynol 3 
(100 mg, 0.50 mmol, 1 eq), umbelliferone (81 mg, 0.50 mmol, 1 eq) and triphenylphosphine 
(beads, 0.75 mmol, 1.5 eq) was added dry THF (5 mL). DIAD (150 mg, 0.75 mmol, 1.5 eq) in 
dry THF (2 mL) was added dropwise. The mixture was stirred (90 min at rt). Afterwards, the 
mixture was diluted with EtOAc (20 mL), filtered, and extracted from aq. NH4Cl (20 mL) with 
EtOAc (3x40 mL). The crude was reduced in vacuo to yield the product as a yellow sticky oil, 
which can be directly transferred to the deprotection step (140 mg, 0.42 mmol, 83%). 
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1H NMR (500 MHz, DMSO-d6) δ 8.00 (d, J = 9.5 Hz, 1H), 7.66 (d, J = 8.7 Hz, 1H), 7.07 (d, J = 
2.4 Hz, 1H), 7.00 (dd, J = 8.6, 2.4 Hz, 1H), 6.32 (d, J = 9.5 Hz, 1H), 5.22 (td, J = 5.5, 2.1 Hz, 
1H), 3.98 – 3.92 (m, 2H), 3.65 (d, J = 2.0 Hz, 1H), 0.86 (s, 10H), 0.09 (d, J = 14.7 Hz, 6H). 
HR-MS (ESI, pos): m/z calcd. for C19H24O4SIH+ 345.1517 found 345.1518 [M+H+]+; m/z calcd. 
for C19H24O4SINa+ 367.1336 found 367.1334 [M+Na+]+; 
Substrate 5 was prepared via TBAF deprotection. TMS-substrate 4 (50 mg, 0.146 mmol, 1 eq) 
was diluted in dry THF (5 mL) and cooled (0 °C). A solution of TBAF in THF (0.146 mL, 
0.146 mmol, 1 M in THF) was dropwise added. Reaction control via TLC (every 5 min) is 
required to avoid decomposition. After 15-20 min, the mixture was quenched by the addition 
of aq. NaHCO3 (10 mL). The crude was extracted with EtOAc (3x20 mL), washed with brine 
(10 mL), dried with MgSO4 and reduced in vacuo. Purification via flash column chromatography 
(KP-Sil 10g, 30-60% EtOAc/cyclohexane) yielded the product as a white solid (18 mg, 
0.078 mmol, 54%). 
1H NMR (500 MHz, DMSO-d6) δ 8.00 (d, J = 9.5 Hz, 1H), 7.66 (d, J = 8.6 Hz, 1H), 7.07 (d, J = 
2.4 Hz, 1H), 7.01 (dd, J = 8.6, 2.5 Hz, 1H), 6.32 (d, J = 9.5 Hz, 1H), 5.37 (t, J = 6.1 Hz, 1H), 
5.11 (td, J = 5.5, 2.1 Hz, 1H), 3.78 – 3.73 (m, 2H), 3.62 (d, J = 2.0 Hz, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 160.17, 155.05, 144.22, 129.47, 113.32, 112.95, 112.87, 
102.42, 79.56, 78.69, 69.47, 63.61. 
HR-MS (ESI, pos): m/z calcd. for C13H10O4H+ 231.0652 found 231.0649 [M+H+]+. 
 
 
Aryl acid 14 was prepared according to the procedure of Kirschning and co-workers.226 The 
corresponding product was obtained as a pale yellow solid (497 mg, 3.08 mmol, 77%). The 
spectra are in agreement with literature data. 
1H NMR (500 MHz, DMSO-d6) δ 12.80 (s, 1H), 7.32 (d, J = 1.6 Hz, 1H), 7.25 (d, J = 8.0 Hz, 




Benzyl alcohol 15 was prepared via reduction of aryl acid 14. To a solution of dry THF (10 mL) 
was added aryl acid 14 (483 mg, 3 mmol, 1 eq). The mixture was cooled (0 °C) before slowly 
adding a solution of LiAlH4 (4.5 mL, 4.5 mmol, 1 M in THF, 1.5 eq). Stirring was continued (3 h, 
0 °C to rt) before slowly quenching the mixture with aq. NaHCO3. Upon dilution with EtOAc 
(50 mL) and aq. Rochelle Salt (20 mL), the crude was filtered and extracted with EtOAc 
(4x50 mL), washed with brine (15 mL) and dried with MgSO4. During the workup, the pH of the 
aqueous phase was checked, and if necessary adjusted (>7 pH). The crude was purified via 
flash column chromatography (KP-Sil 50 g, 30-60% EtOAc/cyclohexane) to yield the product 
as a pale yellow solid (137 mg, 0.93 mmol, 31%). 
1H NMR (500 MHz, DMSO-d6) δ 7.10 (d, J = 7.8 Hz, 1H), 6.68 (d, J = 1.3 Hz, 1H), 6.48 – 6.41 
(m, 1H), 5.30 (s, 2H), 5.09 (t, J = 5.8 Hz, 1H), 4.36 (dd, J = 5.8, 0.8 Hz, 2H), 4.25 (s, 1H). 
HR-MS (ESI, pos): m/z calcd. for C9H9OH+ 148.0757 found 148.0754 [M+H+]+. 
Substrate 16 was prepared via a Mitsunobu reaction. To a solution of benzyl alcohol 15 (44 mg, 
0.30 mmol, 1 eq), umbelliferone (39 mg, 0.24 mmol, 0.8 eq) and triphenylphosphine (beads, 
0.36 mmol, 1.2 eq) was added dry THF (5 mL). DIAD (73 mg, 0.36 mmol, 1.2 eq) in dry THF 
(2 mL) was dropwise added. The mixture was stirred (4 h at rt). Afterwards, the mixture was 
diluted with EtOAc (20 mL), filtered, and extracted from aq. NH4Cl (20 mL) with EtOAc 
(3x40 mL). The crude was reduced in vacuo further purified via flash column chromatography 
(KP-Sil 25g, 20-80% EtOAc/cyclohexane) to yield the product as a white solid (12 mg, 
0.04 mmol, 14%). 
1H NMR (500 MHz, CD2Cl2) δ 7.65 (d, J = 9.5 Hz, 1H), 7.41 (d, J = 8.6 Hz, 1H), 7.32 (d, J = 
7.8 Hz, 1H), 6.91 (dd, J = 8.6, 2.5 Hz, 1H), 6.86 (d, J = 2.5 Hz, 1H), 6.79 (d, J = 1.6 Hz, 1H), 
6.72 (dd, J = 7.9, 1.6 Hz, 1H), 6.21 (d, J = 9.5 Hz, 1H), 5.05 (s, 2H), 4.37 (s, 2H), 3.45 (s, 1H). 
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13C NMR (126 MHz, CD2Cl2) δ 162.11, 161.15, 156.27, 149.45, 143.69, 138.79, 133.21, 
129.31, 116.73, 113.64, 113.30, 113.12, 106.52, 102.24, 83.05, 80.47, 70.50. 
HR-MS (ESI, pos): m/z calcd. for C18H13NO3H+ 292.0968 found 292.0966 [M+H+]+; m/z calcd. 
for C18H13NO3Na+ 314.0788 found 314.0788 [M+Na+]+. 
 
 
The synthesis of pro-naphthalene substrates 21 and 23 was performed by Philipp Meyer and 
is also described in his Master Thesis entitled "Gold(I)-catalyzed bioorthogonal uncaging 
of fluorescent probes - towards in vivo imaging and prodrug activation.", handed in to 
the Department of Chemistry at the University of Basel. 
Alkynes 20 and 21 were prepared according to a modified procedure of Prisinanzo and co-
workers.227 First, activated Zinc powder was prepared by suspending zinc powder in aq HCl 
(12 mL, 1 M). After stirring (30 min), the suspension was decanted, washed with water 
(3x6 mL), acetone (3x6 mL) and diethyl ether (2x3 mL) and dried in vacuo. The corresponding 
anisaldehyde 18 (831 mg, 5 mmol, 1 eq) or 19 (1.36 g, 10 mmol, 1 eq) was dissolved in 
THF/DMF (1:1, 100 mL). A solution of propargyl bromide (0.7 mL, 6.5 mmol or 1.4 mL, 
13 mmol, 80% in toluene, 1.3 eq) and activated zinc powder (1.0 g, 15 mmol or 1.96 g, 
30 mmol, 3 eq) was added. The reaction was heated (55 °C, 3 h) before quenching with sat. 
aq. NH4Cl (50 mL). The mixture was filtered, extracted with diethyl ether (3x50 mL), washed 
with brine (3x75 mL), dried over Na2SO4 and concentrated in vacuo. Purification by flash 
column chromatography (KP-Sil 50, 10% EtOAc/cyclohexane) yielded the corresponding 
alkynes 20 (982 mg, 4.8 mmol, 95%) and 21 (1.21 g, 6.9 mmol, 69%) as coloruless oils. The 
spectra were in agreement with literature data.227 
Alkyne 20: 1H NMR (500 MHz, DMSO-d6) δ 6.54 (d, J = 2.3 Hz, 2H), 6.36 (t, J = 2.3 Hz, 1H), 
5.48 (d, J = 4.6 Hz, 1H), 4.60 (td, J = 6.2, 4.5 Hz, 1H), 2.73 (t, J = 2.6 Hz, 1H), 2.50 – 2.43 (m, 
2H). 
Alkyne 21: 1H NMR (500 MHz, CDCl3): δ 7.28 (1H, t, 3J = 8.2 Hz), 6.97 (1H, s), 6.96 (1H, s), 
6.85 (1H, s,), 4.86 (1H, s), 3.82 (3H, s), 2.64 (2H, s), 2.35 (1H, d, 3J = 3.6 Hz), 2.09 (1H, s). 
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Substrates 22 and 23: Alkynes 20 or 21 (227 mg, 1.1 mmol or 100 mg, 0.567 mmol, 1 eq), 
umbelliferone (162 mg, 1 mmol, or 91.9 mg, 0.567 mmol, 1 eq) and PPh3 beads (1.7 g, 
3.8 mmol or 826 mg, 1.9 mmol, 3.4 eq) were added to dry THF (10 mL or 5 mL). A solution of 
DIAD (0.32 mL, 1.9 mmol or 0.17 mL, 0.85 mmol, 1.5 eq) in dry THF (4 mL or 2 mL) was added 
and the mixture was stirred (16 h, rt). After filtration of the mixture, the crude was taken up in 
silica gel and purified by flash column chromatography (KP-Sil 25g, 10-20% 
EtOAc/cyclohexane) to yield substrates 22 (106 mg, 0.30 mmol, 30%) and 23 (55 mg, 
4.5 mmol, 19%) as white oils. 
Substrate 22: 1H NMR (500 MHz, DMSO-d6) δ 7.93 (d, J = 9.5 Hz, 1H), 7.57 (d, J = 8.7 Hz, 
1H), 6.97 (dd, J = 8.6, 2.4 Hz, 1H), 6.94 (d, J = 2.4 Hz, 1H), 6.64 (d, J = 2.3 Hz, 2H), 6.41 (t, J 
= 2.3 Hz, 1H), 6.26 (d, J = 9.4 Hz, 1H), 5.58 (dd, J = 7.0, 5.4 Hz, 1H), 3.71 (s, 6H), 2.90 (t, J = 
2.7 Hz, 1H), 2.88 – 2.82 (m, 1H), 2.78 (ddd, J = 16.9, 5.4, 2.7 Hz, 1H). 
Substrate 23: 1H NMR (500 MHz, CD2Cl2): δ 7.59 (1H, d, 3J = 9.5 Hz), 7.33 (1H, d, 3J = 8.6 
Hz), 7.27 (1H, pseudo-t, 3J = 7.9 Hz), 6.98 (1H, d, 3J = 7.6 Hz), 6.93 (1H,s), 6.86 (1H, dd, 3J = 
8.6 Hz, 4J = 2.4 Hz), 6.83 (1H, d, 3J = 8.2 Hz), 6.74 (d, 3J = 2.4 Hz), 6.16 (1H, d, 3J = 9.5 Hz), 
5.32 (1H, s), 3.76 (3H, s), 2.90 (1H, ddd, 2J = 16.4 Hz, 3J = 6.13 Hz, 4J = 2.6 Hz), 2.80 (1H, 
ddd, 2J = 16.4 Hz, 3J = 6.13 Hz, 4J = 2.6 H), 2.08 (1H, s). 
13C NMR (126 MHz, CD2Cl2): δ 160.70, 160.65, 159.99, 155.61, 143.18, 140.67, 129.83, 
128.79, 118.40, 113.63, 113.59, 113.35, 112.98, 111.82, 103.07, 79.67, 78.72, 70.62, 55.19, 
28.24. 
HR-MS (ESI, pos): m/z calcd. for C20H16O4Na+ 343.0941 found 343.0944 [M+Na+]+. 
 
Carbamate 26 was prepared via chloroformate addition. To a solution of coumarin 25 (52.6 mg, 
1.0 eq) in dry CH2Cl2 (2 mL), triphosgene (44.5 mg, 0.15 mmol, 0.5 eq) and dry NaHCO3 
(75.6 mg, 0.9 mmol, 3.0 eq) were added. The mixture was stirred until reaction completion 
(monitored by TLC) and the volatiles were evaporated in vacuo. The crude material was 
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dissolved in dry CH2Cl2 (2 mL) and added dropwise to a solution of benzyl alcohol 24 (75 mg, 
1.0 eq) and triethylamine (0.08 mL, 2 eq) in dry CH2Cl2 (3 mL). After reaction completion, the 
mixture was concentrated and purified by flash column chromatography (KP-Sil 25 g; 20-40% 
EtOAc/cyclohexane) to yield the product as a white solid (35 mg, 0.77 mmol, 26%). 
1H NMR (500 MHz, DMSO-d6) δ 10.41 (s, 1H), 7.69 (d, J = 8.7 Hz, 1H), 7.54 (d, J = 2.1 Hz, 
1H), 7.44 (dd, J = 8.8, 2.1 Hz, 1H), 7.34 (s, 1H), 7.32 (s, 5H), 7.12 – 7.06 (m, 2H), 6.92 (ddd, 
J = 8.3, 2.5, 1.1 Hz, 1H), 6.23 (d, J = 1.3 Hz, 1H), 5.93 (t, J = 6.3 Hz, 1H), 3.77 (s, 3H), 3.09 
(d, J = 6.3 Hz, 2H), 2.38 (d, J = 1.3 Hz, 3H). 
MS-Direct Injection (ESI, pos) m/z: 454.1 [100%, M+H]+; 476.1 [21%, M+Na]+; (ESI, neg) m/z: 
452.1 [100%, M-H]-. 
Gold-Complex Synthesis 
 
Sulfimide-NHC ligand 33 (20 mg, 0.03 mmol, 1 eq, prepared by Boris Lozhkin) was dissolved 
in dry CH2Cl2 (1 mL). Trifluoroacetic acid (0.1 mL, 1.2 mmol, 40 eq) was added and the mixture 
was stirred (90 min at rt). The deprotection was monitored via ESI-MS direct injection (positive-
mode). After deprotection, the solvent and the acid were removed under high vacuum to afford 
the desired ligand 34 as a yellow solid (13.8 mg, 0.03 mmol, 99%). 
MS-Direct Injection of substrate 33 (ESI, pos) m/z: 627.25 [100%, M-Cl-]+. 






SI Figure 19 Reaction control via ESI-MS direct injection. 
To the crude ligand 34 (13.8 mg, 0.03 mmol, 1 eq) was added Au(Me2S)Cl (8.8 mg, 0.03 mmol, 
1 eq), finely ground K2CO3 (16.6 mg, 0.12 mmol, 4 eq) and acetone (3 mL). The pressure tube 
was sealed and heated (70 °C for 90 min). The solvent was removed in vacuo before adding 
dry CH2Cl2 (5 mL). The mixture was filtered through Celite and the corresponding gold-complex 
was precipitated from little dry CH2Cl2 by the addition of dry hexane to yield complex 35 as a 
white solid (3 mg, 0.005 mmol, 15%). 
MS-Direct Injection (ESI, pos) m/z: 640.18 [100%, M-Cl-+H2O]+. 
HR-MS (ESI, pos): m/z calcd. for C23H30AuN4O2SCH3CN+ 664.2015 found 664.2025  









SI Figure 20 a Peptide-coupling Setup and Kaiser test samples of b Fmoc-cleaved resin and c succinic 





The cyclic peptides were prepared with the help of the M. Fani Group at the University Hospital 
of Basel according to reported procedures by Nico Igareta and Boris Lozhkin.209,210 The gold 
complex 7 was prepared according to reported procedures, see also chapter 1 and 2.95 
Setup: The LM3 and TATE peptides were synthesized on rink amide and trityl resin, 
respectively. They were transferred into a peptide-synthesizer plastic vessel with filter inlet 
(10 mL) which was sealed with a septum. Nitrogen was purged from below through the vessel 
to guarantee a dry and oxygen-free environment while allowing for continuous mixing and easy 
access for the addition of further substrates via syringe. To remove the solvent through the 
bottom filter, the nitrogen line was swapped from bottom to top. Parafilm was used to seal the 
system for longer reaction times. 
Fmoc-Cleaving Procedure: The Peptide-containing resin (ca 25 mg) was soaked in DMF 
(3 mL) under purging (30 min). The solvent was removed and the resin washed with DMF 
(2 mL). The Fmoc-group was removed by the addition of piperidine in DMF (25%, 3 mL). After 
purging (30 min), the solvent was removed, the resin was washed with DMF (2 mL) and the 
deprotection step was repeated one more time. Afterwards, the solvent was removed and the 
resin washed with DMF (3x2 mL). A spatula tip of resin was transferred to an Eppendorf vial 
to perform a Kaiser test.228 In short, three solutions must be prepared for this test: (a) ninhydrin 
(500 mg) in ethanol (10 mL), (b) phenol (80 mg) in ethanol (10 mL) and (c) aq. KCN (2 mL, 
0.001 M) in pyridine (100 mL). From each of this three solutions, ~20 L are transferred to the 
Eppendorf vial containing the sample. The vial is heated to reflux (>10 min) upon which the 
solution will turn blue if amines are present in the solution. The presence of a deep blue solution 
qualitatively confirms the successful deprotection of Fmoc from the peptide. 
Coupling of Succinic anhydride: The resin was removed from the plastic vessel and transferred 
to a glass vial containing succinic anhydride (15 mg) and DMF (2 mL). The mixture was shaken 
in a thermoshaker (90 min, 80 °C). After the mixture cooled down (rt), it was transferred with 
the resin into the plastic vessel. The solvent was removed, and the resin was washed with dry 
DMF (3x2 mL). A second Kaiser test was performed in which the solution remains clear and 
thus confirms the absence of free amines. 
Deprotection of gold complex 7: The Boc-protected complex 7 (48 mg, 0.07 mmol) was 
dissolved in CH2Cl2 (4 mL/mmol) and HCl gas was bubbled through the solution in the dark 
(1 . The HCl gas was generated by the dropwise addition of concentrated sulfuric acid to 
ammonium chloride in a second flask and transferred via cannula into the reaction mixture (the 
controlled release of HCl gas from the system must be guaranteed to avoid overpressure). The 
solution was stirred in the dark (1 h, rt) while the deprotection step was monitored by thin-layer 
chromatography (MeOH/CH2Cl2 1:9) or Kaiser test. The solvent was evaporated (high vacuum) 
and the resulting solid was dissolved in dry DMF (2 mL). 
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Coupling of gold complex 8 to the peptides: In case the resin was stored temporarily after the 
addition of succinic anhydride, the resin should be soaked with dry DMF (30 min), purged and 
then washed with dry DMF (2x2 mL) before further continuation. To the vessel was added 
HATU (27 mg, 0.07 mmol), DIPEA (24 L, 0.14 mmol) and dry DMF (1.5 mL). The mixture was 
purged (10 min) and the pH was checked (must be basic, else more DIPEA was added). 
Afterwards, the deprotected gold complex 8, dissolved in dry DMF (2 mL) was added to the 
mixture. The seal was reinforced with Parafilm and the mixture was purged with N2 overnight. 
The solvent was removed and the resin was washed with dry DMF (5x2 mL). 
Cleaving from the resin:229 Two cleaving procedures were tested: (1) harsh conditions with 
TFA:TIPS:H2O (95.0:2.5:2.5) and (2) mild conditions with CH2Cl2:TFA:TIPS (92.5:5.0:2.5). 
Therein, the corresponding cleaving mixtures (2 mL) were added to the resin in the plastic 
vessel. The mixtures were purged (90 min, rt). Under harsh conditions a color change from 
yellow to dark grey was observed. A pointed microwave vial was used to collect the filtrated 
mixture afterwards. The gold-functionalized peptides were precipitated by the addition of ice-
cold diethyl ether and isolated via centrifugation of the precipitate. Further RP-HPLC may be 
necessary to further purify the desired compound.  
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Spectrum 126 1H NMR spectrum of butynol 3 in DMSO-d6. 
 





Spectrum 128  1H NMR spectrum of substrate 5 in DMSO-d6. 
  










Spectrum 131  1H NMR spectrum of arylacid 14 in DMSO-d6. 
 





Spectrum 133  1H NMR spectrum of substrate 16 in DMSO-d6. 
 





Spectrum 135 1H NMR spectrum of substrate 20 in DMSO-d6. 
 




Spectrum 137 1H NMR spectrum of substrate 22 in DMSO-d6. 
 




Spectrum 139 13C NMR spectrum of substrate 23 in DMSO-d6. 
 
 




Spectrum 141  1H NMR spectrum of gold-complex 35 in CD2Cl2. 
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